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Abstract
This thesis outlines two alternative approaches to investigating the role of H-ras in 
mouse skin tumour development. The first, the in vitro approach utilises a number of 
unique cell lines representative of a late stage of tumorigenesis, the conversion from a 
well differentiated squamous carcinoma to a undifferentiated spindle form. Through 
manipulation of the gene dosage ratio of mutant:normal H-ras in these cell lines, by 
plasmid transfection and virus infection, it was hoped to provide some clues as to the 
function of H-ras in this late stage transition event. The second approach involves the 
technique of gene targeting. The aim of this approach was to create a mouse 
hemizygous or completely deficient in H-ras and to examine the effects in the context 
of both chemical carcinogenesis studies and normal mouse development.
Initial observations of the squamous/spindle transition event showed that the cell lines 
representative of both phenotypes were characteristically very different. The 
squamous cell line B9 produced a well differentiated tumour when injected into nude 
mice whereas the spindle cell lines A5 and D3 gave rise to aggressive, disorganised 
tumours with a much reduced latency. Genetic analysis of the cell lines showed that 
the most dramatic difference between the squamous and spindle derivatives was in the 
copy number and expression levels of H-ras. Both spindle cell lines A5 and D3 
showed an approximate 5-10 fold increase in mutant H-ras, best explained by a 
genetic amplification mechanism. Experimentally overexpressing mutant H-ras in the 
squamous cells, and vice versa the levels of normal H-ras in the spindle variants, was 
unable to mimic the conversion event. However it was found that several A5 and D3 
transfectant clones showed a dramatic reduction in tumorigenicity. This correlated 
not with the levels of the introduced normal H-ras but the absolute levels of 
endogenous mutant H-ras. Spontaneous loss of mutant copies of H-ras resulted in 
clones that morphologically
resembled spindle cells yet produced tumours with a vastly increased latency period. 
It seems therefore that in this system mutant H-ras is the critical determinant of 
tumorigenicity, and relates perhaps to the growth of the tumour cell in vivo, possibly 
providing the driving force for the conversion. However, alteration of the H-ras gene 
dosage ratio was not in itself sufficient for the transition of a squamous to a spindle 
cell carcinoma, implying that another locus as yet unknown must play a role in 
controlling the epithelial phenotype.
Finally, the gene targeting approach, provides a means to examining the earlier stages 
of mouse skin tumorigenesis, in particular the proposed role of normal H-ras in 
suppressing the development of papillomas from an initiated cell. For instance, if the 
consistent duplication of the chromosome carrying the mutant H-ras gene, seen in the 
development of papillomas, is related to overcoming a suppressive effect of normal 
H-ras, then carcinogen treatment of a mouse deficient in H-ras may result in a mouse 
more susceptible to tumorigenesis. Experiments with the gene targeting technique are 
on going and as yet no targeted ES cell clone has been isolated, but hope remains that 
this approach will provide new insights into the functions of H-ras both in early 
tumorigenesis and normal development.
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Chapter 1 
Introduction
1.1 The history of oncogenes
1.1.1 Lessons from viruses
The identification of oncogenes as genes with the potential to cause cancer, initially 
arose from the study of a class of retroviruses called acute transforming viruses. 
Many of these acute transforming viruses, like the Rous sarcoma virus (RSV) isolated 
over 80 years ago, were identified in crude extracts of spontaneously arising tumours, 
as agents that could reproducibly induce the growth of tumours in previously healthy 
animals, after a very short latency period ( reviewed by Bishop, 1983).
Compelling evidence that RSV encoded a protein that induced transformation came 
in 1970 from the isolation of mutants that were temperature-sensitive for 
transformation (Martin, 1970). Spontaneous revertants that were unable to transform 
at any temperature arose by deletions of the RNA genome that occurred during RSV 
replication.
The gene or oncogene defined by the deletion, which gives RSV its ability to 
transform cells and induce tumours was called src (Stehelin et al., 1976a). cDNA 
probes from the region of the src oncogene were shown to anneal to normal genomic 
DNAs from several avian species (Stehelin et al., 1976b). Sequences homologous to 
src were shown to be widespread among vertebrate species, and to be expressed in 
normal cells (Spector et al., 1978)
The concept that the viral oncogene, v-src, had a cellular counter-part or "proto­
oncogene", c-src, that had been in some way transduced by the virus, indicated for the 
first time the existence of cellular genes with the potential to cause cancer (Bishop,
1981).
Perhaps 40-50 oncogenes have now been identified as components of retroviruses, 
isolated from a number of different species. The astounding conservation of these 
oncogenes can be appreciated when one estimates that the nucleotide sequence of the
chicken and human c-src genes have diverged by only 10-15 percent (Shilo and 
Weinberg, 1981; Shibuya et al., 1980). This high degree of genetic stability suggests 
a critical role for the proto-oncogenes in cellular metabolism.
Many other oncogenes have been identified not as a component of a retrovirus, but 
rather as a cellular gene disrupted by the integration of a retrovirus within or close to 
the coding region of the gene. In many cases, this brings the gene under the powerful 
transcriptional control of the viral LTRs. This class of oncogenes will be discussed in 
the context of oncogene activation, Section 1.2.2.
1.1.2 Lessons from gene-transfer studies
The establishment of mouse 3T3 cells that can be transformed in vitro (Shih et al.,
1981), and the technique of calcium phosphate transfection (Graham and van der Eb, 
1973), together formed the basis for the 3T3 transformation assay. This assay has 
played a prominent role in the study of cellular oncogenes, by enabling the 
introduction of single copy genes into mammalian cells inorder to determine their 
transforming abilities (Shih et al., 1979b).
Transfection of DNA from chemically transformed mouse fibroblasts into monolayer 
cultures of NIH3T3 cells resulted in the development of transformed foci (Shih et al., 
1979a). This suggested that the original mutagenic event which resulted in chemical 
transformation of the cells was dominant and transmissible through several rounds of 
transfection.
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It could be argued that despite the presence of cellular counterparts, oncogenes were a 
peculiarity of RNA tumour viruses, and played no role in human cancer. However 
this appeared less likely when high molecular weight DNA from the human bladder 
carcinoma cell line, T24 (Perucho et al., 1981) or EJ (Tabin et al., 1982; Pulciani et 
al., 1982), and lung carcinoma lines A2182 and LX-1 (McCoy et al., 1983; Der et al.,
1982) were shown to transform recipient NIH3T3 cells. Through the use of human 
specific repetitive Alu sequences, it was possible to follow the cosegregation of the 
human fragments with the phenotype of malignant transformation, leading to the 
eventual isolation and cloning of the candidate genes (Perucho and Wigler, 1981).
The transforming genes of the bladder and lung cell lines were shown to hybridise to 
the Harvey and Kirsten sarcoma viruses. These were not new oncogenes but instead 
cellular homologues of the transforming retroviruses, themselves able to induce 
cellular transformation. This suggested a causal role in the development of certain 
human tumours, by an alteration event that did not change the gross structure of the 
genes.
Thus from both the study of acute transforming viruses, and the study of human 
tumours, the same genes were recognised as being causal and were subsequently 
cloned. The obvious question that now arose was what were the qualitative or 
quantitative changes that enabled a cellular gene, present and expressed in normal 
cells, to become a cancer causing gene ?
1.2 Mechanisms of activation of cellular oncogenes:
It had been clear for some time that many different agents could induce cancer in 
animals. For instance, the early work on the carcinogenic properties of X-rays 
(Muller, 1927), coal tar, and nitrogen mustards (Auerbach et al., 1947), as well as the 
abundant data on viral oncogenesis, Section 1.1.1. It appeared there was the same 
diversity at the genetic level. Viral transduction of a cellular gene could induce rapid 
tumorigenesis in a healthy host, whereas the Avian leukosis virus (ALV) induced
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lymphomas only after a long latency period, as a result of viral integration at a unique 
genomic site (Hayward et al., 1981). This led to the notion that proto-oncogenes 
could be activated by proviral insertions as well as by viral transduction. In addition, 
early observations by Rowley using chromosome banding suggested a gross 
chromosomal mechanism for oncogene activation (Rowley, 1973). The Philadelphia 
chromosome associated with chronic myelogenous leukemia, was shown to be a 
result of a balanced translocation between human chromosomes 9 and 22. The 
observations of Barbacid and Weinberg, indicated that single point mutations were 
capable of activating cellular proto-oncogenes (Pulciani et al., 1982; Tabin et al.,
1982). Clearly there were a number of different mechanisms for the generation of 
genetic alterations associated with neoplasia.
1.2.1 Point mutation
The first demonstration of a lesion in cellular DNA, whose occurrence was directly 
related to the carcinogenic process, came from analysis of the human bladder cell line 
EJ (Tabin et al., 1982) or T24 (Reddy et al., 1982; Taparowsky et al., 1982). 
Differences were detected in the migration of the p21 proteins of the H-ras gene. The 
alternative species were the result of a single point mutation leading to an amino acid 
substitution, glycine to valine at codon 12 of the p21 product. It was also shown that 
the Harvey sarcoma virus deviated from its cellular counterpart at the same position 
with a glycine to arginine substitution (Tabin et al., 1982). It thus appeared that a 
single point mutation in a cellular gene was sufficient to alter its normal function.
In agreement, a single point mutation in the neu proto-oncogene (Bargmann et al., 
1986a; Schechter et al., 1984), leading to an amino acid substitution in the 
transmembrane domain of the protein occurs in the development of rat neuro- and 
glioblastomas (Bargmann et al., 1986b). However, as yet no point mutations in the c- 
neu gene have been identified in human tumours.
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The pp60 product of the c-src gene is also modified by several point mutations (Levy 
et al., 1986), leading to amino acid changes in the tyrosine kinase domain of the 
protein. The result is an elevation of the tyrosine kinase activity of pp60src, which is 
thought to directly induce cellular transformation. As with the c-neu oncogene, there 
are no examples of c-src activation by point mutation in spontaneously arising human 
tumours. However, the FMS proto-oncogene which encodes the receptor for colony- 
stimulating factor 1 and the gsp oncogenic G protein, gsp, have been reported to be 
activated in human tumours by the mechanism of point mutation (Sherr et al., 1985). 
Mutations in codons 301 and 969 of the FMS gene were seen in several patients with 
myelodysplasia and acute myeloblastic leukemia (Ridge et al., 1990), whereas gsp has 
been shown to be activated both in tumours of the thyroid and pituitary (Clementi et 
al., 1990; Suarez et al., 1991; O’Sullivan et al., 1991).
Clearly substitution of amino acids as a result of a point mutation, is sufficient to alter 
the activity of a protein product, and constitutes a common mechanism for activation 
of a proto-oncogene.
1.2.2 Pro-viral insertion
Replicating retroviruses can cause tumours in a host animal after long incubation 
periods, in contrast to the acute transforming retroviruses, which with the exception of 
v-src are replication incompetent (Temin, 1963). The tumours show common pro- 
viral insertion sites, implying the dominant cis-activation of cellular genes by viral 
sequences (for a review see Nusse, 1986).
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The first oncogene recognised as being activated in this manner was the myc 
oncogene, which had previously been identified as the transduced component of 
myelocytomatosis virus 29, or MC29. Levels of myc-specific RNA were 30-100 fold 
higher in ALV-induced lymphomas as a direct result of viral integration at several 
sites upstream of the c-myc gene (Hayward et al., 1981; Robinson and Gagnon, 
1986). This was the first finding to suggest that over-expression of a normal cellular 
gene could result in neoplastic transformation, and led to the unmasking of the c-myc 
and c-abl genes at chromosomal breakpoints in non-viral tumours (Section 1.2.4). 
Transcriptional enhancement is also seen in the activation of the int-1 and int-2 genes 
by MMTV (Nusse et al., 1984). The protein encoding domains of the int genes 
remain intact, indicating tumorigenesis is caused by the over-expression of an 
unaltered gene product (Nusse, 1988). Insertions of MLV near Pim-1 follow the same 
principle, most frequently found in the 3' untranslated region of the gene, perhaps 
indicating stabilisation of the Pim-1 mRNA as a contributing factor (Selten et al., 
1986).
Proviral insertions are also found in the c-erb-B gene in chicken erythroleukemias 
(Nilsen et al., 1985), and in the c-myb oncogene in mouse lymphosarcomas (Sheng- 
Ong et al., 1986). In both cases, the protein product is disrupted by the provirus 
insertion, resulting in a novel spliced viral-oncogene transcript.
Thus insertional activation of cellular genes by the transcriptional enhancement or 
generation of novel chimeric proteins represents an additional mechanism responsible 
for oncogenesis.
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1.2.3 Amplification
Another mechanism which results in increased dosage of cellular oncogenes, occurs 
through genetic amplification of a region harbouring the proto-oncogene. This 
represents a frequent event in tumour cells, and is thought to provide an indicator to 
the clinical prognosis of some malignancies (Nau et al., 1985).
Amplification of the cellular myc oncogene was originally seen in the human cell line 
HL-60 (Favera et al., 1982b; Collins and Groudine, 1982). The list of amplified 
oncogenes presently includes the myc and ras genes as well as abl, myb, EGFR, 
ERBB2(neu) (Semba et al., 1985), and HST. Amplification is more common in solid 
tumours than with haematopoietic malignancies which only rarely show signs of 
amplification. In addition, certain solid tumour types display genetic amplification 
more readily, such as neuroblastomas, small cell lung cancers, breast, ovarian and 
colon cancers ( for a recent review see Schwab and Amler, 1990).
The copy number of the amplified gene ranges from 5 to 700. The c-Ki-ras gene is 
amplified 30-60 fold in mouse adrenocortical tumours, often residing on double 
minutes or homogeneously staining regions (Schwab et al., 1983) ( reviewed by 
Cowell, 1982).
Amplification has been shown to correlate with the status and clinical prognosis of 
malignancy, for example, the most aggressive forms of neuroblastoma, stage III and 
IV, display genetic amplification of the N-myc oncogene (Schwab et al., 1984; 
Brodeur et al., 1984). Also the large cell variants of small-cell lung carcinomas have 
amplified c-, N- ,and L-myc genes, and show a poorer prognosis accordingly (Nau et 
al., 1985).
The structure of the amplified cellular oncogene appears unaltered with the exception 
of a single colon carcinoma line, COLO 320 (Schwab et al., 1986), and a single 
neuroblastoma cell line, NMB (Amler and Schwab, 1989).
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The neu oncogene reported in an earlier section as being activated by point mutation 
has also been shown to be amplified in breast carcinomas (Slamon et al., 1987). The 
amplified gene is normal and shows no point mutations (Slamon et al., 1989). It thus 
appears, that at least in some cancers, overexpression of a normal oncogene product 
constitutes an important factor in the progression to a malignant phenotype.
1.2.4 Chromosomal translocation
Chromosomal translocations have been shown to be associated with a variety of 
haematopoietic malignancies ( reviewed by Haluska et al., 1987 ). In 1973, Rowley 
with the use of chromosome banding, showed that the Philadelphia chromosome was 
as a result of a balanced translocation between human chromosomes 9 and 22. In 
1982 molecular analysis of the chromosome translocation involved in Burkitts 
lymphoma, provided an explanation for the occurrence of translocations in neoplasia. 
The distal end of the long arm of chromosome 8 where the c-myc oncogene resides is 
translocated to chromosomes 14, 22, or 2. The outcome is that the c-myc gene is 
juxtaposed to an immunoglobulin gene on the respective chromosome, resulting in 
elevated constitutive expression of c-myc (Favera et al., 1982a; DeKlein et al., 1982; 
Taub et al., 1982).
Other oncogenes that are activated by translocation include bcl-1, bcl-2, and c-abl 
(Tsujimoto et al., 1984b; Tsujimoto et al., 1984a; Groffen et al., 1984; Tsujimoto and 
Croce, 1986).
Activation of the ret proto-oncogene in human thyroid papillary carcinomas occurs 
not by rearangement between different chromosomes but by an intra-chromosomal 
alteration between two genes that reside close to each other at position q ll.2  of 
chromosome 10. The result is a fusion between the novel PTC (for papillary thyroid 
carcinoma) gene and the tyrosine kinase domain of the ret oncogene (Grieco et al., 
1990).
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In summary, the activation of cellular oncogenes may be acheived by a number of 
alternative mechanisms. In addition, the same oncogene may be activated in certain 
malignancies by different means ( see Table 1 ). For example, in human breast 
carcinomas the c-neu proto-oncogene is amplified several-fold (Slamon et al., 1987), 
whereas in rat neuro- and glioblastomas a single point mutation represents the 
activating event (Bargmann et al., 1986b).
1.3 Evidence for oncogene cooperation
A number of oncogenes have now been identified from the analysis of consistent 
genetic changes associated with specific tumour types, and from in vitro assays of cell 
transformation. These can be grouped into a small number of classes, on the basis of 
shared functional properties and on the basis of the nuclear or cytoplasmic 
localisation of the gene products ( reviewed by Weinberg, 1985). Among the nuclear 
oncogenes are variants that exhibit some structural homology such as c-myc, N-myc, 
myb, and adenovirus E l A. These along with other nuclear oncogenes, such as p53, 
polyoma large T (Rassoulzadegan et al., 1983), and SV40 large T, display some 
common functions, namely the ability to immortalise primary rat embryo fibroblasts ( 
REFs ) (Mougneau et al., 1984).
In contrast, the cytoplasmic oncogenes such as H-ras, K-ras, N-ras, src, and 
polyomavirus middle T antigen, are generally weak in their ability to immortalise 
cells but strong in their ability to promote the phenotypes of anchorage independence, 
alterations in cell shape and reduction in growth factor requirements.
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Transfection of polyoma middle T, El A, or ras oncogenes alone, are unable to 
transform cultures of primary cells. However, combinations of oncogenes, such as 
E1A and E1B, or polyoma middle T with large T, were shown to fully convert 
primary cells to tumorigenic cells (Land et al., 1983; Ruley, 1983). The concept of 
activated oncogenes collaborating to fully transform cells in culture, provided 
credance to the nuclear/cytoplasmic classification, since the oncogene products that 
act in the nucleus cooperate best with those that act in the cytoplasm (Weinberg,
1985).
Most of the nuclear oncoproteins can cooperate with activated ras to elicit 
transformation of primary REFs (Land et al., 1986; Parada et al., 1984)(for review a 
see Ruley, 1990).
However, there are exceptions to the rule, in that certain adenovirus E l A mutants 
collaborate with ras but not with the cytoplasmic product of polyoma middle T 
(Ruley, 1987). There are also examples of two nuclear oncoproteins ( GLI and E l A ) 
(Ruppert et al., 1991), or two cytoplasmic oncoproteins ( bcl-2 and c-H-ras ) that 
cooperate to transform REFs (Reed et al., 1990).
Additional evidence for oncogene cooperation has come from studies with transgenic 
mice. FI offspring from a cross between MMTV-myc and MMTV-ras transgenic 
mice showed considerable acceleration in the appearance of tumours compared to the 
parental strains (Sinn et al., 1987). The concept of functional complementation 
between oncogenes, suggests a limited number of inter-related regulatory pathways 
governing cell proliferation. In addition, the necessity for two oncogenes to cooperate 
to fully transform a primary cell, provides perhaps the first indication that multiple 
oncogenic events are responsible for the development of a tumour.
To understand the molecular basis of oncogene cooperation, it is necessary to 
examine the functions of the various proto-oncogenes.
11
1.4 The functions of cellular oncogenes
It is now clear that proto-oncogenes cover the full array of cellular interactions, from 
growth factors and growth factor receptors, through cytoplasmic protein kinases and 
GTP binding proteins, to nuclear transcription factors.
Growth factors such as the platelet-derived growth factor (PDGF) and epidermal 
growth factor (EGF), and the inhibitory factor, transforming growth factor p, TGFp, 
activate a variety of cellular signaling devices through transmembrane receptors 
(reviewed by Cross and Dexter, 1991). The end point in the signaling pathways that 
govern cell proliferation appears to be at the level of transcription.
Activation of receptor tyrosine kinases transduce the signals across the plasma 
membrane. Stably linked transmembrane homodimers ( Insulin receptor ), or 
monomers induced to form homo- or hetero-oligomers ( PDGF receptor and NGF 
receptor ), autophosphorylate on tyrosine residues upon activation. Receptor 
autophosphorylation is thought to act as a switch to induce the binding of cytoplasmic 
signaling proteins to the receptor. The SH-2 domains found in a variety of 
cytoplasmic molecules including GAP, PLC-y, and src (Sadowski et al., 1986), are 
thought to complex with the autophosphorylated receptors to enable the catalytic 
domains of the cytoplasmic molecules to come into close proximity with the receptor 
kinase domain. The subsequent phosphorylation of the cytoplasmic signaling 
molecules stimulates downstream pathways, such as the ras pathway ( for a recent 
review see Pawson, 1992).
Mutant forms of growth factor receptor have been identified such as the EGFR 
encoded by the v-erb-B gene (Ullrich et al., 1984), or the CSF1R, a product of the v- 
fms oncogene (Coussens et al., 1986).
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Other oncogenes can be grouped as mutant proteins associated with the inner surface 
of the plasma membrane such as the src non-receptor protein tyrosine kinase or the 
ras gene products. Whereas, Mos, Pim-1 and Raf represent an additional group of 
cytoplasmic oncogenes whose products are protein serine-threonine kinases, involved 
in signal transduction and cell cycle regulation (Sagata et al., 1989; Roy et al., 
1990)(reviewed by Cantley et al., 1991).
The transcription factor oncogenes represent the final group of oncogenes which can 
release a cell from the constraints of normal signal transduction processes (reviewed 
by Lewin, 1991). They can be divided into three classes. The first are the nuclear 
receptors for ligands such as steroid and thyroid hormones, an example of this class is 
the c-erbA gene product. The second class represented by the c-fos and c-jun 
proteins, are inducible by extracellular signals and are nuclear in location. The final 
class is also inducible by upstream signals but cytoplasmic in location ( c-rel).
Mutant forms of fos and jun are thought to elicit their oncogenic response by 
increasing the transcription of genes required for growth, whereas mutant forms of rel 
and erb A are thought to promote growth by repressing the transcription of genes that 
suppress growth (Lewin, 1991).
It thus appears that the cellular function of oncogenes fall into a number of classes, 
which cover the entire spectrum of cellular responses, from mitogenic stimulation to 
transcriptional regulation.
In recent years it has been recognised that the cooperation of genes to elicit a 
transformed phenotype not only involves the dominant interaction of oncogenes, but 
also recessive alterations in negative growth controlling genes, losely termed "tumour 
suppressor genes". The inactivation of such genes whose function may counteract the 
stimulatory effect of dominantly acting oncogenes, offers an additional array of genes 
now believed to play a critical role in tumorigenesis.
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1.5 Tumour suppressor genes
1.5.1 Evidence from cell fusion studies
The idea that loss-of-function mutations participate in the development of tumours 
first came from studies on the tumorgenicity of cell hybrids (reviewed by Harris, 
1988).
The fusion of malignant cells to non-malignant cells can produce non-tumorigenic 
hybrid cell lines, which can subsequently segregate to become tumorigenic once again 
(Harris et al., 1969; Ephrussi et al., 1969; Engel et al., 1969). Analysis revealed the 
tumorigenic segregants had lost several chromosomes present in the non-tumorigenic 
hybrids (Stanbridge et al., 1981). Stanbridge and colleagues noted the loss of 
chromosomes 11 and 14 in HeLa x fibroblast tumorigenic hybrids. Klinger also noted 
the loss of chromosome 11 as well as other chromosomes such as 2, 13, 17, and 20, in 
similar HeLa x fibroblast hybrids (Klinger, 1982).
Hybrid studies between tumorigenic fibrosarcoma x fibroblast cell lines implicated 
the loss of chromosomes 1 and 4, suggesting perhaps that for different malignancies 
there was a unique set of tumour suppressor genes involved (Benedict et al., 1984). 
Experiments with the technique of microcell transfer enabled the introduction of a 
single chromosome from a donor to a recipient cell (Saxon and Stanbridge, 1987; 
Fournier and Ruddle, 1977). The transfer of chromosome 11 derived from a normal 
human fibroblast cell, into a Wilms' tumour cell line (Weissman et al., 1987), HeLa 
cells, and tumorigenic HeLa x fibroblast hybrids, resulted in the suppression of 
tumorigenicity (Saxon et al., 1986). This provided direct evidence for the existence of 
a tumour suppressor gene on chromosome 11.
Viral and oncogene induced, as well as spontaneous tumorigenicity, has been shown 
to be suppressed in hybrid studies. For example, hybrids between SV40 transformed 
and non-tumorigenic BALB/c3T3 cells produced some non-tumorigenic clones. 
Analysis of these clones showed the presence of integrated SV40 DNA and the
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expression of T antigen (Howell and Sager, 1981). Similarly a Chinese hamster 
embryo fibroblast cell line when fused to a tumorigenic transfectant carrying the EJ c- 
H-ras oncogene showed suppression in most hybrids despite the continued presence 
and expression of the H-ras oncogene (Craig and Sager, 1985). This data indicates 
that suppression proceeds independent of the presence of the oncogene encoded 
product.
1.5.2 Evidence from familial studies
The concept that loss of tumour suppressor genes could assist in the development of 
neoplasia was further endorsed by the study of familial cancers (reviewed by 
Knudson, 1986). Knudson originally suggested that retinoblastomas resulted from 
two sequential mutations (Knudson, 1971). This became more specific from the 
finding that the two target loci are the two copies of the Rb gene, and that critical 
alterations serve to inactivate Rb function (Friend et al., 1986; Bookstein et al., 1988; 
Horowitz et al., 1989). In the familial case, a mutant allele is inherited, whereas in 
the sporadic forms of the disease both mutant alleles develop from somatic mutations. 
Loss of heterozygosity studies have been used to identify candidate suppressor genes 
both in familial and sporadic forms of tumours. To date, there are six known, or 
presumptive human tumour suppressor genes that have been isolated as molecular 
clones. These include p53 (Baker et al., 1989), retinoblastoma (Rb)(Friend et al., 
1986), von Recklinghausen neurofibromatosis type 1 (NFl)(Cawthon et al., 1990), 
Wilm’s tumour (WT-1) (Call et al., 1990), familial adenomatosis polyposis (FAP) 
(Solomon et al., 1987; Bodmer et al., 1987), and deleted in colon carcinoma (DCC) 
(Fearon et al., 1990; Marshall, 1991b). All with the exception of DCC have been 
shown to be passed through the germline causing a congenital predisposition to a 
variety of tumours. However, there is circumstantial evidence to suggest a role for 
DCC in a syndrome, with autosomal dominant inheritance, which predisposes 
individuals to carcinomas of the colon, and other organs (Lynch et al., 1985).
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1.5.3 The functions of tumour suppressor genes
The biochemical functions of most of the tumour suppressors are still poorly 
understood. However, the fact that it is loss of gene function which contributes to 
tumorigenesis, infers that the gene products may act as repressors of cellular 
proliferation or inducers of differentiation.
An initial clue to the function of the Rb gene product came from the discovery of its' 
association with the E1A protein (Whyte et al., 1988). Loss of normal function of 
pRB by mutation or sequestration by a viral oncoprotein, in some way contributed to 
the neoplastic process. It now appears, there is a role for pRB in the regulation of 
transcription during the cell cycle. The Rb product has been shown to be an 
inhibitory component of the E2F transcription complex (Chellappan et al., 1991; 
Hiebert et al., 1992). In addition, pRB is phosphorylated just before the S-phase of 
the cell cycle (Buchkovich et al., 1989; Chen et al., 1989). Binding to the E2F 
complex is inhibited by pRB phosphorylation. In this way, pRB may control the 
transcription of genes governing the cell cycle (DeCaprio et al., 1989). This may in 
turn be controlled by the phosphorylation status of pRB. An additional factor which 
may play a role in this particular scheme, is the inhibitory growth factor TGF-p, 
which can prevent the cell cycle dependent phosphorylation of pRB (Laiho et al.,
1990). One consequence of loss of pRB function may therefore be a loss of 
responsiveness to TGF-P (Roberts et al., 1991).
There is some evidence to suggest a link with the cell cycle in the function of the p53 
protein. Over-expression of the wild-type p53 gene was shown to block the growth of 
osteosarcoma and colorectal carcinoma cells, by preventing entry into S phase (Diller 
et al., 1990; Baker et al., 1990).
Although the specific function of cellular p53 is still unknown, it is thought to inhibit 
DNA synthesis following DNA damage, by blocking the cells at the G1 phase of the 
cell cycle. Increased levels of p53 protein were detected in proliferating normal 
human bone marrow progenitor cells after DNA damage (Kastan et al., 1991). The
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increase in p53 protein occurred via a post-transcriptional mechanism and was 
temporally correlated with a transient arrest in the G1 phase of the cell cycle. 
However, cells with mutant p53 or no p53, continued through the cell cycle after 
DNA damage. The exact role for this increase in p53 protein is unclear, although it 
may provide a mechanism allowing surveillance of the genome for genetic damage. 
The interaction of the normal p53 protein with DNA appears to be direct. A 
concensus binding sequence has been identified in several genomic clones consisting 
of two copies of a 10 base pair motif. Mutants of the p53 protein failed to bind to the 
concensus dimer (El-Deiry et al., 1992). Co-transfection studies have shown that 
wild-type p53, but not oncogenic forms of the protein, are able to activate expression 
of genes adjacent to the p53 DNA binding sites (Kern et al., 1992). Furthermore, co­
transfection of mutant and normal constructs indicated that mutant p53 was capable of 
inhibiting the inducing activity co-ordinated by the normal gene. This may be 
explained by complexes forming between the wild-type and mutant proteins which 
are unable to bind DNA and thus unable to control the transcription of genes 
necessary for the proper maintenance and regulation of the cell cycle.
In contrast to the nuclear localised normal products of the p53 and RB genes, the 
DCC gene, a candidate suppressor gene located on chromosome 18q, commonly 
inactivated in colon carcinomas (Fearon et al., 1990), shows considerable homology 
to the cell adhesion molecule N-CAM. It is therefore presumed to act at the cell 
surface. The reduction in expression of a putative cell adhesion molecule in 
colorectal epithelial cells may suggest a mechanism of clonal expansion by loss of 
growth-restraining signals associated with cell adhesion (Fearon and Vogelstein,
1990). A recent paper by Narayanan and co-workers provides the first biological 
evidence for DCC as a tumour suppressor. High levels of DCC antisense RNA 
resulted in inhibition of cell adhesion in Rat-1 fibroblasts. The Rat-1 fibroblasts were 
capable of anchorage-independent growth and showed an increased tumorigenicity in 
vivo (Narayanan et al., 1992).
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The functions of tumour suppressor genes appear as diverse as the functions of 
dominantly acting oncogenes. In very few cases, are two oncogenes activated in the 
same tumour, but there are several instances where two or more tumour suppressor 
genes display alterations. For example in lung and osteosarcomas both p53 and RB 
show genetic alterations (Harbour et al., 1988; Takahashi et al., 1989), and in 
colorectal tumorigenesis possibly three putative suppressor genes, FAP, DCC, and 
p53, are implicated at various stages of progression (Fearon and Vogelstein, 1990). 
Thus tumorigenesis occurs as a result of the inactivation of multiple tumour 
suppressor genes, and the concerted activation of dominantly acting oncogenes. No 
doubt additional tumour suppressor genes will be uncovered, which may allow further 
elucidation of the synergistic pathways by which tumour suppressors and oncogenes 
control cell growth.
1.6 The mammalian ras proto-oncogenes are members of a ras 
superfamily
The products of the mammalian ras proto-oncogenes, Harvey-ras (H-ras), Kirsten-ras 
(K-ras), and N-ras, are members of a family that includes at least 40 ras-related small 
GTP-binding proteins, which share the ability to interconvert between an inactive 
(GDP-bound) and an active (GTP-bound) state (for a review Barbacid, 1987). They 
are involved in a wide spectrum of biological functions, such as growth, 
differentiation, organisation of the actin cytoskeleton and intracellular vesicle 
transport and secretion ( reviewed by Hall, 1990).
The ras gene super-family can be divided into 3 classes, the ras-related, the rho- 
related (Drivas et al., 1990) and the rab-like proteins (Zahraoui et al., 1989) In the 
context of this thesis, we will concentrate on the ras-related family.
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The various ras-related family members are about 50-60% identical, in terms of 
amino acid homology, and their molecular masses vary from 21kDa (for ras) to 
27kDa (for ral). In addition to the ras proto-oncogenes, mammamlian members 
include Ral(A and B), Rapl(A and B), Rap2, and R-ras. Many other homologues 
have been identified in lower eukaryotes such as in the fruit fly Drosophila 
melanogaster (Neuman-Silberberg et al., 1984), the yeasts Saccharomyces cerevisiae 
and Schizosaccharomyces pombe (Powers et al., 1984; DeFeo-Jones et al., 1985), and in the 
slime mould Dictyosteliwn discoideum (Reymond et al., 1984).
Several members of the ras gene superfamily have been isolated by screening with 
highly conserved oligonucleotide probes, for example spanning the GTP binding site 
(Touchot et al., 1987). Others such as the rapl and rap2 genes were isolated by low 
stringency screens of human cDNA libraries using the Drosophila Dras3 probe (Pizon 
et al., 1988), or in the case of the human R-ras gene with the v-H-ras probe (Lowe et 
al., 1987).
1.7 The structure of the mammalian ras proto-oncogenes
The ras proto-oncogenes H-ras, K-ras, and N-ras are expressed in most, if not all 
mammalian cell types and have remarkable sequence conservation. The first 85 
amino acids encoded by the three genes are identical between mouse and human. The 
product of the genes is a 21kDa protein, encoded by four exons, except for K-ras-2 
which possesses two alternative fourth coding exons ( exons TV A  and IVB ) encoding 
two isomorphic p21 proteins of 188 and 189 residues (McGrath et al., 1983; Capon et 
al., 1983).
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The promoter regions of the cellular ras genes resemble so-called housekeeping 
genes, in that they lack a TATA box but possess multiple copies of the sequence 
GGGCGG, the SP1 concensus binding site (Ishii et al., 1986; Ishii et al., 1985). The 
promoter structure together with the degree of sequence conservation, lends support 
to the belief that the ras proteins perform essential cellular functions.
As in the case of the distantly related G proteins, normal p21ras binds to GTP and 
catalyses its hydrolysis to GDP (Scolnick et al., 1979; Shih et al., 1980). The ras 
protein cycles between an active GTP-bound and an inactive GDP-bound state. The 
regions important for GTP binding have been identified by mutagenesis (Sigal et al., 
1986; Lacal et al., 1986) and X-ray crystallography studies (Krengel et al., 1990). 
Oncogenic mutations of p21ras occur at or near the sites of interaction with the P- and 
y-phosphates of the nucleotide (residues 12, 13, 59, 61, and 63)(Colby et al., 1986; 
Der et al., 1986; Fasano et al., 1984), or sites of interaction with the guanine base 
(residues 116, 117, 119 and 146)(Walter et al., 1986; Der et al., 1988; de Vos et al., 
1988). The former reduce the GTPase activity of the protein while the latter decrease 
its' affinity for nucleotide, hence increasing the rate of exchange of bound GDP for 
cytosolic GTP. The overall effect is to cause an accumulation of the GTP-bound 
active form of p21, thus eliciting an oncogenic signal (Barbacid, 1987).
While some substitution mutations reduce the biological effect of ras proteins ( in 
yeast complementation and mammalian NIH3T3 focus forming assays ), they do not 
disrupt their nucleotide binding, cellular localisation or stability. In this respect, 
residues 32-40 have been associated with the effector activity of the ras proteins 
(Sigal et al., 1986). This region is hydrophilic and presumably lies on the external 
surface of the ras molecule (Willumsen et al., 1986). X-ray crystallography studies 
have shown that this region in particular shows dramatic conformational changes after 
GTP hydrolysis (Jumak et al., 1990; Milbum et al., 1990). The trigger for these 
alterations appears to be a change in the coordination of the active-site Mg^+ ion as a 
result of loss of the y-phosphate of GTP (Schlichting et al., 1990).
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1.8 Processing of the ras protein
To function properly the ras protein must be localised to the plasma membrane. This 
localisation involves a complex series of post-translational modifications, centering 
on the carboxy-terminal motif CAAX ( where C is cysteine, A any aliphatic amino 
acid and X any uncharged amino acid) found in almost every ras superfamily protein. 
Processing begins with the proteolytic removal of the three C-terminal amino acids to 
leave Cysl86 at the carboxyl terminus. Carboxyl methylation of Cysl86 and the 
attachment of a polyisoprenyl group then proceeds (Gutierrez et al., 1989; Hancock et 
al., 1991b). Further processing occurs for H-ras, N-ras and K-rasA with 
palmitoylation of the two upstream cysteines (181 and 184). However, the 
predominant form of K-ras, K-rasB lacks these upstream cysteines and is 
consequently not palmitoylated (Hancock et al., 1989). Instead a string of basic 
residues close to Cysl86 appear to be important in its' membrane localisation 
(Hancock et al., 1990; Hancock et al., 1991a).
Mutation of the Cysl86 residue has been shown to block both membrane localisation 
and transformation (Willumsen et al., 1984), thus providing proof that membrane 
attachment is essential for cellular transformation.
1.9 Biochemical aspects of ras regulation
The ratio of GTP:GDP on p21ras can in theory be regulated by either altering the rate 
of GTP hyrolysis or by altering the rate of nucleotide exchange. There is evidence 
that both mechanisms operate in the regulation of the ras pathway, indeed perhaps 
acting synergistically to contribute to ras activation (Feig and Cooper, 1988b).
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1.9.1 Isolation of GAP - a GTPase-activating protein
In 1987 Trahey and McCormick reported that a cytoplasmic factor present in Xenopus 
oocytes was capable of stimulating the rate of GTP hydrolysis of purified injected 
p21N-ras (Trahey and McCormick, 1987). The factor stimulated GTP hydrolysis 
more than 200-fold compared to the intrinsic in vitro rate of purified p21ras, although 
it was shown to have no stimulatory effect on two codon 12 ras mutants (Trahey and 
McCormick, 1987). The factor, GTPase-activating protein (GAP), was shown to 
interact with p21ras at a site previously identified as the "effector" site (Cales et al.,
1988). It was subsequently purified and cloned from bovine brain and human 
placenta (Trahey et al., 1988; Vogel et al., 1988). The transforming ability of these 
mutants most probably results from the accumulation of the active p21 GTP-bound 
state.
GAP is a 120kDa protein that is mainly cytosolic, although the amino terminal which 
is dispensable for GTPase activation is extremely hydrophobic, and is thought to play 
a role in membrane attachment. The region of GAP carboxy to this is highly 
conserved, 98% identical between bovine and human species (McCormick, 1989). 
The protein contains two SH2 and one SH3 motifs, regions of homology to non- 
catalytic portions of pp60src (Sadowski et al., 1986), thought to bind phosphotyrosine 
residues of other proteins.
From the evidence to date, it appears that GAP operates as an upstream negative 
regulator of ras, but it may also function as a downstream effector. Data to support 
this, has come from ras proteins with mutations in the "effector" region, residues 32- 
40 (Adari et al., 1988; Cales et al., 1988). Mutations of this domain prevent GAP 
interaction and delete the transforming potential, but do not effect the nucleotide 
binding, membrane localisation, and stability of the ras proteins. Additional data to 
support GAP having an effector function has come from studies on the effects of ras 
and GAP on the opening of receptor-coupled potassium channels in atrial cells 
(Yatani et al., 1990). The blocking of the channels was shown to occur through the
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interaction of p21ras with GAP, by the uncoupling of the heterotrimeric G protein, 
Gj ,^ from its receptor. These experiments propose a role for GAP as a downstream 
effector. Further corrobarative data, comes from mutation studies such as the double 
yeast mutant of ras, Leu68/RASl(term.), which is truncated at residue 185 and thus 
lacks the membrane localisation site. The mutant protein is kept in the GTP bound 
form and is cytosolic in location. The resultant block in ras action induced by the 
double mutant can be overcome by simply increasing the amount of GAP in the cell 
(Gibbs et al., 1989).
However, evidence against GAP having a major effector role has emerged from 
studies where GAP overexpression in cells transformed by v-src and high levels of 
normal ras, caused reversion to a normal phenotype, indicating a solely negative role 
(Zhang et al., 1990; DeClue et al., 1991; Nori et al., 1991).
1.9.2 Regulation of GAP
At the very least, GAP functions as a negative regulator of p21ras. It thus seems 
important to be able to, in turn, regulate GAP. A possible mechanism for such 
regulation, has been proposed by Tsai and colleagues, who have shown that GAP 
activity is blocked by the interaction of lipids and breakdown products such as 
phosphatidic acid, phosphatidylinositol phosphates and arachidonic acid (Tsai et al., 
1989b). The model proposes that activation of tyrosine kinases by mitogenic stimuli, 
which involves phospholipid metabolism, can in turn activate the ras pathway by 
inhibiting GAP activity (Tsai et al., 1989a). A potential problem with this theory, is 
that the concentration of lipids necessary to inhibit GAP are unlikely to represent the 
levels found in vivo. However, another protein which may compete with GAP has 
been shown to interact with certain lipids (Tsai et al., 1990). This so called GTPase 
inhibitory protein, is activated by phospholipids which normally inhibit GAP. 
Phospholipids produced as a result of mitogen stimulation may thus inhibit GAP and
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stimulate the GTPase inhibitory protein, with the overall effect of increasing the 
proportion of ras bound to GTP, and promoting the biological activity of ras.
A number of growth stimulatory receptor and non-receptor tyrosine kinases have been 
shown to phosphorylate GAP (Molloy et al., 1989; Ellis et al., 1990). However, 
tyrosine phosphorylation of GAP does not alter its activity. Instead, the more likely 
outcome of phosphorylation appears to be the formation of heteiomeric complexes 
either directly with the tyrosine kinases (for example the activated PDGF and CSF-1 
receptors) or with other cytoplasmic proteins. Two such proteins p62 and p i90 have 
been shown to associate with GAP (Ellis et al., 1990; Moran et al., 1991). In v-src or 
EGF stimulated fibroblasts, up to half of the cytosolic GAP is found complexed with 
pl90 compared to very little in normal proliferating fibroblasts. Complexes of GAP 
with p62 and pl90 may reduce the capacity of GAP to interact with p21ras, thus 
promoting accumulation of p21-GTP and activation of the pathway. However, the 
alternative explanation cannot be ruled out, that complex formation stabilises an 
active conformation of GAP that functions as an effector for ras signalling.
An additional factor in ras/GAP regulation has come from the isolation of a cDNA 
encoding a 21kDa protein with 50% amino acid homology with p21ras. Rapl A or K- 
revl, was isolated on the basis of its ability to revert a Kirsten sarcoma virus 
transformed NIH3T3 cell (Kitayama et al., 1989; Pizon et al., 1988). The product 
binds to GAP in a strictly GTP-dependent manner, but does not undergo GAP- 
mediated hydolysis (Freeh et al., 1990). If GAP bound to oncogenic p21 elicits a 
response, then K-rev-1 may act to block this effect by sequestering the available GAP 
molecules.
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1.9.3 Isolation of another GAP-like molecule, product of the 
neurofibromatosis gene
The story is further complicated by the isolation of an alternative GAP-like molecule 
the product of the neurofibromatosis 1 (NF1) gene. As previously discussed ( Section 
1.5.2: Tumour Suppressor Genes ), the NF1 locus represents a tumour suppressor 
gene. The NF1 protein shows strong homology to GAP and to the yeast equivalent 
proteins, IRA1 and IRA2 (Buchberg et al., 1990). Furthermore, expression of the 
NF1 homology domain is able to complement the loss of the yeast IRA genes, and is 
able to stimulate GTPase activity of yeast RAS2 and human H-ras proteins. 
However, as in the case of GAP, it is unable to stimulate the GTPase activity of 
oncogenic H-rasva^ '^  and yeast RAS2va ‘^^  mutants (Xu et al., 1990), and is also 
unable to bind to the ras effector mutants. Interestingly, it has a much higher affinity 
for p21ras than GAP ( more than 20-fold), but has a slower turnover ( 30-fold lower 
specific activity ) (Martin et al., 1990). The exact significance of NF1 to ras 
regulation remains uncertain, but the kinetics suggest that NF1 may play a significant 
role particularly at low p21ras concentrations, whereas at high p21ras concentrations 
GAP may be the more critical regulator (Martin et al., 1990).
1.9.4 Guanine nucleotide exchange factors
The rate of exchange of guanine nucleotides from the ras proteins is very slow in the 
presence of physiological concentrations of Mg^+. It therefore seemed necessary for 
the presence of a factor able to accelerate the release of GDP. Such a factor was 
discovered in yeast encoded by the CDC25 gene (Jones et al., 1991), and also in the 
Drosophila system of eye development, encoded by the Sos gene (Simon et al., 1991). 
Similar exchange factors have now been identified in eukaryotes. A 60kDa protein 
has been isolated in cytoplasmic extracts of human placenta (REP for Ras Exchange- 
Promoting) (Downward et al., 1990) and a 100-160kDa factor isolated from rat brain
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cytosol (RAS-GRF) (Wolfman and Macara, 1990). Both have been shown to act 
reversibly, and to promote exchange of GDP for GTP even on ras mutants insensitive 
to the action of GAP. These factors identify what appears to be a common 
mechanism for the control of the ras pathway, acting in opposition to the GTPase 
enhancing activity of GAP and NF1. In the case of the rho proteins, there are two 
types of GDP/GTP exchange proteins, the GDP dissociation stimulator (GDS), 
similar in function to the exchange factors already described (Isomura et al., 1991). 
In addition, there is a GDP dissociation inhibitor (GDI) factor, which inhibits the 
GDP/GTP exchange reaction (Ueda et al., 1990; Fukumoto et al., 1990). The 
interaction of these factors with the rho proteins, may present an additional means of 
regulation, at the level of post-translational modification and membrane localisation. 
GDI forms a cytosolic complex with rho-GDP. An unknown signal may induce 
complex dissociation, and allow the GDS factor to form a rho-GTP membrane 
localised complex. Rho GAP may then catalyse the hydrolysis reaction to a rho-GDP 
bound form, which would then reunite with GDI to stimulate its1 removal from the 
membrane (Isomura et al., 1991). Post-translational modifications of the C-terminus 
of rho have been shown to be important for the membrane localisation and interaction 
with the GDP/GTP exchange proteins, but not with GAP (Hori et al., 1991). Whether 
a similar mechanism exists for the regulation of the mammalian ras proteins remains 
to be seen.
It therefore appears, that regulation of the ras signaling pathway is complex, involving 
the interaction of multiple factors, both stimulatory and inhibitory. These themselves, 
may in turn be regulated by an additional set of molecules.
26
1.10 Studies of lower eukaryotes
A comprehensive understanding of the complexities of the mammalian ras pathway 
may come from studies of lower eukaryotes such as yeast, the nematode worm ( 
Caenorhabditis elegans or C. elegans), and the fruit fly ( Drosophila melanogaster). 
In the yeast, Saccharomyces cerevisiae, the ras proteins, RAS1 and RAS2 regulate 
adenylate cyclase activity and cAMP concentrations ( reviewed by Broach and 
Deschenes, 1990). The concentration of cAMP controls the growth and cycling of the 
yeast cells. Nutritional starvation results in a decrease in cAMP and exit from the cell 
cycle. The link between the nutritional state of the cell and cAMP concentrations, is 
thought to occur through the action of the product of the yeast CDC25 gene. 
Evidence suggests, that the CDC25 product is a guanine nucleotide exchange factor 
for RAS, and is itself regulated by nutrients and metabolites. The yeast RAS genes 
are also negatively regulated by two GAP/NF1 homologues, products of the IRA1 and 
IRA2 genes. The biochemical similarities between the yeast and mammalian 
pathways are marked, considering the evolutionary distance. However, there is no 
evidence that mammalian ras controls cellular levels of cyclic AMP.
Similar biochemical analogies have surfaced from the studies of C. elegans . The 
product of the let60 gene of C.elegans has been shown to be 84% identical in its first 
164 amino acids to other vertebrate and invertebrate ras gene products. The let60 
gene product is necessary for specifying the fate of vulval precursor cells, through a 
signal transduction pathway, during inductive processes in normal development (Han 
and Sternberg, 1990).
Mutations that elevate the expression of let60 activity or extrachromosomal arrays 
containing about 30 copies of wild-type let60 cause a multivulva (Muv) phenotype. 
Whereas recessive partial loss-of-function mutations, that lead to the reduction of 
let60 activity result in an opposite vulvaless (Vul) phenotype. Thus the level of 
expression of the let60 gene is critical for the outcome of cell fate. Dominant 
activating mutations of let60 which result in a Vul phenotype are caused by point
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mutations of codonl3, which results in an amino acid substitution, glycine to glutamic 
acid (Beitel et al., 1990).
The discovery of another C.elegans gene let23 necessary for vulval induction may 
shed some light on the mammalian ras pathway. The product of let23 is a tyrosine 
kinase of the EGF receptor family (Aroian et al., 1990). Let23 functions upstream of 
let60 ras, indicating a link between growth factor receptors and ras.
A similar link between a tyrosine kinase and ras has emerged from studies of a 
Drosophila system. The product of the Drosophila sevenless (sev) gene encodes a 
transmembrane protein tyrosine kinase which has been implicated in the development 
of the Drosophila compound eye (reviwed by Ridley and Hall, 1992b). In the 
absence of functional sev each ommatidia of the eye lacks a particular photoreceptor, 
the R7 cell. It seems that sev functions as a receptor for a signal ( most likely Boss, 
Bride of sevenless ) that determines whether R7 develops into a photoreceptor or non­
neuronal cell. By screening for mutations in genes which decreased the effectiveness 
of signalling by Sev, the gene Sos (Son of sevenless), was isolated (Simon et al.,
1991). Sos is homologous to the yeast CDC25 product and is thought to act as a 
guanine nucleotide exchange factor for Rasl (Peters, 1990). In addition, a Drosophila 
GTPase activating protein, Gapl has been isolated by Gaul and co-workers. Their 
genetic data from loss-of-function mutants, indicates a solely negative role for Gapl 
in the Sev signaling pathway (Gaul et al., 1992). Recently, Rubin and colleagues 
have shown that Boss and Sev null mutants can be rescued by transgenic activated 
Raslva*12 mutants, providing proof that ras activation is a direct result of signal 
transduction from the sev receptor (Fortini et al., 1992).
Hence, from the studies of lower eukaryotes, it may be possible to decipher something 
of the complexities of the mammalian ras signal transduction pathway. In particular, 
it would be useful to learn more about the downstream effectors of ras-mediated 
signal transduction.
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1.11 Ras signalling pathways and cellular transformation
The biological effects of ras on cell growth have been well documented. Both 
proliferative and differentiative cellular responses have been accredited to the effects 
of ras.
Microinjection of ras proteins induces fibroblasts to proliferate, in particular the 
oncogenic form of ras, which elicits dramatic effects on cell morphology, causing 
plasma membrane ruffling, enhancing fluid-phase pinocytosis, and stimulation of 
phospholipase A (Bar Sagi and Feramisco, 1986). However, in rat 
pheochromocytoma (PC12) cells ras induces NGF-like differentiation, altering the 
adrenal chromaffin-like cells into sympathetic neuron-like cells (Bar Sagi and 
Feramisco, 1985).
The biological response to ras-mediated signals, therefore appears to reflect intrinsic 
properties of a specific cell type, which are as yet not fully understood. However, the 
roles for normal ras as an intermediate in signal transduction, and oncogenic ras in 
cellular transformation, are gradually becoming clearer.
The introduction of oncogenic ras into a cell activates gene transcription via AP-1 
transcription factors, of which Fos and Jun are members (Bos et al., 1988; Rauscher et 
al., 1988; Sassone-Corsi et al., 1988; Chui et al., 1988). In addition, it has been 
shown that insulin-induced expression of Fos can be blocked by the introduction of 
ras inhibitory mutants, H-ras(Asn-17) and H-ras(Leu61,Ser-186) (Medema et al.,
1991). Similarly the dominant negative H-ras(Asn-17) mutant can inhibit the effects 
of both v-src and H-ras on c-Jun activity and phosphorylation (Smeal et al., 1992). 
The mechanism for c-Jun induction by Src or Ras is thought to involve disruption of 
the c-Jun:inhibitor interaction which is postulated to operate through the 8 negative 
regulatory region (Baichwal et al., 1991).
29
Together these data advocate a role for ras as an intermediate in a growth factor- 
induced signalling cascade. Fos and Jun appear likely candidate transription factors, 
able to convert signals from growth factors and transforming oncoproteins into 
changes in gene expression.
Differentiation of neuronal PC 12 cells can be induced by the treatment with nerve 
growth factor (NGF), which results in the tyrosine phosphorylation of multiple 
cellular proteins. These proteins have now been identified as serine/threonine or 
tyrosine kinases which function as part of a mitogen stimulated protein 
phosphorylation cascade (Thomas et al., 1992; Wood et al., 1992).
In a recent paper, the serine/threonine kinase encoded by the c-Raf-1 gene has been 
shown to be an upstream activator of the serine/threonine kinase MAP kinase-kinase, 
MAPK-K (Kyriakis et al., 1992). This protein kinase in turn tyrosine phosphorylates 
and activates MAP kinase, which is thought to exert its effect through stimulation of 
c-Jun activity. While oncogenic H-ras is a constitutive stimulator of c-Jun activity 
and phosphorylation, normal H-ras is a serum dependent modulator of Jun activity 
(Smeal et al., 1992).
In addition to the kinase-cascade pathway, there appears to be a protein kinase C 
(PKC)-dependent pathway. The end-point of which, once again appears to be through 
the modulation of transcription factors such as Fos and Jun. The exact mechanism 
through which ras activates PKC is still unclear, but may be a result of enhanced 
phospholipid turnover ( reviewed by Marshall, 1991a).
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A further component of signalling pathways from activated receptors has been 
recently reported by Pelicci and colleagues (Pelicci et al., 1992). SHC proteins bind 
to activated EGF receptors with high affinity in vitro. The highly conserved SHC 
gene encodes at least two different protein products. Both contain a single SH-2 
domain but differ in their N-termini. They are hypothesised to act as intermediates, 
possibly binding to downstream effectors with their alternative N-terminal domains. 
Interestingly, overexpression of the SHC gene in NIH3T3 cells leads to 
morphological transformation and tumour formation in nude mice, suggesting an 
oncogenic role in signal transduction.
In conclusion, cellular transformation by activated ras appears to act through PKC- 
dependent and PKC-independent pathways, which terminate in an alteration of the 
cellular transcription program.
1.12 Prevalence of ras mutations
The products of the H-ras, K-ras and N-ras genes are expressed in almost every 
human fetal and adult tissue (Furth et al., 1987). In some cell lineages, immature 
cells express more p21ras than mature cells. However, in some fully differentiated 
cells, such as neurons and epithelial cells of the endocrine glands, p21ras is expressed 
in abundant amounts.
In human tumours, the ras mutations observed include those of codon 12, 13 and 61 
(Parada et al., 1982; Bos et al., 1985) (for a review Bos, 1989). The overall incidence 
of ras mutations in human tumours is estimated to be about 10-15% (Barbacid, 1987). 
The incidence of K-ras mutations is high in colon adenocarcinomas 40-50%, and in 
lung adenocarcinomas 20-30%, while almost all pancreatic adenocarcinomas harbour 
K-ras mutations (Bos et al., 1987). In some cases, the frequency of ras mutations in a 
particular tissue, correlates with the level of expression of the ras gene, for example in 
the colon and pancreas. There are exceptions, such as in lung and liver where the
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level of expression of the ras genes is very weak yet the incidence of mutations is 
relatively high (Leon et al., 1987).
1.13 Timing of ras activation
The causal nature of ras activation in tumorigenesis is best demonstrated by studies of 
transgenic animals. Mice carrying the ras oncogene under the control of tissue 
specific promoters show a correlation in tissue expression and tumour formation (Sinn 
et al., 1987). However, in many cases, oncogene expression precedes tumour 
formation by several months, for example MMTV LTR-ras showed a latency period 
of 1-6 months (Sinn et al., 1987; Groner et al., 1987). These observations suggest that 
oncogene expression is necessary, but not in itself sufficient to generate tumours.
The incidence of ras mutations at different stages of human malignancy has been 
investigated by Lemoine and co-workers. They found that the frequency of ras 
activation in human thyroid tumours was similar at all stages: benign microfollicular 
tumours (50%), differentiated follicular carcinomas (53%), and undifferentiated 
follicular carcinomas (60%), with all three ras genes displaying mutations (Lemoine 
et al., 1989). This data demonstrates the presence of ras mutations in benign lesions, 
establishing ras activation as an early step in tumorigenesis.
Similarly, ras mutations have been identified in benign lesions such as 
keratocanthomas of the skin (Leon et al., 1988) and adenomatous polyps of the colon 
(Bos et al., 1987; Forrester et al., 1987).
However, tumour heterogeneity in human seminoma implys that at least in this 
system ras activation is not the initiating event (Mulder et al., 1989). In addition, in 
the case of acute myeloid leukemia (AML), N-ras mutations are considered to occur 
at a late stage of progression (Farr et al., 1988).
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1.14 Animal models
Tumours can be induced in animals either by the inbreeding of laboratory strains 
susceptible to spontaneous tumour development, or more commonly through the 
treatment of animals with carcinogenic agents. The development of animal model 
systems for the study of tumorigenesis, offers the experimentor a more controlled and 
reproducible environment, than for instance, the analysis of human tumours.
Such model systems for the study of tumour induction and progression, include the 
rodent mammary model system. Mammary carcinomas develop in 90% of the 
animals, with a latency period of about 6-12 months after a single dose with the 
alkylating agent N-nitrosomethylurea (NMU) (Derynck et al., 1986).
In contrast, lymphomas of the thymus can be induced with intraperitoneal injections 
of NMU after a latency period of about 3 months. Gamma irradiation of mice also 
results in thymic lymphomas but with a longer latency period, of about 6 months 
(Guerrero et al., 1986). The spectrum of ras mutations are different depending on the 
treatment used, with activation of N-ras occurring after NMU exposure (Guerrero et 
al., 1985), whereas K-ras mutations are more prevalent after radiation treatment 
(Guerrero et al., 1984; Guerrero and Pellicer, 1987). Additional genetic factors are 
clearly important, with differences in tumour yield occurring between different mouse 
strains. For example, the mouse strain 129/J develops a high incidence of tumours 
after NMU treatment but a low yield after whole body radiation (Meruelo et al., 
1981). The precise reason for these differences remain unclear.
Studies of tumours of the central and peripheral nervous system have been aided by 
the observation that a single dose of the alkylating agent ethylnitrosourea (ENU), 
between 15 days of gestation and 10 days post-partum, develop neuroectodermal 
tumours with a high incidence 4-10 months later (Rajewski et al., 1979).
However, the model system that shall be discussed in the context of this thesis is the 
mouse-skin model system. It provides an organ which is accessible to treatment, and 
easily monitored for the development of tumours.
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1.15 The mouse-skin carcinogenesis model
1.15.1 Introduction
The two-stage protocol for the mouse-skin model system, involves the treatment of 
mouse skin with initiating and promoting agents. The initiation step is considered 
irreversible because initiated cells can remain dormant in the skin, capable of 
activation by promoter application for up to one year (Van Duuren et al., 1975). This 
is followed by a reversible promotion stage, involving multiple applications of a 
tumour-promoting compound. After several weeks the formation of benign 
papillomas develop, some of which (10-20%) progress to form carcinomas.
The complete carcinogenesis protocol on the other hand, involves a large single dose 
of carcinogen, or multiple small doses of an initiator such as DMBA. This results in 
fewer papillomas but more carcinomas.
1.15.2 Mechanisms of initiation
The observation that the initiating chemical used correlated with the type of mutation 
formed, supported the proposal by Barbacid and co-workers (Zarbl et al., 1985b; 
Zarbl et al., 1985a), that the carcinogen interacts directly with the DNA to create a 
genetic mutation.
In studies of skin carcinogenesis with DMBA as the initiator, over 90% of papillomas 
that developed after promotion with TPA displayed the same A -> T transversion 
mutation at codon 61 of the H-ras gene (Quintanilla et al., 1986). The same mutation 
was not observed when MNNG was used as the initiating chemical (Quintanilla et al.,
1986).
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The notion that a genetic mutation of the H-ras gene could act as an initiating event in 
mouse skin tumorigenesis was substantiated by experiments in our laboratory. It was 
shown that viral ras genes could substitute for the chemical initiation stage of mouse 
skin carcinogenesis. When Harvey- or Balb-murine sarcoma viruses were applied to 
mouse skin, followed by treatment with TPA, papillomas developed after 4-5 weeks, 
some of which progressed to form carcinomas (Brown et al., 1986).
In addition, transgenic mice expressing mutant H-ras from a suprabasal-specific 
keratin 10 promoter, develop generalised hyperkeratosis of the skin and forestomach. 
Animals that survived to the age of 7-8 weeks developed highly differentiated 
papillomas at sites of wounding (Bailleul et al., 1990). This data has since been 
corroborated by Leder and colleagues using a similar transgenic model (Leder et al., 
1990). A transgenic line carrying a fusion gene, consisting of an embryonic globin 
promoter linked to the activated v-H-ras oncogene, developed papillomas at sites of 
skin abrasion. In addition, more than 90% of the mice developed papillomas within 6 
weeks of application of phorbol 12-myristate 13-acetate ( PMA ).
1.15.3 Mechanisms Of Tumour Promotion
1.15.3.1 The Role Of TGF-p
In its most simplistic form, promotion can be viewed as selection for an initiated cell 
amongst the background of normal cells. This "clonal selection" hypothesis has 
gained credibility from the study of growth factors TGF-a and in particular TGF-p. 
These factors are released from platelets (Wakefield et al., 1988), produced by 
keratinocytes upon wounding (seen as a promotional stimulus), and after treatment of 
the skin with tumour promoters such as TPA (Akhurst et al., 1988; Pittelkow et al.,
1989). TGF-a is thought to provide a mitogenic stimulus to epithelial cells, while 
TGF-p has been shown to inhibit keratinocyte proliferation in vitro (Furstenberger et 
al., 1989a; Coffey et al., 1988).
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We (Haddow et al., 1991) and others (Glick et al., 1991), have shown that epidermal 
cells which harbour mutant H-ras genes can still respond to the negative effects of 
TGF-p. These data present an apparent paradox, in that the growth of "initiated cells" 
can still be down-regulated in vitro by TGF-p. A possible explanation has come from 
in situ hybridisation data, and immunocytochemical staining of skin tumours. While 
both benign and malignant tumours produced high levels of TGF-p mRNA, only low 
levels of protein could be detected. Early tumours may therefore evade the negative 
effects of TGF-P by altered translational or post-translational processing of the newly- 
synthesised factor (Haddow et al., 1991).
There is evidence to suggest that TGF-P mediates its inhibitory effect on cell 
proliferation through c-myc expression (Pietenpol et al., 1990a). The block in c-myc 
expression occurs at the level of transcriptional initiation and is thought to be 
mediated by the product of the retinoblastoma gene, pRB (Pietenpol et al., 1990b). 
Intrestingly, a retinoblastoma cell line that was resistant to the negative effects of 
TGF-p was shown to have lost TGF-p receptors from the cell surface (Kimchi et al., 
1988).
1.15.3.2 TPA and PKC
Phorbol esters such as TPA, may also exert an effect on gene expression through the 
modulation of the PKC subspecies.
The functions of the various PKC proteins are diverse. They appear to have dual 
functions, both positive, in the control of gene expression such as induction of the 
interleukin-2 receptor and some proto-oncogenes, and negative such as in the control 
of cell proliferation (Nishizuka, 1986).
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TPA stimulates PKC activity it is thought by masquerading as a diacylglycerol-like 
molecule, the normal activator of PKC. TPA, as well as activating PKC, also 
degrades the protein, and it has been suggested that removal of PKC from the cell 
may relieve the negative control on cell proliferation, leading to uncontrolled cell 
growth (Nishizuka, 1988).
TPA has been shown to induce c-jun expression (Lamph et al., 1988), and most 
recently it has been reported that phorbol esters can enhance the trans-activation 
potential of c-Jun by phosphorylation of residues 63 and 73 (Franklin et al., 1992). 
Indirect evidence that TPA may stimulate cell proliferation through the ras kinase 
signalling cascade, comes from the observation that antigen stimulation of the T cell 
receptor results in the hyperphosphorylation of c-raf via the serine/threonine kinase 
PKC (Siegel et al., 1990).
1.15.3.3 TPA and genetic damage
An alternative aspect to tumour promotion, is the role of TPA in the creation of DNA 
damage (Furstenberger et al., 1989b). TPA can induce sister chromatid exchanges in 
hamster fibroblasts (Kinsella and Radman, 1978). It is also capable of creating DNA 
single strand breaks in human leukocytes (Bimboim, 1982), and in mouse 
keratinocytes (Hartley et al., 1985).
TPA, but not the second stage promoter RPA, has also been shown to contribute to 
the aneuploid state of the cell, with the appearance of double minutes being a 
common feature. These structural aberrations are described as non-random with 
mouse chromosomes 1, 2, 5, 6, and 18 displaying a preference for genetic alterations 
(Petrusevska et al., 1988).
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In summary, it appears that the mechanisms of tumour promotion with chemicals such 
as TPA appear multi-faceted. Clonal selection of an initiated cell from the inhibitory 
environment of normal cells may be fulfilled through the action of growth factors 
such as TGF-P or alterations in cellular signalling through a PKC-dependent pathway. 
Genetic damage may also contribute to the outgrowth of papillomas possibly by the 
loss of tumour suppressor genes which control cell growth or genes which control 
genomic stability.
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1.16 Genetic changes associated with mouse-skin tumour 
progression
1.16.1 Allelic imbalance of mouse chromosome 7 is a frequent event in 
mouse-skin tumorigenesis
Although animal model systems have been used to study oncogene activation in 
chemical carcinogenesis (reviewed by Barbacid, 1987; Balmain and Brown, 1988; 
Guerrero and Pellicer, 1987), loss of heterozygosity studies have been hindered by the 
lack of informative polymorphisms in inbred mouse strains. Loss of heterozygosity 
(LOH), at a particular chromosomal locus in a tumour suggests the presence of a 
tumour suppressor gene. However, it may also be that the primary lesion is an 
activating mutation which is unmasked by loss of the corresponding normal allele. 
LOH studies in human tumours have been successfully used to map and clone several 
tumour supprressor genes.
We have previously described an experimental approach to overcome the lack of 
informative restriction length polymorphisms (RFLPs) present in the inbred 
laboratory mouse strain. By crossing different inbred strains, and generating tumours 
in FI hybrids, it has been possible to study genetic events, other than activation of 
oncogenes, that take place in mouse skin tumour progression.
Through the study of such tumours it has been possible to provide the first 
demonstration of mitotic recombination and non-disjunction in mouse tumours 
(Bremner and Balmain, 1990). Initial data indicated that imbalances between parental 
alleles on mouse chromosome 7 arose at high frequency only in tumours carrying 
activated H-ras. Most frequently this occurred by non-disjunction, but in certain 
cases the mechanism was best explained by a mitotic recombination event. Since H- 
ras resides on chromosome 7, it was thought that these gross-chromosomal events 
provided a mechanism by which mutant H-ras was duplicated and/or the normal allele 
lost. Further experiments, using the more informative hybrids between outbred Mus
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spretus and inbred Mus muse ulus, have provided more conclusive data on these 
mouse chromosome 7 imbalances. An Xbal RFLP enables the parental spretus and 
musculus, normal and mutant alleles to be distinguished.
Even in early papillomas it has been shown that the chromosome carrying the mutant 
allele was over-represented in the form of a trisomy of chromosome 7. However, 
under no circumstances was the normal H-ras allele duplicated (Bremner and 
Balmain, 1990). These results, together with the expression data on the levels of the 
normal and mutant alleles ( Jandrig, Haddow, Bremner and Balmain, in preparation), 
indicate that over-representation of the mutant H-ras is a frequent and apparently 
crucial event in mouse skin tumorigenesis.
The underlying impetus for loss of normal and/or duplication of mutant alleles 
implied that there may be some form of tumour suppressor role for the normal H-ras 
gene. Only by loss or under-representation of the normal allele would the malignant 
phenotype induced by the mutant gene manifest itself.
1.16.2 A role for normal ras as a tumour suppressor gene
The question of whether mutant ras acts in a dominant or a recessive fashion in 
tumorigenesis has been considered in the past (Guerrero et al., 1985). Examples of 
loss of the normal allele have been reported by other groups. Human mammary 
carcinoma cell lines that possess the H-ras codon 12 mutation in some cases also 
show the loss or under-representation of the normal allele (Kraus et al., 1984).
This has been demonstrated not only in cell lines but also in primary tumours. In 
murine thymic lymphomas, reduction or loss of normal K-ras and N-ras alleles have 
been reported (Diamond et al., 1988; Guerrero et al., 1985).
This suggests that the mutant gene is co-dominant or even recessive in nature. 
However, what of the in vitro models of ras fibroblast transformation which indicated 
a dominant role for ras ? These experiments may be misleading since they either 
required a complementing oncogene (Land et al., 1983), or very high levels of
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expression (Spandidos and Wilkie, 1984). In addition, there may be inherent 
differences between fibroblasts and epithelial keratinocytes in their response to 
alterations in ras gene dosage.
However, despite the quantity of data on loss of heterozygosity on mouse 
chromosome 7, the co-incident loss of a putative gene closely linked to H-ras cannot 
be eliminated.
1.16.3 Evidence for another locus on mouse chromosome 7
Data from our group that may support the involvement of another locus on mouse 
chromosome 7, has come from the analysis of a primary carcinoma, SN158 ( and a 
lymph node metastasis from the same mouse). Tumour SN158 showed loss of 
heterozygosity for markers distal to H-ras while maintaining heterozygosity at the ras 
locus and for proximal markers. The most likely explanation for the observed allele 
ratios was a mitotic recombination of a region distal to H-ras (Bremner and Balmain, 
1990). This region may therefore harbour a putative tumour suppressor gene. In 
agreement with this concept, are studies of human chromosome 1 1  which contains the 
syntenic region of mouse chromosome 7, including the H-ras locus. Loss of alleles at 
l lp l5  is a common genetic feature in many human tumour types (Mannens et al., 
1988; Koufos et al., 1984; Riou et al., 1988; Mackay et al., 1988).
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As well as loss of syntenic regions on human 11, the l lq l3  region has been shown to 
be amplified in a number of different human cancers, including breast, squamous cell 
and bladder carcinomas (Ali et al., 1987; Lammie et al., 1991; Berenson et al., 1989)( 
reviewed by Lammie and Peters, 1991). The candidate genes for this region include 
INT2, HSTF1 (hst-1), BCL1 and PRAD1 (D11S287). Both HSTF1 and INT2 have 
been implicated in tumorigenesis. INT2 is one of the most frequent targets for 
transcriptional activation by MMTV (Nusse, 1986), whilst HSTF1 originally 
identified in assays of human tumour cell DNA can also be activated by the 
integration of MMTV (Peters et al., 1989). The co-amplification of HSTF1 and INT2 
in about 15% of breast cancers and about 50% of esophageal carcinomas (Tsuda et 
al., 1989) clearly indicates the pathogenic importance of this region in a number of 
different human cancers. However, whereas amplification of these genes does not 
result in detectable transcripts, the closely linked PRAD1 gene shows elevated 
expression in neoplastic mammmary tissue as compared to normal.
Interestingly, there is also a candidate suppressor gene, MEN1 that has been mapped 
to llq l3 . This gene has been implicated in the rare autosomal dominant condition, 
familial MEN1 or Wermer syndrome (Larsson et al., 1988).
Thus several candidate genes residing on regions syntenic to the H-ras locus of mouse 
chromosome 7, have been identified in human malignancies. Whether these genes 
play a role in mouse skin tumorigenesis remains to be seen.
1.16.4 Other genetic changes associated with tumour progression
Through the use of hybrid mice and highly polymorphic microsatellite sequences, 
which can be distinguished by the polymerase chain reaction (PCR), we have 
accumulated LOH data on several mouse chromosomes. These studies have 
confirmed the previously reported chromosome 7 changes (Bremner and Balmain, 
1990), and in addition have shown LOH on mouse chromosomes 11, 6  and at lower 
frequencies on 1 and 4 (C.Kemp and F.Fee, unpublished results). Alterations on 6
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and 7  have been seen in both benign and malignant tumours, whereas changes on 
chromosomes 11, 4, and 1 are only detected in carcinomas. The important gene on 
chromosome 11 is thought to be the p53 tumour suppressor gene. Candidate genes on 
the other chromosomes are as yet unknown.
1.17 Progression of squamous to spindle cell carcinomas
1.17.1 Spindle cell carcinomas represent a distinct entity
Mouse skin tumorigenesis thus appears to occur through a series of discrete steps 
associated with specific genetic alterations, from an initiated cell, to a benign 
papilloma, and subsequently to a fully malignant carcinoma. It now seems that this 
final carcinoma stage can be categorised into two distinct histological entities. This 
sub-division is between a well-differentiated form of carcinoma, termed the squamous 
cell carcinoma, and a much less differentiated form, the spindle cell carcinoma. 
Spindle cell carcinomas have been characterised in human tumours for many years 
(Evans and Smith, 1980). However, the origin of these tumour cells have been the 
subject of much controversy. Some pathologists have classified the tumours as 
epidermal in origin, whereas others believe they are derived from fibroblasts 
(Battifora, 1976).
In humans, spindle cell carcinomas are found as rare components of cancers mostly of 
the oral cavity and upper aero-digestive tract. Clinicians define the tumours as 
biphasic, with a carcinomatous and a sarcomatous component. Spindle metaplasia 
has also been identified in neoplastic tissue of the lung (Matsui and Kitagawa, 1991), 
breast (Kaufman et al., 1983) and the uterine cervix (Steeper et al., 1983).
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1.17.2 Spindle cells show loss of differentiation markers
Intermediate filaments are cytoskeletal components of cells expressed in a tissue 
specific fashion. Epithelial cells normally express keratins, whereas mesenchymal 
cells express vimentin. In epithelial cells, it has been suggested that vimentin 
expression correlates with reduced cell-to-cell contact, which may reflect a reversion 
to a more embryonic pattern. It has been shown that during embryogenesis cells that 
express vimentin intermediate filaments can be derived from keratin-positive cells 
which apparendy switch off keratin intermediate filament expression (Franke et al., 
1981).
Studies on tumours induced in vivo have demonstrated changes in the cytokeratin 
specific differentiation markers (Klein-Szanto et al., 1983; Roop et al., 1988). 
Cytokeratins (CK) 8  and 18 are the pair of keratins associated with simple epithelia, 
and early stages of embryogenesis. CK 8  and 18 are not found in adult epidermis but 
have been shown to be reexpressed in human skin carcinomas, SV40-transformed 
human epidermal keratinocytes (Hronis et al., 1984), and in mouse keratinocytes 
transfected with oncogenic H-ras (Diaz-Guerra et al., 1992).
Studies by our group have shown a similar loss of differentiation markers in a number 
of mouse spindle cell lines. The highly malignant carB spindle cell line fails to 
express any keratins and the cell adhesion protein, E-cadherin. However, other 
spindle cell lines A5 and D3, still express keratins but stain negatively for E-cadherin 
( Stoler, Steinback and Balmain, submitted). This suggests that A5 and D3 represent 
an earlier stage of the spindle phenotype, and that E-cadherin may be lost before the 
keratin filament network is disrupted.
Although vimentin and keratin expression provide markers for the spindle cell 
phenotype, they in themselves do not give rise to the spindle phenotype (Sommers et 
al., 1992), with reexpression of E-cadherin in the spindle cell line, carB, producing no 
obvious morphological change (A.Cano, unpublished data).
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1.17.3 A role for H-ras in the squamous to spindle conversion
Analysis of mouse skin tumours containing both differentiated and spindle cell parts, 
both components carried the same H-ras codon 61 mutation. However, the spindle 
component had a much higher mutantrnormal H-ras gene dosage ratio. This 
correlation was obtained from PCR amplification using H-ras amplimers of material 
derived from paraffin sections of carcinomas of defined histological types (Buchmann 
et al., 1991). In addition, over the past few years we have isolated several cell lines 
from tumours at differrent stages of progression. Recently, we have been fortunate 
enough to obtain cell lines, representing both the squamous and spindle components 
from a single primary tumour, MSC11. Preliminary analysis of these cell lines, 
provided further correlative data for a role for H-ras in the squamous to spindle 
conversion ( Data presented in Chapter 3 of the Results Section). Figure 1 provides a 
schematic overview of the genetic changes associated with the various stages of 
mouse-skin tumorigenesis, from H-ras activation in the initiated cell, through trisomy 
of chromosomes 6  and 7 in papillomas to mutational inactivation of p53 in the well 
differentiated squamous form of carcinomas. Finally as discussed, there is the 
transition to a undifferentiated spindle cell carcinoma, with the as indicated 
involvement of H-ras and possibly other loci. It is the investigation of this late stage 
of tumour progression that forms a large body of the work covered in this thesis. 
However, as will become clearer, we are also interested in the involvement of H-ras 
in the earlier stages of tumour development, symbolised by the consistent trisomy of 
mouse chromosome 7.
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1.18 Experimental approaches to investigating the role of H-ras 
in mouse skin tumorigenesis
This thesis outlines two alternative approaches to investigating the function of H-ras 
in mouse skin carcinogenesis.
The first is an in vitro approach: to investigate the effect on cell growth, morphology 
and tumorigenicity, of altering the gene dosage ratio of mutant:normal H-ras in 
specific mouse tumour cell lines.
The second approach involves an in vivo study of H-ras function. The ultimate aim of 
this approach is to create a mouse hemizygous for normal ras through the technique of 
gene targeting. This mouse can then be treated with carcinogens to examine the 
effect on tumour development of having only one functional copy of the normal H-ras 
gene.
1.18.1 The in vitro approach
To study the function of H-ras in mouse skin tumorigenesis it was decided to 
experimentally manipulate the levels of normal and mutant ras in specific cell lines. 
The cell lines that were chosen represent the transition event seen in mouse skin 
carcinomas, from a well differentiated squamous cell carcinoma to an undifferentiated 
spindle cell carcinoma.
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Single cell clones representing both phenotypes were derived from a carcinoma, 
MS Cl 1, that had both squamous and spindle components ( refer to Results section for 
more details ). Genetic analysis of these cell lines revealed the same H-ras codon 61 
mutation and the same p53 mutations independent of cellular morphology. These 
observations together demonstrated that the spindle carcinoma had developed from 
the squamous cell carcinoma, whilst indicating that additional genetic alterations were 
responsible for the transition event. However, the levels of mutant H-ras were 
substantially different between the squamous and spindle cell lines. There was at 
least a 5-fold increase of mutant H-ras in the spindle cell line (see the Results section 
for a more detailed account).
The obvious question that arose from these observations was what was the role for H- 
ras in this conversion event ? Were alterations in H-ras gene dosage levels alone 
sufficient for the conversion event, or was another locus involved ? In addition, was 
the increase in mutant H-ras necessary to overcome a suppressor function of the 
normal gene, or was it more directly related to increasing the tumorigenicity of the 
cells ?
It was hoped, that by altering the levels of mutant and normal H-ras in these clonally 
derived cell lines, we would be able to elucidate a role for H-ras in the distinct 
transition event, from a well differentiated carcinoma to a undifferentiated more 
aggressive form.
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1.18.2 The in vivo approach
The in vivo approach to investigating the function of H-ras involves creating a mouse 
that has only one functional H-ras allele in every cell. This can be acheived through 
the technique of gene targeting. By utilising the mechanism of homologous 
recombination in pluripotent embryo-derived stem (ES) cells, it is possible to 
introduce finite mutations into a specific genomic locus. The mutations most 
commonly take the form of an inactivating, or "knock-out" mutation, which render 
the gene of interest functionally obsolete.
ES cells are derived from the inner cell mass of a mouse blastocyst. It is possible to 
maintain the ES cells in a pluripotent state in culture, either by growing the cells on a 
feeder layer, or by addition of a growth factor termed LIF (Leukemia Inhibitory 
Factor) or DIA (Differentiation-Inhibiting Activity )(Smith and Hooper, 1987; 
Lindsay Williams et al., 1988).
The mutated ES cells can then be reintroduced into a mouse blastocyst, which is then 
implanted into a pseudo-pregnant mouse. The ES cells colonise the developing 
embryo resulting in a chimaeric mouse ( for a shematic outline of the gene targeting 
approach see Figure 2 ).
It is therefore possible, to go from in vitro manipulation and mutation of ES cells, to 
the introduction of the desired mutation into the somatic cells, and in some cases the 
germline component of a developing mouse ( reviewed by Robertson, 1986).
In this way, it has been possible to study the function of many different genes ranging 
from oncogenes, tumour suppressor genes, as well as genes controlling mouse 
embryogenesis.
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To study the function of the H-ras gene in mouse-skin tumorigenesis, it was proposed 
to "knock-out" the H-ras gene, so that it would no longer be functional. Creating a 
mouse that possessed only one copy or no copies of H-ras should enable a functional 
analysis of the gene, both in embryogenesis, and in mouse-skin carcinogenesis 
studies. By treating a hemizygous or homozygous null mouse with chemical 
carcinogens, it should be possible to determine the role of H-ras in the early stages of 
tumour progression, in particular the proposed tumour suppressor role assigned to ras. 
If normal H-ras can suppress one copy of the mutant in the case of an initiated cell, 
then a hemizygous mouse that is initiated with DMBA would in theory have no 
functional H-ras to suppress tumour development, and thus should be more 
susceptible to tumorigenesis.
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1.19 Gene targeting by homologous recombination in mouse 
embryonic stem cells
1.19.1 The mechanism of homologous recombination
Little is understood of the exact mechanism of homologous recombination. It is 
thought to occur by the Holliday model of recombination (Holliday, 1964). The 
model outlines a mechanism for reciprocal strand exchange between gapped duplex 
DNA and homologous linear duplex DNA, provided the linear DNA has an end 
complementary to the single-stranded DNA in the gap (West et al., 1982). Strand 
exchange then initiates at the single-stranded region of the gap and proceeds 5' to 3* 
by a process termed branch migration. Resolution of the recombination structures is 
thought to occur by specific endonucleolytic cleavage. The RecA protein has been 
shown to be important in promoting strand exchange in Escherichia coli, while T4 
endonuclease VII isolated from the bacteriophage T4 cleaves Holliday junctions in 
vitro (Muller et al., 1990).
Gene targeting was first observed in mammalian fibroblast cells by Lin and 
colleagues in an artificial locus (Lin et al., 1985), and was subsequently demonstrated 
to occur at the endogenous p-globin gene by Smithies and colleagues (Smithies et al., 
1985).
The homologous recombination events occur fairly rapidly after DNA transfection. 
In the case of two co-introduced plasmids, recombination was detectable within a 1- 
hour interval after the introduction of the plasmid DNAs into the cell nucleus (Folger 
et al., 1985). In the case of homologous recombination between transferred and 
chromosomal DNA, recombinants were detectable 2 days after transfer (Shulman et 
al., 1990).
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1.19.2 The frequency of gene targeting
In general, the frequencies of gene targeting are relatively low in mammalian cells, in 
part, due to the competing pathway of random integration.
Random integration of the targeting vector occurs much more readily than the desired 
homologous recombination event. It is thus necessary to incorporate mechanisms in 
the vector design to overcome this bias. These will be discussed in more detail in the 
next section and in the Results section.
Factors that affect the frequency of homologous recombination are many and varied. 
Early experiments showed that restriction endonuclease cut, linear molecules offered 
better substrates for homologous recombination (Lin et al., 1984; Wake et al., 1982). 
The frequency of recombination has been shown to increase linearly with the length 
of homology (Thomas and Capecchi, 1987; Shulman et al., 1990), with a two-fold 
increase in homology enhancing the targeting frequencies 20-fold or 4-fold, 
respectively.
Transcription has also been included as a factor that may effect the frequency of 
homologous recombination. Dexamethasone-induced transcription has been shown to 
stimulate recombination 6 -fold over the non-induced levels (Nickoloff and Reynolds, 
1990). This data refers to homologous recombination between plasmid vectors 
introduced into Chinese hamster ovary cells by electroporation. These findings are in 
direct contrast to the observation that genes such as adipsin and aP2 which are both 
transcriptionally inactive in ES cells, were none the less readily disrupted by 
homologous recombination (Johnson et al., 1989). It now appears, that efficient 
transcription of a gene, is not a prerequisite for it's successful disruption by 
homologous recombination.
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Most recently Bems and colleagues, have reported a 20-fold increase in targeting 
frequencies at the Rb locus, by utilising isogenic DNA (te Riele et al., 1992). 
Ensuring that the recipient ES cells are of the same strain as the vector DNA 
presumably minimises possible mismatches that may occur through strainal 
divergence.
Factors such as length of homology, length of heterology, the site of linearisation and 
the source of vector DNA may all play a role in determining the frequency of gene 
targeting. However, the precise determinants of efficient homologous recombination 
are still unclear. Careful consideration to the design of the targeting vector is thus 
critical.
1.19.3 Targeting vectors: design and alternative strategies
A targeting vector is designed to recombine and mutate a specific chromosomal locus. 
The minimal components of such a vector are homologous sequences and a plasmid 
backbone. However, since the transfection and targeting frequencies can be quite 
low, it is desirable to incorporate various selection and enrichment schemes into the 
design of such a vector.
The use of a positive marker such as the neomycin resistance gene, allows for 
selection of those cells that receive the plasmid vector during the transfection 
procedure. The marker gene can also act as a mutagen, for instance, if it is cloned 
into, or replaces coding exons of the gene of interest.
There are two basic designs of targeting vector, the replacement vector, and the 
insertion vector. They differ in the site of linearisation and consequently the 
mechanism of integration.
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The replacement vector is linearised in the plasmid backbone, and integrates into the 
genome by a double cross-over event. The insertion vector, on the other hand, is 
linearised in the region of homology, and as a result integrates by a single cross-over 
event ( Figure 3 ). In order to enrich for homologous recombinants, as opposed to 
random integrants, certain features can be included in the construction of the vector. 
For instance, removing the promoter or polyadenylation sequences from the vector 
DNA (Schwartzberg et al., 1990; Charron et al., 1990). In theory, only when properly 
incorporated into the desired locus, should the positive marker gene be expressed and 
consequently give a selectable phenotype.
The more commonly employed system to enriching for homologous recombinants is 
to use a negatively selectable marker. This usually takes the form of the viral Herpes 
simplex thymidine kinase (HSVtk) gene. Homologous recombination results in loss 
of the gene from the ends of the vector DNA. However, random integration of the 
construct, should result in stable incorporation of the HSVtk gene, thus enabling these 
cells to be killed using the drug Gangcyclovir ( Figure 4 ) (Capecchi, 1989; Thomas et 
al., 1986; Mansour et al., 1988).
The vectors so far described generally result in the insertion of a positive marker gene 
into the locus of interest very often as an inactivating mutational event. This results 
in a disruption (over lkb in length) of the endogenous locus. Such a rearrangement of 
the normal locus may complicate the interpretation of any observed phenotypes. 
Inorder to create more subtle mutations in the mouse genome, Bradley and co­
workers have pioneered a strategy termed the "hit and run" approach (Hasty et al., 
1991c). Hit and run vectors are modified insertion vectors that possess a mutation in 
the homologous sequences. They contain both a positive and a negative selection 
cassette situated in the plasmid backbone.
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The vector is first positively selected to encourage an insertion event, and then 
negatively selected (for example with gancyclovir) for a intrachromosomal "loop-out" 
event. The end result is reformation of the endogenous locus with the exception of 
the engineered subtle mutation ( Figure 39 ). This technique has been successfully 
used to generate a point mutation in the mouse homeobox Hox 2.6 gene (Hasty et al., 
1991b).
1.19.4 Phenotypes and the case for redundancy
The various strategies outlined above have been employed to successfully target a 
variety of genes. In a number of cases the inactivation of a gene has resulted in an 
anticipated phenotype. This is the case for the c-abl knock-out mice, c-abl shows 
highest expression in the thymus and spleen and was thought to play a role in 
lymphopoiesis or haematopoiesis. It was also known that activated c-abl was 
associated with tumours of the haematopoietic system. Homozygote c-abl"/c-abr 
mice became runted and died 1-2 weeks after birth. Autopsy showed thymic and 
spleen atrophy and T and B cell lymphopenia (Tybulevicz et al., 1991; Schwartzberg 
et al., 1991).
Similar expected phenotypes have been reported for the cystic fibrosis gene knock­
outs, which mimic several features of the human condition, in particular altered 
chlorine ion transport (Dorin et al., 1992).
In addition, mice homozygous for the null p53 allele develop normally but are 
susceptible to the spontaneous development of a variety of neoplasms by 6  months of 
age (Donehower et al., 1992). This phenotype correlates with the tumour suppressor 
role allocated to the p53 gene.
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However, not all null mice display the predicted phenotypes, and indeed in some 
cases, there are no observable changes what so ever. This is the case for the HPRT 
(hypoxanthine-guanine phosphoribosyltransferase) knock-out mouse, which although 
possesses no functional enzyme, fails to display the characteristic neurological 
phenotype of the human condition, Lesch-Nyhan deficiency syndrome. The mice are 
completely viable and die of old age (Hooper et al., 1987)(A.Clarke, personal 
communication).
A similar story is apparent for the mouse homologue of the Drosophila engrailed 
gene, En-2. Despite being essential for Drosophila embryonic segmentation and 
development, mice deficient for the En-2 gene showed no obvious defects in 
embryonic development, but instead show a subtle phenotype in the adult cerebellum. 
This is explained by the authors as functional redundancy with the related En-1 gene 
product (Joyner et al., 1991).
It seems therefore, that the predicted phenotype of a null mouse is not always realised. 
In the case of H-ras it may be speculated that the hemizygous mice would be more 
susceptible to chemical carcinogenesis. However, in the case of a mouse with no 
functional H-ras, the phenotype may be homozygous lethal, produce a mouse highly 
susceptible to tumorigenesis or result in yet another situation of functional 
redundancy. The actual phenotype of a hemizygous or homozygous H-ras null mouse 
thus remains to be confirmed.
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Chapter 2
Materials and methods
56
2.1 Materials
Restriction enzymes were obtained from Boehringer Mannheim, Lewes, East Sussex; 
New England Biolabs ( CP Labs, Herts.; Northumbria Biologicals Limited (NBL), 
Northumberland; or from GibcoBRL, Paisley. Proteinase K, RNase A and Klenow 
fragment of Escherichia coli (E.coli) were obtained from NBL. Polynucleotide 
kinase was obtained from Pharmacia Ltd., Milton Keynes, Buckinghamshire, and Taq 
polymerase from Promega, Southampton. The Sequenase"^ kit used in double- 
strand sequencing reactions was from Cambridge Biosciences, Cambridge, and the 
SP6/T7 transcription kit used in the RNase protection assay was obtained from 
Boehringer Mannheim.
Deoxynucleotides and mixed hexanuleotides were from Pharmacia. All radioisotopes 
came from Amersham International P.L.C., Amersham, Buckinghamshire.
DNA size markers (lambda/Hindlll, d>X174/HaeIII) for gel electrophoresis, and the 
RNA ladder used in Northern blotting were supplied by Gibco/Bethesda Research 
Laboratories, Paisley, as were the Ultrapure^M agarose and urea.
Nitrocellulose and nylon membranes were supplied by Sartorius Instruments Ltd., 
Belmont, Surrey; Gelman Sciences Ltd., Broadmills Northampton and Amersham 
International.
The Geneclean^M kit for DNA fragment isolation was obtained from Stratech 
Scientific Ltd., Luton, Beds..
Bacto-tryptone, Bacto-agar and yeast extract were from DIFCO Laboratories, Detroit, 
Michigan, U.S.A.
Phenol was delivered as a water-saturated liquid from Rathbum Chemicals Ltd., 
Walkerbum, Peebleshire.
Absolute ethanol was supplied by James Burroughs (F.A.D) Ltd., Witham, Essex.
All other chemicals were obtained from BDH Laboratory Supplies, Poole, or Sigma 
Chemical Co. Ltd., Poole, Dorset.
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Serum, media and supplements for cell culture were obtained from Gibco. The 
growth factor LIF and the drug Gancyclovir, used in the culturing and selection of 
embryonic-derived stem cells, were gifts from Martin Hooper, Department of 
Pathology, Edinburgh.
Plastic-ware for cell culture was supplied by Nunc Intermed, Roskilde, Denmark; 
Sterlin Ltd., Feltham, Middlesex; or by Falcon^M, Becton Dickinson, Dublin.
Nude mice were from Marian Olac Ltd., Bichester, Oxon.
2.2 Bacterial transformation
Commercial competent cells, D H 5a^^ , supplied by GibcoBRL, were used for most 
purposes, otherwise competent cells were made according to Mandel and 
Higa,(Mandel and Higa, 1970). All ligations were carried out in Falcon 2063 
polypropylene tubes. DNA ligations were diluted 5-fold in lOmM Tris-HCl (pH 7.5) 
and ImM Na2 EDTA, and l-5ul (approximately lOng) of the dilution was added to 50 
or lOOul of thawed competent cells kept on ice. The cells were left on ice for 30 
minutes, then heat shocked at 42°C for 45 seconds. The cells were left to recover for 
2 minutes on ice, then incubated with 450 or 900ul of L broth (supplemented with 
20mM glucose) at 37°C for 1 hour. The tubes were spun at IK for 5 minutes, the 
supernatant poured off, and the pellet gently resuspended in residual supernatant 
This was spread onto LB plates (7.5g of Bacto-agar in 500ml of L Broth) 
supplemented with lOOug/ml ampicillin. The plates were incubated overnight at 
37°C.
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2.3 Preparation of plasmid DNA
2.3.1 Mini-prep method for rapid screening
l-5ml of L broth( with lOOug/ml ampicillin) was inoculated using a loop. The 
cultures were incubated overnight at 37°C. Cells were spun in 2ml eppendorf tubes. 
The pellets were resuspended in lOOul of lysis solution ( 25mM Tris-HCl(pH 8.0); 
lOmM EDTA; 50mM glucose; 0.5mg/ml lysozyme ). 200ul of alkaline/SDS solution 
( 0.2N NaOH, 1% SDS ), was added to the tubes and mixed. 150ul of NaOAc 
(pH4.8) was then added and the tubes vortexed. After incubation on ice for 5 minutes 
(optional), the tubes were spun, and the supernatant added to a fresh tube containing 
400ul of isopropanol. The tubes were spun at 10K for 15 minutes. The pellet was left 
to air dry and resuspended in 200ul of d l^O . A further precipitation step with 100% 
ethanol is optional. RNaseA (lOOug/ml f/c) was included at the time of restriction 
enzyme digestion.
2.3.2 Bulk-prep
A 10ml starter culture was prepared overnight. This was then added to 500ml of L 
broth containing antibiotic (lOOmg/ml ampicillin) and incubated for at least 16 hours. 
The culture was spun in 500ml Sorvall bottles at 5K for 5 minutes at 4°C. The pellet 
was resuspended in 25mls of ice cold lysis solution (as Section 2.3.1). After 15 
minutes on ice 50mls of alkaline /SDS solution (as Section 2.3.1) was added, and the 
solution mixed vigorously by swirling. Finally 37.5 mis of potassium acetate solution 
(60mls 5M potassium acetate, 11.5mls glacial acetic acid and 28.5 mis d l^O ) was 
added and the bottles incubated on ice for approximately 15 minutes. The bottles 
were spun at 6 K at 4°C for 15 minutes. The supernatant was decanted through gauze 
and isopropanol precipitated with 0.6 volumes of isopropanol. The pellet was 
resuspended in TE (lOmM Tris-HCl; ImM EDTA pH8.0). Further purification was
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carried out using the Cesium chloride-Ethidium bromide gradient method (according 
to Maniatis (Maniatis et al., 1982), depending on the required quality of the DNA.
2.4 Restriction enzyme digestion of DNA
Plasmid DNA was digested with 5-10 units enzyme/ug DNA for 1-5 hours dependent 
on suppliers instructions. Genomic DNA was digested under overnight conditions 
with 10 units/ug DNA. Digestions were analysed for completeness, by gel 
electrophoresis.
2.5 Agarose gel electrophoresis
Agarose gel electrophoresis of DNA was performed using the appropriate horizontal 
gel apparatus, with agarose concentrations between 0.7-2.0% w/v, depending on the 
desired fragment resolution. The agarose was dissolved and cast routinely in TAE 
buffer (40mM Tris-HCl pH7.8; 20mM Sodium acetate; ImM EDTA ), which was 
also used as the running buffer. Ethidium bromide (lug/ml) was either added direct 
to the molten agarose, or in the case of Southern blotting, the gel was soaked in an 
ethidium bromide solution, prior to UV illumination and photography.
2.6 Cloning techniques
2.6.1 Purification of DNA fragments from agarose gels
Using UV illumination, the fragment of interest was excised with the minimum 
amount of agarose. Purification was carried out by two methods depending on the
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fragment size. For fragments 500bp-3kb the g e n e c l e a n ^ M  technique (Stratech 
Scientific Ltd.) was used efficiently (see manufacturers instructions). For slightly 
larger DNA fragments 2-10kb spin-X tubes ( supplied by Costar ) were found to be 
most effective.
2.6.2 End-fill reactions
The conversion of DNA fragments with protruding 3' and 5' ends, to blunt end 
species, was carried out according to Maniatis (Maniatis et al., 1982), using the 
Klenow fragment of E. coli DNA polymerase I.
2.6.3 Removal of 5' phosphate groups from DNA
The dephosphorylation of DNA for the purposes of minimising recircularisation of 
vector DNA was accomplished by treating the restricted DNA with calf intestinal 
phosphatase (CIP). The protocol for this procedure is outlined in Maniatis (Maniatis 
et al., 1982).
2.6.4 Ligation of fragments
The ligation of DNA fragments was performed using bacteriophage T4 DNA Ligase. 
Fragments with sticky complementary ends were ligated overnight at 14°C, whereas, 
blunt-end ligations were carried out at 4°C for at least 24hrs. The total quantity of 
DNA per reaction varied, but the molar ratio of insert to vector was always greater 
than 3:1. The quantitation of vector to insert DNA was accomplished roughly, by gel 
electrophoresis. The vector DNA was usually phosphatased according to Section 
2.6.3, inorder to minimise vector recircularisation. Fresh commercial 5X ligation 
buffer was routinely used. The volume of the reaction was kept to a minimum, 
usually 5-10ul.
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2.6.5 Ligation of linkers
The linkers supplied in dry form by Promega, either phosporylated or non- 
phosphorylated, were made up in dP^O to a concentration of 20pM/ul. The linkers 
were blunt-end ligated to the linearised DNA (approximately 6 ul or 1.2nM linkers to 
400ng of a linear fragment, approximately 3kb in size) according to Section 2.6.4.. 
The excess linkers were removed firstly by ethanol precipitation and then by enzyme 
digestion. The redesigned fragment was then cloned into the desired restriction site of 
a phosphatased vector, according to Section 2.6.4.
2.7 Preparation of radioactively labelled probes
Labelled probes from double-stranded DNA were made by the random priming 
method (Feinberg and Vogelstein, 1984; Feinberg and Vogelstein, 1983). 
Approximately 50ng of purified insert DNA was boiled for 10 minutes to ensure 
denaturation, and then labelled in a total volume of 50ul containing lOul of OLB 
buffer (see below), 2ul of BSA (lOug/ml stock). Finally, 1.85x10^ MBequerel of (a- 
32P)dCTP and 5 units of Klenow enzyme were added, and the reaction incubated at 
room temperature for at least 6  hours.
The unincorporated nucleotides were removed by running the probe through a NICK- 
column™* (Pharmacia), and the specific activity estimated using a scintillation 
counter.
Oligonucleotide buffer (OLB);
62ul 1M Tris pH 7.4 
6 ul lMMgCl2  
lul 2-Mercaptoethanol 
2ul 15mM dATP 
2ul 15mM dGTP
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2ul 15mM dTTP 
125ul 2M HEPES pH6 . 6
50ul 150 OD/ml Calf Thymus Hexanucleotides (Pharmacia)
Stored in aliquots at -20°C.
Probes used in Southern and Northern blot hybridisation:
BS9 probe; 300bp EcoRI insert of BS9 (Ellis et al., 1980).
Neomycin probe; 2kb Hindin insert from pIC20Hneo, derived by cloning the 
Xhol/Sall neomycin fragment from pMClPOLA (Thomas and Capecchi, 1987) into 
pIC20H.
pB5 probe; 576bp insert liberated by a BssHII digest of plasmid vector pB5ras, 
created by PCR amplification of NMRI mouse RNA, generating a cDNA-type probe. 
P6 KpnI upstream probe; 600bp BamHI/Kpnl fragment of original 1.8kb BamHI P6  
fragment, created so as to avoid repetitive sequences.
Human H-ras specific probe; 500bp Smal/Hindin fragment of human ras plasmid 
pR8.T24 (Bailleul et al., 1988).
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2.8 Southern blot transfer of DNA
DNA fragments were separated by agarose gel electrophoresis and transferred to 
nylon membranes (Hybond-N^^ or Biotrace-RP^^) by the method of Rigaud et al, 
(Rigaud et al., 1987). The gel was soaked in ethidium bromide solution and 
photographed. It was then soaked in 1.5M NaCl, 0.5M NaOH for 2x 20 minutes, and 
then in 1M NH4 OAC, 0.02M NaOH for 2 x 30 minutes. The gel was then transferred 
onto a nylon membrane (Hybond, Amersham, or Biotrace RP), by capillary transfer 
overnight in NH4 OAc/NaOH transfer solution. Alternatively vacuum transfer of the 
gel was used according to manafacturers' guidelines.
The membrane was then fixed by baking at 80°C for 2 hours and hybridised as 
described in Section 2.10.
2.9 Northern blot transfer of RNA
10-20ug of total RNA was freeze dried and resuspended in freshly made sample 
buffer (50% formamide; lxMOPS; 16.6% formaldehyde up to 100% with (fr^O). 
This was incubated at 60°C for 15 minutes, then on ice for 5 minutes. 5ul of "blue 
juice" ( 50% glycerol, lOuM Sodium phosphate pH 7.0, and a few bromophenol blue 
crystals) was added to the samples prior to loading the gel (1% agarose; lxMOPS; 
and 18% formaldehyde). The gel was run in lxMOPS (for 11 of lOxMOPS: 42g 
MOPS; 6 .8 g NaOAc; 3.7g EDTA pH 7.0). The RNA ladder was supplied by BRL. 
The RNA was blotted onto nitrocellulose membrane (Sartorius^^) and hybridised as 
below, Section 2.10.
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2.10 Hybridisation of single copy probes
Filters were prehybridised at 42°C for a minimum of 4 hours in sealed plastic 
containers with 20-50ml of pie-heated solution {50% formamide; 4xSSPE(20xSSPE 
is 3.6M NaCl; 200mM Nat^PC^ pH 7.4); 0.5%w/v dried milk(marvel); 1% SDS; 
10% dextran SO4 ; 1 mg/ml denatured salmon sperm DNA). After the alloted 
prehybridisation time, radio-labelled probe (see section 2.7) was denatured by boiling 
for 10 minutes and added direct to the pre-hybridisation solution. Hybridisation was 
normally overnight. Filters were washed on a shaker with lxSSC/0.1% SDS, then 
0.5xSSCy0.1%SDS, at room temperature each wash for 15 minutes. The final wash 
was with 0.1xSSC/0.1%SDS at 50-65°C for 10-30 minutes with constant monitoring 
of the background with a geiger counter. The filters were exposed to Kodak X- 
OMAT AR or X-OMAT S film at -70°C in cassettes containing intensifying screens.
2.11 Western blot transfer of protein
The protein samples were prepared as in Section 2.19. The protein content was 
estimated using the Bio-rad assay (see manafacturers' guidelines). For the detection 
of H-ras specific bands the samples were first treated with 50% IgPAS (Protein A 
sepharose, see below), and then immunoprecipitated with antibody 172 ( H-ras 
specific antibody, Oncogene Science Inc.), as follows: 1 mg/ml of protein was made 
up with lysis buffer (see Section 2.19). lOOul of 50% IgPAS was spun down, and the 
lysates added directly onto the PAS. These were incubated on a rotator at 4°C for 2 
hours. The supernatant was removed and respun to get rid of any residual PAS. To 
these pie-cleared lysates, a 1:100 dilution of antibody 172 and lmg/ml f/c BSA were 
added and incubated at 4°C overnight. lOOul of 50% IgPAS was added over the 
lysates and incubated for 2 hours at 4°C on a rotator. The tubes were spun and the 
pellets finally resuspended in a volume of 35ul of western sample buffer { 10% B- 
mercaptoethanol; 2% (w/v) SDS; 30% (w/v) glycerol; 0.025% bromophenol blue a
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few crystals of methyl green in 0.05M Tris-Hcl pH6 . 8  }. This was boiled for 5 
minutes and the supernatant transferred to a fresh tube, which could if necessary be 
stored at -20°C. The samples were run on a vertical 17.5% polyacrylamide gel ( 
17.5% acrlyamide; 375mM Tris-HCl pH 8 . 8  ;0.1% SDS; 0.1% Ammonium 
Persulphate; lul/ml TEMED with a 5% polyacrylamide stacking gel) in Tris/Glycine 
running buffer (for 11: 3.025g Tris base; 14.4g Glycine; lg  SDS, pH8.5). For size 
markers, Amersham Rainbow Protein molecular weight markers ranging from MW 
2350-46000, were used.
The gel was trimmed to size (using the coloured size markers as a guide) and placed 
in the electroblotter as folows. Firstly 6  sheets of whatman paper soaked in Anode 
solution 1 (0.3 Tris/ 20% methanol pH 10.4), then 3 sheets of whatman paper soaked 
in Anode solution 2 (25mM Tris/ 20% methanol pH 10.4). The nitrocellulose 
membrane was then placed on top of the sheets of whatman paper followed by the gel 
itself. Finally 9 sheets of whatman paper soaked in Cathode solution (40mM 6 - 
amino-n-hexonoic acid; 20% methanol pH7.2), were put in place and the 
electroblotter connected to a 50mA source for 30 minutes. The membrane was 
incubated with the primary antibody ( Pan ras antibody - Oncogene Science Inc.) 
overnight at room temperature, and then washed in Blotto (5% Marvel in PBS with 
0.1% NP40) for 90 minutes. Incubation with the secondary antibody (anti-mouse 
peroxidase, Amersham International Ltd.) was carried out for 30 minutes at room 
temperature and was then followed by washing in blotto for 1 hour and TBST 
(lOxTBS for 11: 12.1 lg Tris base; 90.0g NaCl pH7.4) for another hour. Luminol 
solutions (Amersham ECL kit) were mixed in equal proportions and the filter emersed 
for 1 minute. The filter was then placed in saran wrap and exposed to fast film for 30 
seconds to several minutes.
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2.12 RNase protection assay
The probe for the RNase protection assay, either mouse H-ras exon 2 or human 
specific, was generated using the SP6/T7 transcription kit (Boehringer Mannheim) 
following the manafacturers instructions.
10-20ug of total RNA was dried down in a speedivac, along with 1x10** cpm of 
labelled probe. This was resuspended in 20ul of 80% FAB (80% formamide; 400mM 
NaCl; 40mM Pipes pH6.4; ImM EDTA) and incubated for 16 hours at 50°C. The 
samples were then placed on ice and 300ul of digestion buffer (lOmM Tris pH 7.6; 
5mM EDTA; 0.3M NaAc pH 7.0; and 40ug/ml RNaseA, 150U/ml RNaseTl f/c) was 
added to each tube. The samples were digested for 1 hour at 30°C. Then 2.5ul of 
lOmg/ml Proteinase K and 3.2ul of 20% SDS was added to each tube and the mixture 
incubated at 37°C for 15 minutes. 5ul of yeast tRNA (stock 1 mg/ml) carrier was 
added to each sample. The samples were then phenol/chloroform extracted and 
precipitated with 100% ethanol, followed by 70% and 100% ethanol washes. The 
RNA digested samples were freeze dried and resuspended in 5ul of loading buffer ( 
8 ml formamide, 1ml lOxTBE, 20ul 0.5M EDTA, lOmg xylenecyanol, lOmg 
bromophenol blue, and 1ml of ctf^O). The samples may be stored at -70°C, or run 
on an 8 % polyacrylamide gel (8 M urea; lxTBE; and dilution of 40% acrylogel 
solution, with ammonium persulphate and TEMED added prior to pouring). The 
samples were heated to 90°C for 5 minutes prior to loading. Gel electrophoresis was 
at 40-50W for 2 hours. The gel was then dried down under heated vacuum and 
exposed to film (Kodak X-OMAT AR or S).
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2.13 Oligonucleotide synthesis
Oligonucleotides were synthesised on an Applied Biosystema 381A Synthesiser, 
using the manufacturers protocols and reagents. After deprotection in ammonia at 
55°C overnight, the oligonucleotides were precipitated and used without further 
purification.
2.14 DNA sequencing
Sequencing of double-stranded DNA was carried out using the Sequenase'™ T7 
DNA polymerase kit and a-35S d-ATP. lOug of Cesium chloride prepared plamid 
DNA was digested with the appropriate restriction enzyme, ethanol precipitated and 
resuspended in 20ul dH20. 7ul of this was combined with 2ul of the annealing buffer 
supplied, and 0.5pmol of the designated primer. The protocol and reagents were 
supplied as for the USB (United States Biochemical) Sequenase kit.
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2.15 Amplification by the polymerase chain reaction (PCR)
DNA was amplified according to Saiki and colleagues, (Saiki et al., 1988). A 50ul 
reaction containing up to lug of genomic DNA, or in the case of plasmid DNA, 
concentrations were in the picomolar range. Commercial lOx buffer supplied by 
Promega ( 500mM KC1; lOOmM Tris-HCl pH9.0 at 25°C; 15mM MgCl2; 0.1% 
gelatin w/v; 1% Triton X-100), each amplimer at 7ug/ml and each dNTP at 200uM 
f/c, were combined in a 0.5ml PCR tube. 2.5 units of thermostable DNA polymerase 
from Thermus aqiiaticus (Taq polymerase supplied by Promega) was finally added to 
the mixture. Thermal cycling was controlled by a programmable heating block 
(Perkin Elmer Cetus, DNA Thermal Cycler 480 or GeneAmp PCR System 9600). 
Three-step temperature cycling conditions varied, depending on GC content of 
amplimers, and length of amplification. Optimum amplimers were designed by a 
computer program ( Oligo 4.0-2008 Primer Analysis Software ), and made as in 
Section 2.13. Inorder, to avoid cross contamination of samples, aerosol resistant tips ( 
A R T™  supplied by BCL ) were employed, and care was taken to ensure that the 
positive controls were set up last.
Sequence of commonly used amplimers:
Neomycin gene amplimers used in homologous recombination screening:
neo.4: 5’> ctg gat tea teg act gtg gc <3'
neo262: 5’> gac ege ttc etc gtg ctt tac <3'
neo319: 5'> tat ege ctt ctt gac gag ttc <3'
neo320: 5'> ate gcc ttc ttg acg agt tct <3'
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H-ras exon 3 amplimers used in homologous recombination screening:
RC3: 5'> gcg age age cag gtc aca c <3'
RC4: 5f> gga tgc cat age tgc gag caa <3'
RAS365: 5 ’> ttg gca cat cat ctg aat ctt <3'
RAS366: 5’> att ggc aca tea tct gaa tct <3'
RAS372: 5'> age acc att ggc aca tea tct <3'
RAS373: 5’> cag cac cat tgg cac ate ate <3'
Microsatellite primer pairs 21 and 28 as used in microsatellite analysis of cell line 
DNA were gifts from J. Todd and described as in original paper N.A.R. 18:4123-4130 
(1990), with original names Igh (T161):pp21 and Il-lb (T49):pp28.
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2.16 General culture of mammalian cell lines
2.16.1 Medium and supplements
Cell lines were grown routinely in Special Liquid Medium (GibcoBRL) supplemented 
with 10% foetal bovine serum (FBS), 4mM glutamine, and 5ug/ml penicillin. Cells 
were grown in 25,75 or 175cm^ flasks or 9cm dishes gased with 5% CO^, and placed 
in 5% CC> 2  ; 37°C incubators. Cells were washed with phosphate buffered saline or 
PBS (0.14M NaCl; 27mM KC1; lOmM Na2 HP04; and 15mM K2 H P04). Trypsin for 
cell disagregation was used at 0.025% w/v in PE (phospate buffered saline; EDTA pH 
7.8). Trypsin was inactivated with 10-fold volume of serum containing medium. Cell 
numbers were estimated using a Coulter counter.
Rati cells, used as a positive control cell line in the soft agar assays, were grown in 
Dulbeco modified Eagles medium (DMEM), for recipe see Section 2.21.
2.16.2 Freezing and storage of cell lines
Cells for freezing were grown to near confluence, typsinised and spun at IK for 5 
minutes. The cells were resuspended in equal proportions of growth medium and 
freezing medium (25% FCS; 20% DMSO; 55% growth medium). Cells were stored 
in l- 2 ml nunc vials in liquid nitrogen.
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2.17 Transfection of eukaryotic cells
2.17.1 Calcium phosphate technique
5ug of supercoiled plasmid DNA was mixed with 35ug of carrier DNA ( normally 
Salmon Sperm DNA ) in a solution of TE (l.OmM Tris pH8.0; O.lmM EDTA pH8.0) 
to a final volume of 500ul. To this was added 400ul of TE(as above) and lOOul of 
2.5M CaCl2  ( refractive index 1.401). This mixture was added slowly to 1ml of 2X 
HBS:( 280mM NaCl; 50mM HEPES; 1.5mM Na2 HP0 4 .2H20  :pH 7.12-Critical ) 
and left for 30 minutes at room temperature to form a precipitate. This was then 
added to 4ml of medium, mixed gently and placed over a sub-confluent culture of 
cells. After 24 hours the transfection medium was replaced with fresh growth 
medium and incubated at 37°C for a further 1-2 days. The cells were then split 1:10 
and selection applied as appropriate.
2.17.2 Lipofection technique
The technique of cationic liposome mediated transfection as described by Feigner and 
Holm (Feigner et al., 1987)(GibcoBRL Focus (11)2, 1989) was used to transfect a 
number of mouse epithelial cell lines. The protocol was as for the DOTAP^M 
reagent supplied by Boehringer Mannheim.
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2.18 Preparation of DNA and RNA from cultured cell lines
Genomic DNA was prepared by treating adherent cultured cells grown in 75 or 
175cm^ flasks with 2 or 5mls of lysis buffer ( 50mM Tris pH8.0; 50mM EDTA; 
lOOmM NaCl; 5mM dithiothreitol; 1% SDS and 0.5mM spermidine) respectively. 
The cell lysate was scraped from the flask using a sterile scraper, and placed in a 
15ml Falcon tube, to which 200ul (lOmg/ml solution) of proteinase K was added. 
The tubes were incubated at 37°C in a rotator, overnight. The contents were then 
phenol/chloroform extracted, and subsequently isopropanol precipitated. The gloppy 
pellet was spooled and washed in 70% then 100% ethanol, then allowed to air dry. 
The genomic DNA was finally resuspended in 200-400ul of TE (lOmM Tris pH7.4; 
and ImMEDTA).
RNA was prepared using the RNAzol^M protocol ( Biogenesis Ltd.). To 10^ 
adherent cells, 2ml of RNAzol was added directly to the flask, and the lysate scraped 
off using a sterile scraper. This was placed in a 15ml Sorvall tube and one tenth 
volume of chloroform added. After shaking, the tube was spun at about 5K at 4°C for 
15 minutes. The colourless upper phase was transferred to a fresh tube, and the RNA 
precipitated using an equal volume of isopropanol. The RNA was then pelleted and 
washed with 75% ethanol and allowed to air dry. The pellet was then resuspended in 
Diethylpyrocarbonate (DEPC) treated water. Care was taken to ensure that all 
solutions used were RNase free. RNA should be stored at -20°C.
2.19 Preparation of protein from cultured cell lines
A 9cm dish of subconfluent cells was washed three times with ice cold PBS. 1ml of 
lysis buffer (1%  Triton X100; 0.5% Deoxycholate.Na; 0.1% SDS; lOOmM NaCl; 
50mM Tris-HCl pH7.4; 5mM MgC12; and 3mM PMSF added just before use) was 
added direct to the cells and left for 15 minutes on ice. The lysate was scraped off the
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dish and transferred into an eppendorf tube. After a 15 minute spin at 4°C the 
supernatant was transferred to a fresh tube and stored at -20°C. Preparation of protein 
samples for Western analysis is described in Section 2.11.
2.20 Virus preparation and cell infection
Virus producer cell lines were grown until 80% confluent. The medium was replaced 
with the minimum volume of growth medium to ensure coverage. This was left for 
24 hours removed and filtered through a series of syringe filters 1.2 -0.2 microns. 24 
hours prior to harvesting the viral supernatant, 5 x 1 0 ^ cells ( cells for infection ) were 
seeded per 25cm^ flask. To each flask was added a mixture of 1ml of viral 
supernatant, 210ul of polybrene (0.8mg/ml), made up to 7ml with growth medium. 
After 48 hours the medium was changed with normal growth medium and 2 days later 
the cells were split into 9cm dishes and selection with geneticin commenced if 
appropriate.
To estimate the titre of a virus, the NRK focus forming assay was used. Early 
passage NRK cells were seeded into 24 well plates, at 10^ cells per well. The next 
day the medium is replaced by limit medium ( 5% FCS; 1% DMSO; 6 ug/ml 
polybrene in lx DMEM ). Then the following day virus dilutions ( 5^-5"^ ) of the 
filtered virus stock were added direct to the wells ( 33ul per w ell). After 4 days the 
plates were refed with limit medium minus polybrene. After another 5 days the foci 
were counted and the titre of the virus ( in focus forming units per ml, or ffu/ml) 
calculated.
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2.21 Growth in soft agar
Soft agar assays were used as an indicator of anchorage independent growth. 40ml of 
2.5% Difco bacto-agar in a 200ml Duran bottle was melted in a microwave and 
cooled to 44°C. 40ml of 2xDulbeccos Modified Eagles medium or 2xDMEM (for 
lOOmls :20mls lOxDMEM; 2m1 200mM glutamine; 2ml lOOmM pyruvate; 10ml 
7.5% NaHC03; 4ml 1M HEPES made up with dH20 plus antibiotics) and 20ml 
newborn calf serum was added to the cooled agar, and the volume made up to 2 0 0 ml 
with 100ml 1XDMEM. The resulting 0.5% agar solution was maintained at 44°C for 
pouring (about 5ml per 60mm plate). Base plates were allowed to set at room 
temperature or 4°C. 10^ cells were resuspended in 0.5ml of growth medium and 
mixed in a plastic universal with 1ml of cooled (37°C) base agar. A base plate was 
carefully overlayed with this soft agar/cell mix and allowed to set at room 
temperature. Plates were set up in triplicate and examined after 2 weeks incubation at 
37°C.
2.22 Culture of primary tumour explants
Tumour samples for explants were cut up into fine pieces and incubated in Special 
Liquid Medium supplemented with 20% v/v foetal bovine serum (FBS); 4mM 
glutamine; 5ug/ml penicillin; lOOug/ml streptomycin in 5% CO2  at 37°C. The 
concentration of FBS was reduced to 10% as soon as the tumour cell line was 
established.
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2.23 Specialised culturing of embryonic stem (ES) cells
2.23.1 Electroporation of ES cells
A 175cm^ flask of confluent ES cells were trypsinised and the trypsin inactivated 
with serum containing medium. The cells were first washed with Phosphate Buffered 
Saline (PBS), and then resuspended in about 0.4ml of PBS. In an eppendorf tube 75- 
150ug of linearised plasmid DNA was resuspended in 0.4ml of PBS and mixed with 
the cell suspension. The contents were transferred to a sterile Bio-Rad
electroporation cuvette. The cuvette was placed in the Bio-Rad Gene Pulser^M 
ensuring that the electrodes were connected. The capacitance was set at 3uF (not on 
extender), whilst the voltage was set at 0.8kV. Both pulse buttons were held in until 
the buzzer sounded acknowledging that the pulse has been delivered. The cuvette 
was removed and the contents added to 50-100ml of prewarmed growth medium and 
plated into 9cm dishes. Selection was begun 24-48 hours after electroporation.
2.23.2 Culturing and Selection of ES Cells
The ES cells were grown in Glasgows Modification of Eagles medium, supplemented 
with non-essential amino acids and 0.1 mM P-mercaptoethanol. In addition, the 
growth factor LIF was added to a final concentration of 10^ units/ml ( stored as a 
lO'Vml stock in medium at -20°C ). Selection was carried out using geneticin at a 
final concentration of 200ug/ml and Gancyclovir ( or Cymevene, Syntex Corp.) at a 
final concentration of 2uM ( stored as a 10,000-fold stock at 4®C).
2.23.3 Picking ES cell clones
After about 2 weeks in selection, the clones that developed were picked and 
expanded. This was accomplished using a drawn-out pasteur pipette connected to a
76
length of tubing with a mouthpiece and an in-line-filter. With the aid of a stereo- 
microscope the colony was scraped and sucked up into the pipette, and transferred to 
a drop of trypsin on a 9cm plastic plate. Care was taken to minimise the amount of 
medium sucked up as this inactivates the trypsin. The plate was covered and 
incubated for approximately 10 minutes. The dispersed colony was then transferred 
using the drawn out pasteur into a 24 well plate and grown up as desired.
2.23.4 Freezing ES cells
Freezers were made from half a confluent 2 5 c m ^  flask. The cells were spun down 
and resuspended in freezing medium( 8 mls growth medium; 1ml FCS; 1ml DMSO ), 
and frozen in 1ml nunc cryotubes. Storage was in liquid nitrogen.
2.23.5 Preparation of DNA from ES cells
DNA was made from half a confluent 25cm^ flask using the rapid lysis method 
described in Section 2.18. The remaining half of the flask was frozen down ( as 
Section 2.23.4) and stored at -70°C.
2.24 Assay for tumorigenicity
Cell lines were tested for their degree of tumorigenicity by sub-cutaneous injection of 
nude mice. Cells were trypsinised, counted and resuspended in SLM at a 
concentration 1 x 1 0 ^  cells/ml. lOOul volume was injected per site, two sites per 
mouse. The mice were checked regularly for tumour development.
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2.25 Tumour histology
Tumours were fixed in 5% formalin before embedding in paraffin sectioning, and 
staining in hematoxylin and eosin.
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Introduction: Tumour progression is associated with an
increase in the H-ras mutant:normal gene ratio
The mouse skin carcinogenesis model has been used extensively to study the 
biological and biochemical features of tumour initiation and progression.
Skin tumours induced by the standard DMBA/TPA protocol display an A:T -> T:A 
transversion at codon 61 of the H-ras gene. This mutation introduces a novel Xbal 
restriction site, generating a tumour-specific RFLP.
Previous studies have suggested an important role for the oncogenic mutation of H- 
ras, and duplication of the chromosome carrying the mutation, in early stages of 
mouse skin tumorigenesis. Such alterations are thought in some way, to provide a 
selective environment to the initiated cell, permitting clonal expansion to produce a 
benign papilloma.
Genetic alterations at the H-ras locus have been shown not only to be associated with 
early events in tumorigenesis. RFLP studies of carcinomas generated by the 
DMBA/TPA protocol show a strong correlation between the increase in 
mutant:normal gene ratio and the generation of the anaplastic phenotype. However, 
loss of heterozygosity studies were unable to conclude whether the main determinant 
of these consistent chromosomal changes was H-ras itself, or a linked tumour 
suppressor gene. More recent studies, using spretus/musculus hybrid mice have 
shown that it is always the parental chromosome carrying the H-ras point mutation 
that is duplicated (C.J. Kemp, personal communication). Although these observations 
suggest a causative role for H-ras, it is still impossible to rule out the involvement of 
another linked gene. To try to dissect a function for H-ras in tumour progression, we 
have chosen two alternative approaches.
The first, termed the in vitro approach concentrates on the rather distinct transition 
event between the well-differentiated squamous carcinoma, and the much more 
undifferentiated, refractile spindle cell tumour.
80
Previous PCR studies using paraffin sections of carcinomas of defined histological 
types suggested a role for H-ras in this transition (Buchmann et al., 1991). In four 
cases, where both squamous and spindle cell components could be identfied within 
the same tumour, the spindle component had a much higher mutantrnormal gene ratio. 
In addition cell lines representing both the squamous and spindle phenotypes, have 
been isolated from a single carcinoma, MSC11. These clonally derived cell lines 
have offered a unique in vitro system for analysing the role of H-ras in the later stages 
of tumour progression.
The alternative approach, which we have termed the in vivo approach, uses the novel 
technique of gene targeting. This enables one to study the function of genes in 
mammalian development, or in our case, the consequence of loss-of-function 
mutations in the H-ras gene for tumour development. The results from these 
alternative approaches to examining the role of H-ras in tumorigenesis are split into 
the following chapters 3 and 4 of this thesis.
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Chapter 3
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3.1 The role of Harvey-ras in the squamous to spindle 
conversion
3.1.1 The squamous to spindle conversion is a discrete step in tumour 
progression
The analysis of the role of H-ras in tumour progression and loss of differentiation, has 
been facilitated by the isolation of cell lines representative of specific stages of 
tumour development.
One such cell line MSC11 was explanted from a carcinoma generated by treating a 
Mus spretusl Mus musculus hybrid mouse with multiple treatments of DMBA ( see 
Figure 5). It was noticed from histological analysis, that two distinct cellular 
morphologies existed within the same tumour. Three single cell clones, representing 
both morphologies were derived from the parental MSC11 cell line. B9 denotes the 
squamous cell component, while A5 and D3 represent the spindle cell phenotype (see 
Figure 6 ).
Southern blotting analysis of the three cell lines, utilising the Xbal polymorphism, 
indicated that all three clones had the same codon 61 H-ras mutation in the Mus 
musculus allele. In addition, sequence analysis of the conserved regions of the p53 
locus showed that the cell lines of both morphologies, had the same p53 point 
mutations, in the musculus allele at codon 241 (Asn->Ile) and in the spretus allele at 
codons 236 (Cys->Phe), and 246 (silent change) (Bums et al., 1991). These data 
together, provided clear proof that the spindle cell phenotype arose from the 
squamous component of the same tumour. It also indicated, that genetic alterations of 
the p53 locus occur prior to, and are not responsible for, the squamous to spindle 
transition. Thus alterations of another locus or loci must be involved.
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Isolation of squamous and spindle cell lines 
from mouse-skin carcinoma MSC11
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Figure 6.
Morphology o f MSC11 cell clones.
(A) MSC11 single cell clone B9
(B) MSC11 single cell clone A5
(C) MSC11 single cell clone D3 
(25 x objective)
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3.1.2 The spindle cell lines are more tumorigenic and histologically 
distinct compared to their squamous counterparts
Just as with PDV and PDVC57 the ratio of mutantmormal H-ras, directly correlates 
with the tumorigenicity of the cell lines. B9 is much less tumorigenic than both A5 
and D3. A mixing experiment was carried out using 1 0 ^ B9 cells along with varying 
numbers of A5 cells. As few as 10 A5 cells along with 10^ B9 cells, when injected 
subcutaneously into a nude mouse, had a discernible effect on the latency of tumour 
development. After a month, only one out of the four B9 injected mice showed a 
small flat nodule at the site of injection, whereas the B9 cells combined with the 
equivalent of only about 10 A5 cells showed 5-7mm nodules in 2/4 mice and smaller 
nodules in the remaining two mice.
Subcutaneous injection of nude mice with 10^ B9 cells resulted in 1 cm tumours, after 
a latency period of about 6  weeks. On the other hand, A5 and D3 cell lines produced 
similar sized tumours in only 3 weeks. Histological analysis of tumour sections, 
revealed characteristically well differentiated tumours in the case of the B9 squamous 
cell line, but very disorganised, aggressive tumours in the case of the spindle cell lines 
A5 and D3 (Figure 7).
There was a slight difference in tumorigenicity between A5 and D3, with A5 having a 
marginally shorter latency period. This difference was observed over several nude 
mouse injection experiments.
3.1.3 The squamous to spindle conversion is concomitant with an increase 
in the copy number and level of expression of mutant H-ras
Examination of an Xbal Southern blot of the three clones showed a clear increase in 
copy number of the mutant H-ras gene between B9 and A5/D3 ( Figure 8 A ). The 
normal musculus H-ras gene resides on a 12kb Xbal fragment. However, due to the 
Xbal polymorphism at codon 61 of H-ras, Xbal restricts the mutant musculus allele
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Figure 7.
Histology of MSC11 cell clones injected sub-cutaneously into nude mice.
(a) Tumour histology resulting from injection of MSC11 B9 cells
(b) Tumour histology resulting from injection of MSC11 A5 cells 
Magnification xlOO, (Photo courtesy of P.A. Bums).
Figure 8.
Relative copy number and expression of H-ras mutant and normal 
in MSC11 B9, A5 and D3 cell lines.
(A) Xbal Southern blot of cell lines, lOug genomic DNA.
PDV and PDVC57 cell lines included as controls with relative 
mutant:normal H-ras ratios of 1:2 and 2:1 respectively.
Size markers as shown, (ps) spretus H-ras pseudogene 
Refer to figure 9. for schematic details.
(B) RNase protection analysis of MSC11 cell clones.
20ug of total RNA from each cell line was hybridised to mouse H-ras 
exon 2 specific probe. C5N and carC represent control cell lines which 
express only normal or mutant H-ras transcripts, respectively.
(N) position of H-ras normal transcript
(M) positions of mutant specific protected fragments
size markers in nucleotides.
(Data courtesy of S.Haddow)
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into a 4 and a 8 kb fragment. However, the Xbal fragment representing the spretus 
normal allele is 13kb in size. Xbal digestion of the spretus DNA carrying the codon 
61 mutation results in a 4kb and a 9kb fragment ( Figure 9 ). The Xbal Southern blot 
in Figure 8 A, shows the cell lines B9, A5 and D3 as well as PDV and PDVC57 
included as controls. The top band of the B9/A5/D3 lanes represents the 13kb normal 
spretus allele and the band just below, the spretus H-ras pseudogene. The mutant 
bands are 8 kb and 4kb in size indicating that these cell lines have required a codon 61 
mutation in the musculus allele. Comparison of copy number can be made with the 
cell lines PDV and PDVC57, which have mutantmormal H-ras gene ratios of 1:2 and 
2:1, respectively (Quintanilla et al., 1991). These particular cell lines were derived 
from a musculus background, and therefore display the normal 1 2 kb and mutant 8 kb 
and 4kb bands. It can be estimated that the ratio of mutantmormal in B9 is about 2:1 
similar to PDVC57. However, the ratio is much higher in the case of A5 and D3, in 
the range of 5:1 to 10:1. Such a dramatic increase in copy number cannot be readily 
explained by imbalance of chromosome 7 in favour of the mutant. It seems more 
likely the result of a local genetic amplification event. Data to support this notion, 
has come from PCR microsatellite studies ( C.J.Kemp, personal communication ). 
The ratio of microsatellite markers flanking the H-ras locus on chromosome 7 
correlated with the expected trisomic status.
Interestingly, independent evidence for a possible amplicon on mouse chromosome 7, 
that may include H-ras, has come from studies of human breast and squamous cell 
cancers which show amplification of the PRAD1 oncogene (Lammie et al., 1991). 
PRAD1 maps to human llq l3  and to the syntenic region in mouse 7 close to the H- 
ras locus (Rosenberg et al., 1991).
However, preliminary data ( S.Haddow, unpublished ) has shown no differences in 
PRAD1 copy number or expression levels between B9 and A5/D3.
This increase in mutant copy number correlates with the expression data of the mutant 
gene as determined by the RNase protection assay ( Figure 8 B ). lOug of total RNA 
from the cell lines B9, and A5/D3 were treated as in Section 2.12 of the Materials and
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Figure 9.
Methods. The cell lines C5N and carC were included as controls. C5N expresses 
only normal H-ras, whereas carC only expresses mutant. The protected fragments 
which hybridise to the mouse H-ras exon 2 probe, represent the normal transcript (N), 
and the mutant (M), respectively. From Figure 8 B the most striking difference 
between B9 and A5/D3 appears to be a decrease in the expression level of the normal 
gene. This is dicussed in the following Section 3.1.4. In addition, there is an increase 
in the amount of mutant transcript, concurrent with the squamous to spindle 
conversion. However, the increase represented by this particular RNase protection 
assay, is not as dramatic as the Southern blot suggests. It is however difficult to 
quantify the exact ratios, without incorporating loading controls. Examination of the 
protein levels of the normal and mutant p2 1  species in the squamous and spindle cell 
lines, by Western blot analysis, correlates in general with the RNase protection data, 
with an increase in the mutant p21*eu^  species ( Figure 10 ), and a decrease in the 
normal p21 protein. However, the increase in the amount of mutant protein present in 
the spindle cell lines appears to correlate with the Southern blot data, rather than the 
more modest increase suggested by the RNase protection results. However, once 
again, the lack of a measure for internal loading, implies that care must be taken in 
interpreting the precise ratios of normal to mutant protein levels in the cell lines 
analysed.
3.1.4 The squamous to spindle conversion correlates with an apparent 
decrease in level of expression of normal H-ras
There is substantial data to support the correlation between tumour progression and 
the increase in the copy number and level of expression of mutant H-ras.
However, there is also evidence to suggest that the normal allele is lost or down- 
regulated in many carcinomas. In the PCR studies of paraffin sections of carcinomas, 
the squamous to spindle transition correlated not only with an increase in mutant but 
also a decrease in the amount of normal H-ras alleles present (Buchmann et al., 1991).
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Figure 10.
Western blot analysis of MSC11 cell clones 
and B9 cells infected with HaMSV.
Separation of H-ras p21 species, highlighted by dashes, as follows:
(M l2); Mutant H-ras Arginine substitution at codon 12 of HaMSV
(N); normal p21 H-ras species
(M61); Mutant H-ras Leucine substitution at codon 61.
Additional top band in B9HT3 1ml represents phosphorylated mutant Argl2
In the transition from B9 to A5/D3 there appears to be a reduction in the level of 
expression of the normal gene as determined by the RNase protection data ( Figure 
8 B ). This reduction in the level of the normal transcripts appears quite dramatic, 
whereas the copy number of the normal gene does not appear to change from B9 to 
A5/D3. This suggests transcriptional down-regulation of the normal H-ras gene 
rather than complete gene loss. Western blot analysis correlates with the RNase 
protection data and shows the apparent loss of the band representing the normal p2 1  
species ( Figure 1 0 ).
3.1.5 Conclusions
In summary, the data indicate that the transition from a well differentiated squamous 
carcinoma to an undifferentiated spindle cell carcinoma represents a discrete step in 
mouse skin tumorigenesis. Analysis of the clonally derived cell lines B9 and A5/D3, 
representing the squamous and spindle phenotypes respectively, excludes a role for 
p53 as a critical factor in the transition event. Instead, the conversion of squamous to 
spindle cells correlates with a dramatic increase in the mutant H-ras gene copy 
number and corresponding increase in the levels of mutant transcript and protein. The 
increase in levels of mutant copy number (5-10 fold ) are best explained by genetic 
amplification of a region on chromosome 7 including the H-ras locus.
In addition, there appears to be a reduction in expression of the normal H-ras gene 
and levels of protein.
On the basis of these results, the spindle cell phenotype may arise by alterations in the 
mutantmormal H-ras gene dosage ratio. Inorder to investigate this theory further, it 
was proposed to experimentally alter the H-ras gene dosage ratios in squamous and 
spindle cell lines.
Perhaps, by increasing the level of mutant H-ras in a squamous cell line it would be 
possible to convert it to a spindle cell phenotype. The converse may also be feasible. 
By increasing the levels of normal H-ras in a spindle cell line it may be possible to
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induce a reversal of the spindle phenotype to a more differentiated squamous form. 
Both of these experimental approaches are outlined in the following sections of this 
chapter.
3.2 Experimentally increasing mutant H-ras in squamous cell 
lines
The squamous carcinoma cell line B9 was transfected using the lipofection protocol 
(see Section 2.17.2 of Materials and Methods), with the plasmid construct pH06Tl 
(Spandidos and Wilkie, 1984). This contains a 6 .6 kb BamHI fragment of the human 
T24 H-ras oncogene (carrying the codon 12 mutation) is under the transcriptional 
control of its own promoter sequences. The plasmid also contains a SV40 enhancer 
region, and a neomycin resistance gene under the control of the Moloney murine 
sarcoma virus long terminal repeat (MoLTR).
3.2.1 Mutant H-ras appears cytotoxic to the cells
Stable transfection of this construct appeared cytotoxic to the cells. Even when the 
transfection efficiency was high ( as established using a neomycin resistance plasmid, 
Homer6  (Spandidos and Wilkie, 1984), very few mutant transfected colonies survived 
selection. This correlates with other transfection experiments carried out in our 
group, using mutant H-ras constructs ( K.Brown and W.Lambie, unpublished data ). 
Two clones of B9 transfected cells (pH06Tl II and HI) were ring-cloned and grown­
up as cell lines, along with control clones, transfected with the neomycin vector 
(Homer 6 ) alone.
In addition, to try to avoid "stressing" the cells, by G418 selection using an enhancer 
based plasmid construct, a high titre non-selectable Harvey murine sarcoma virus ( 
HaMSV ), was used to infect a pool of B9 cells. The producer cell line HT3 was
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generated by infecting HaMSV along with a helper virus into NIH3T3 cells. 
Supernatant from the producer cell line HT3 was collected and used directly to infect 
B9 cells using the polybrene method outlined in Section 2.20 of the Materials and 
Methods. Two separate pools of infected cells were isolated, B9HT3 1ml and B9HT3 
2 ml.
Figure 10 shows Western blot data on the two independent pools of infected cells 
B9HT3 1ml and B9HT3 2ml. The codon 12 mutant form of p21, representing the 
introduced HaMSV species, can be seen as a specific band in particular in the pool 
B9HT3 1ml. The separation of the different proteins is perhaps not ideal. In addition, 
the pattern of dots rather than homogeneous bands appears to be a problem with this 
particular Western blot protocol. The lines to the left of each lane help to define the 
position of the bands. However, it can still be seen that B9HT3 1ml shows the 
highest level of expression with an additional fourth band representing the 
phosphorylated species of v-ras p21 ( Figure 10 ). B9HT3 2ml does appear to express 
the virus specific codon 12 species but at a lower level than B9HT3 1ml.
3.2.2 The morphology and growth characteristics of the transfectants and 
infectants remain characteristically squamous in vitro
The morphology of both transfected cell lines, pH06Tl II and HI remained 
characteristically squamous in appearance ( Figure 11). However, they formed less 
regular "cobblestone" colonies than did the B9 Homer6  control transfectants. These 
slight irregularities in colony distribution were also seen in the virally infected clones 
( data not shown). It was also apparent that many of the cells formed what appeared 
to be vacuoles in their cytoplasm. This can be seen in figure 11 and an extreme 
situation in figure 12. These intracellular vesicles were more noticeable in 
subconfluent rather than confluent cultures. The significance of these observations 
will be discussed at a later date.
89
B9 Hom er B9 pH 06T l III
Figure 11.
The morphology of B9 cells overexpressing 
mutant H-ras remains characteristically squamous
Figure shows morphology of control B9 cells transfected 
the neomycin vector Homer6 and experimental clone 
transfected with human codon 12 mutant H-ras plasmid 
p H 0 6 T l.
(25  x objective)
Figure 12.
Vacuolation of B9 cells overexpressing mutant H-ras
Cells as shown, B9HT3 lml.
(25x objective).
To examine the growth characteristics of B9 cells overexpressing mutant H-ras, the 
highest expressor clone, B9HT3 lml, was plated under anchorage-independent 
conditions. Parental B9 and A5 cells along with src transformed rat fibroblasts were 
also seeded in soft agar, according to Section 2.21 of the Materials and Methods.
Both parental B9 and B9HT3 lml were unable to form colonies under anchorage 
independent conditions. However the spindle cell line, A5, formed colonies in the 
soft agar but to a lesser degree than the positive control Rat-1 src-transformed 
fibroblasts. A comparative field of view of both the Rat-1 and A5 seeded soft agar 
plates can be seen in figure 13.
The cell lines overexpressing mutant H-ras did not appear to grow at appreciably 
different rates compared to the parental B9 cells, although no detailed kinetic growth 
studies have been carried out.
3.2.3 Increasing mutant ras correlates with increased tumorigenicity
Tumorigenicity was assayed by subcutaneous injection of 10^ cells into nude mice (as 
in Materials and Methods).
The transfectant clones, B9pH06Tl II and B9pH06Tl III, and the infected pool 
B9HT3 lml were all determined to be more tumorigenic than parental B9 cells. After 
4 weeks post-injection, parental B9 cells produced only one large nodule on one 
mouse, and four small nodules on two mice with one mouse showing apparently 
nothing. Whereas, injection of B9HT3 lml resulted in large tumours mostly between 
8 -10mm in size. Similar sized tumours were seen in the B9 pH06Tl transfectants 
whereas B9HT3 2ml showed only one large tumour between four mice. In general 
therefore, the degree of tumorigenicity of the clones correlated with the expression 
level of mutant H-ras.
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Figure 13.
Growth of spindle A5 cells in soft agar.
Comparison with Rat-1 src transformed cells 
seeded at same cell density, 10 cells per 60mm plate 
(10 x objective)
SOFT AGAR ASSAY
RAT 1
Src
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3.2.4 The histology of tumours induced by B9 virus infected cells shows 
two distinct components
The tumour histology of the B9pH06Tl nude mouse tumours showed a differentiated 
organisation characteristic of the parental B9 squamous cell carcinomas. Thus 
although the tumorigenicity, as measured by the latency period for a specfic sized 
tumour to develop, had increased, the resultant tumours were still squamous in 
phenotype.
However, the data on the histology of the B9HT3 nude mouse tumours appeared 
intriguing. There was evidence of dimorphism, with what appeared to be spindle and 
squamous components within an individual tumour. On the other hand, tumours that 
resulted from subcutaneous injection of 1 0 ^ B9 or B9 Homer6  cells have repeatedly 
shown only a squamous well-differentiated structure. It appeared therefore, that 
injection of the virus infected mutant overexpressor clones B9HT3 1ml and B9HT3 
2 ml, were able to convert to a spindle morphology when presented with an in vivo 
environment. Several tumours were taken and explanted in culture as described in 
Section 2.22 of the Materials and Methods.
Explants from the B9HT3 tumours, reflected two very different morphologies, one 
squamous and the other characteristically spindle in phenotype. Some of the 
explanted colonies showed both morphologies emanating from the same tumour 
section, whereas others showed only squamous or spindle ( Figure 14 ). The initial 
2 0 % v/v foetal bovine serum concentration was reduced to 1 0 % as soon as the 
explants had taken.
Ring-clones representing both phenotypes were isolated and grown up as cell lines.
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Figure 14.
Morphology of nude mouse tumour explants 
generated by sub-cutaneous injection of B9 cells infected 
with HaMSV.
(25 x objective)
(a); squamous /spindle explant
(b); spindle explant
a.
b.
B9HT3 TUMOUR EXPLANTS
3.2.5 The” spindle” cell lines derived from the tumour explants are in fact 
host fibroblasts
After about a week in culture the "spindle" looking cell lines began to take on a much 
flatter appearance.
3/7 of the "spindle" cell lines continued to grow with a flat fibroblast appearance, the 
others began to senesce displaying characteristic features such as stress fibres and 
very flat "kite" shaped cells.
With the possibility that these spindle-shaped cells were in fact of host origin, i.e. 
nude mouse fibroblasts, it was considered important to examine the origin of these 
cells. DNA was made from both squamous and "spindle" cell lines derived from the 
same tumour. These samples were analysed by the PCR microsatellite assay. Owing 
to the fact that B9 was derived from a Mus spretus / Mus musculus hybrid mouse, the 
microsatellite approach was able to distinguish between the alleles, displaying two 
bands on an agarose gel. Figure 15 shows an agarose gel with products of the PCR 
amplification reactions clearly resolved. Panel A and B represent the same DNA 
samples but with different polymorphic microsatellite primer pairs, pp2 1  and pp28, 
located on mouse chromosome 12 and 2 respectively. The figure shows four DNA 
samples from cell lines from squamous tumour explants (sq), and four DNA samples 
from the so-called spindle cell lines (sp?). Control samples include pure musculus 
DNA (m), spretus DNA (s), and DNA from the spleen of a musculus/spretus hybrid 
mouse (h).
Analysis of the squamous tumour DNA samples shows the expected polymorphism 
and appearance of two distinct bands, characteristic of the musculus and spretus 
alleles respectively. Analysis of the so-called "spindle" DNA samples shows a clear 
absence of the spretus alleles ( Figure 15 ). This is evident in PCR reactions with 
both primer pairs. Therefore, the loss of the spretus allele from the "spindle" cell 
lines cannot be readily explained as loss of a spretus chromosome, since the primer 
pairs employed reside on different mouse chromosomes. It seems therefore, that
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Figure 15.
Host fibroblast origin of spindle-like cell lines from tumour explants
(as shown in figure 14.). Nude mouse tumours generated from HaMSV 
infected B9 cells.
PCR microsatellite analysis of both squamous (sq),and spindle (sp?) 
cell lines. PCR products electrophoresed on 1.7% agarose gel.
(h); musculus/spretus hybrid control DNA 
(s); spretus control DNA 
(m); musculus control DNA
A and B represent PCR reactions with primer pairs, pp21 and pp28 
respectively.
these spindle-shaped cells, infiltrating the squamous tumours induced by sub­
cutaneous injection of B9HT3 1ml and 2ml, are in fact host derived fibroblasts. This 
was intriguing since only the virus infected clones had shown this effect. One 
possible explanation for host fibroblast infiltration, was the infection of surrounding 
host fibroblasts by HaMSV produced by the injected cells.
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3.2.6 The B9HT3 cells produce infective virus
For this reason the cell line B9HT3 1ml was analysed for the production of infectious 
virus, using the NRK assay.
Conditioned medium from the B9HT3 1ml cells was used to transform early passage 
NRK cells. Focus formation was measured against serial dilutions of the conditioned 
medium as described in Section 2.20 of the Materials and Methods. The titre of the 
producer line HT3 was calculated as 1.2x10^ focus forming units/ml whereas B9HT3 
lml showed a five-fold lower titre of 2 .4 x 1 0 ^ ffu/ml. Nevertheless, B9HT3 1ml was 
capable of virus production, which was not surprising due to the fact that the producer 
cell line possessed a helper virus which enables packaging of the virus particles.
3.2.7 The apparent absence of integrated virus in host fibroblasts
The possibility that integration of the HaMSV was responsible in some way for 
recruitment of the host fibroblasts was examined. Two Southern blots of several 
squamous and three immortal fibroblast cell line DNA samples, hybridised with the 
H-ras probe (BS9), can be seen in figure 16 . Figure 16A shows 16 squamous DNA 
samples restricted with PstI ( top panel ) and Bgin ( bottom panel ). The same 
quantity of DNA of each sample was used in both enzyme digests, with the lanes 
lined up according to the DNA sample. PstI cuts once in the HaMSV and 
consequently shows the pattern of integration sites. Bgin cuts internally to the 
HaMSV, and thus gives an indication of the copy number of the virus. The 2kb PstI 
band represents the endogenous H-ras PstI fragment, and therefore provides a rough 
means of controlling for loading between samples. However, it was apparent from 
examination of the agarose stained gel, that sample 23 had very different amounts of 
DNA in the PstI and the Bgin lanes. This was probably due to a loading problem or a 
leaking well in the agarose gel. This explains the stark contrast between the amount 
of DNA indicated by the 2kb endogenous PstI band, and the copy number of the virus
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Figure 16.
Stable integration of HaMSV in the squamous tumour explant 
cell lines, but not in the fibroblast cell lines
Southern blot analysis, (A): top panel; PstI digest, bottom panel;
Bglll digest. 10 ug of genomic DNA of each of cell lines 1-23: squamous 
tumour explant cell lines, HT3(virus producer cell line), and B9HT3 1ml 
( B9 infected with HaMSV).
(B): PstI digest of three fibroblast cell lines 10/13/22, derived from virus 
tumour explants and squamous explant cell lines 6-9 
BS9 insert used as probe.

as indicated by the 1.8kb Bglll band. The producer cell line HT3 shows multiple 
integrations of the virus as one may expect. B9HT3 1ml represents a pool of virus 
infected B9 cells and consequently the individual integration patterns are too faint to 
be seen in the Southern blot. The squamous tumour explant cell lines show on 
average 1-3 different virus integrations. The bottom panel of figure 16A showing the 
Bglll digest of the same DNA samples indicates that the HT3 producer cell line as 
expected from the pattern of integrations has a high copy number of integrated virus. 
The B9HT3 1ml on the other hand shows a very faint 1.8kb band. Because the 
endogenous 2kb PstI band provides a rough internal loading control, comparison of 
tumour cell lines 15-18 which have about the same amount of DNA as B9HT3 1ml 
show a much higher copy number of the virus. It seems therefore, that there may be a 
selection for the cells possessing the virus in vivo. Figure 16B shows a similar PstI 
Southern blot with three host derived fibroblast explant DNA samples and four 
squamous explant DNA samples. It can be seen that while there are viral integrations 
in the DNA from squamous explants there appears to be a complete absence of 
HaMSV in the host recruited fibroblasts.
Further experiments have been carried out, using an alternative virus producer cell 
line, H9. This producer cell line does not possess a helper virus and should therefore 
be non-replicative. This should therefore further clarify the question of virus 
infection of host fibroblasts. In addition, an alternative virus construct RPDpsi6  (gift 
from D. Wynford-Thomas) which possesses the codon 61 mutation and the neomycin 
resistance gene, was used to infect both B9 cells and another squamous cell line 
SN161. It will be interesting to compare the characteristics of squamous cells 
overexpressing mutant codon 12 H-ras with those overexpressing the codon 61 
mutation. These cell lines have been selected, ring-cloned and frozen-down. Data 
including expression analysis of these clones should provide a clearer picture of the 
role of overexpressing mutant H-ras in squamous cell carcinomas.
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3.2.8 Summary
These data indicate that increasing the levels of mutant H-ras in the squamous cell 
line B9 is unable to convert the cells to a spindle phenotype. Overexpression of the 
mutant H-ras gene appears detrimental to the cells causing cell death in the case of 
G418 selected transfectants. In addition, there appear to be some minor 
morphological changes in the transfectant and infectant clones, with overexpression 
of mutant H-ras inducing a more irregular cellular distribution. The appearance of 
vacuoles in the cytoplasm was seen both in the plasmid transfected colonies and the 
virally infected pools. It should be pointed out that the same vacuolation was seen in 
parental B9 cells and B9 control Homer6  clones but at a vastly reduced frequency.
The cells overexpressing the codon 12 mutant HaMSV were unable to grow in soft 
agar as were the parental B9 cells. However, the spindle cell line A5 grew in 
anchorage independent conditions and may, in the future, provide a useful means for 
selecting for the isolation of novel spindle cell lines.
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As expected, increasing mutant H-ras in the squamous cell line correlated with a 
slight increase in tumorigenicity as assayed by nude mouse injections. However, on 
the whole the histology of the resultant tumours remained characteristically 
squamous. The exception occured when the virus infected B9 cells were injected into 
nude mice. The result, was a tumour which possessed two distinct histological 
components. The "spindle" looking cells in the tumours showed a distinct 
morphology when initially explanted but soon began to senesce when the serum 
(FBS) concentration was reduced from 20% to 10% v/v. These "spindle" looking 
cells were identified as being host fibroblasts. The mechanism of host fibroblast 
recruitment remains uncertain. However, dimorphism within B9 induced nude mouse 
tumours has not been identified before, both with parental B9 cells and with the B9 
mutant plasmid transfectants. A role for the HaMSV in infection and infiltration of 
the host fibroblasts into the tumour mass was examined, but appeared not to be 
involved. These observations will be discussed in more detail in Chapter 5, Section 
5.4.
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3.3 Overexpressing normal H-ras in spindle cell lines
The converse of the previous experiments would be to increase the level of normal l i ­
ras p2 1  in a spindle cell, with the aim of reverting its morphology to that of a more 
differentiated squamous phenotype.
A5 and D3 were transfected with the constructs pH06Nl and pAGNl (Spandidos and 
Wilkie, 1984).
pH06Nl contains a 6.4kb BamHl fragment of the normal human H-ras gene from 
fetal liver. This was cloned into the BamHl site of Homer6  which contains the 
bacterial aminoglycoside phosphotransferase (aph) gene under the control of the 
MOLTR sequences. The H-ras gene is under transcriptional control from its own 
promoter sequences. The pH06Nl construct in addition possesses a SV40 enhancer 
region.
The pAGNl vector contains the 6.4kb fragment cloned into the BamHl site of 
pAG60. This has the aph gene under conrtrol of the HSY TK promoter. SV40 
enhancer sequences are absent from this construct.
These constructs were lipofected (according to Section 2.17.2 of Materials and 
Methods) into A5 and D3 cells and selected at 400ug/ml of G418 for 2 weeks. 
Resistant colonies were ring-cloned and grown up as individual cell lines. A5 and D3 
cells transfected with the neomycin resistance plasmid, Homer6 , were selected and 
ring-cloned as controls.
3.3.1 The presence and expression of normal ras
The Southern blot of the transfectants shows the stable integration of the human 
normal H-ras plasmid in several of the clones ( Figure 17 ).
The SstI digest should cut out an internal fragment of 2.9kb whereas the BstEII cuts 
out a smaller 1.6kb segment of the gene. As can be quite clearly seen, A5 pH06Nl 2 
and A5 pH06Nl 4 showed the highest copy number of integrated plasmid.
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Figure 17.
Copy number of normal H-ras expressing plasmids, in 
A5 and D3 transfectants
lOug of each transfectant digested with SstI and BstEII as indicated. 
Restriction map of the human H-ras BamHl fragment incorporated into 
plasmids pH06Nl and pAGNl shown beneath. Expected sizes are 2.9kb 
and 1.6kb for SstI and BstEII digestion respectively 
Human T24 specific probe used in the hybridisation of the blot.
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pH06Nl E /F and H all showed altered fragment sizes. The BstEII fragment was 
calculated to be about 3.5kb and a BamHl Southern gave a fragment of approximately 
12kb (data not shown). This suggests a rearrangement may have involved a head to 
head repeat with loss of the intervening BamHl, SstI and BstEII sites.
The D3 clones pH06Nl 1-3 all showed the correct sized restriction fragments with 
varying copy numbers.
Expression of the exogenous as well as the endogenous H-ras genes was examined by 
RNase protection analysis. The RNase protection assay was carried out using two 
probes, one specific for the mouse transcript and the other for the human (for details 
refer to Materials and Methods, Section 2.12). An estimated lOug of total RNA was 
used in the assay. Figure 18 shows the protected fragments which hybridise to both 
the human-specific (H), and the mouse-specific probes, representing both the 
endogenous normal (N) and mutant (M) transcripts.
The expression data correlates with the Southern blot analysis, with clone pH06Nl 2 
showing the highest level of expression of the human specific H-ras transcript 
An interesting observation that came from the RNase protection data, was the 
apparent down regulation of the mutant gene in several of the clones. This appeared 
most evident in the clones which over-expressed the exogenous normal H-ras. 
However, the same apparent down-regulation was also seen in the control A5 Homer 
3, and D3 Homer 2 clones.
Figure 18.
Expression levels of the exogenous and endogenous 
H-ras genes, in A5 and D3 transfectants
RNase protection analysis of cell line RNA, lOug in each lane 
Details as for figure 8, with the addition of a human specific probe 
(H); human specific fragments.
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Another RNase protection assay was carried out on additional clones, with some 
overlap with the previous samples ( Figure 19 ). Although digestion of the RNA is 
not complete in this particular experiment ( as apparent from the ratio of the 
endogenous normal to mutant bands), overall the same conclusions can be made from 
examination of the data. In addition, inclusion of a GAPDH Northern blot of the 
same samples, provided a means of controling for the loading between lanes. If one 
concentrates on the lanes A5 pH06Nl 2, 4 and 5, once again the levels of mutant are 
reduced in A5 pH06Nl 2 and 4 compared to A5 pH06Nl 5, despite there being 
overall less RNA in the A5 pH06Nl 5 lane. In addition, there appears to be 
differences in the levels of endogenous normal transcripts between certain clones. 
For instance clones A5 pH06Nl 2 and 4, have distinctly less endogenous normal 
transcripts than A5 pH06Nl 5.
The precise mechanism for the reduction in the level of expression of the endogenous 
mutant H-ras gene was unknown. The fact that it occurred even in clones not 
overexpressing the exogenous normal gene, suggested that it was not due to some 
form of transcriptional competition between the introduced and mutant genes.
3.3.2 Spindle cells overexpressing normal H-ras remain characteristically 
spindle in nature
Figure 20 shows a representative view of two different transfectant clones. A5 
pH06Nl 5 shows very little expression of the exogenous normal H-ras gene ( Figure 
19 ), whilst A5 pH06Nl 2 was one of the highest normal expressor clones. It can be 
clearly seen, that both cell lines are characteristically spindle in morphology. This 
was the same for all the transfected clones independent of copy number and levels of 
expression of the normal H-ras gene.
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Figure 19.
Expression levels of the endogenous and exogenous 
H-ras genes in additional A5 transfectants
As for figure 18. Lower panel shows Northern blot of 5ug 
from same cell lines hybridised with GAPDH probe.
Transfectant A5pH06Nl 5. Transfectant A5 pH06Nl 2.
Figure 20.
The morphology of the transfectants overexpressing normal 
H-ras remain characteristically spindle
Transfectant A5pH06Nl 2. shows a high copy number (figure 17), and 
level of expression (figure 18) of the normal human H-ras gene, whereas 
A5pH06N 1 5 does not.
(25 x objective)
3.3.3 Reduction in tumorigenicity correlates with loss of endogenous 
mutant
In order to determine the tumorigenicity of the transfectants, a number of the clones 
were injected subcutaneously into nude mice (see Section 2.24 Materials and 
Methods). It became apparent at a very early stage ( within 7 days post-injection), 
that there were marked differences in tumour development between the clones.
At first sight it seemed that the clones that overexpressed normal H-ras were those 
that showed a vast reduction in tumorigenicity. However, one of the control Homer 
transfectants, A5 Homer 3, and two cell lines that were transfected with the plasmid, 
pAGNl, but by Southern analysis were shown not to contain any human H-ras 
sequences, also showed suppression.
The nude mouse injections were repeated with the addition of several other clones. 
The results were conclusive. The same cell lines displayed a reproducible degree of 
suppression.
The data was intriguing, in particular because a similar experiment with 
overexpression of normal H-ras in another spindle cell line, carB, was unable to 
induce any differences in terms of tumorigenicity (S.Haddow and A.Balmain, data not 
shown).
It was realised, that because of the lack of correlation of tumorigenicity with the 
overexpression of the exogenous normal H-ras, and the apparent down-regulation of 
the endogenous mutant gene, that it was important to examine the genetic content of 
the endogenous locus. An Xbal Southern blot of the transfected clones is shown in 
Figure 21 A. From top to bottom, the figure shows the 13kb normal spretus H-ras 
containing fragment, the spretus pseudogene and the 8kb fragment representing one 
of the mutant musculus allele fragments. The samples could be roughly calibrated for 
loading using the intensity of the H-ras pseudogene band. The variation in the levels 
of the mutant H-ras alleles was striking. For example if one concentrates on the lanes 
marked A5 pH06Nl 3, 4, and 5, although they have similar quantities of DNA, as
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Figure 21.
Reduction in tumorigenicity of some transfectant clones correlates 
with loss of the endogenous mutant H-ras gene.
(A) Xbal Southern blot of clones transfected with plasmids pAGNl, 
pH06Nl, and control neomycin plasmid Homer.
Details as for figures 8A and 9.
(B) Graphic illustration of the tumorigenicity of the clones, as 
measured by sub-cutaneous injection of nude mice. Each bar 
represents the average tumour size in mm of 10 separate injection 
points, three weeks post-injection.
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indicated by the intensities of the spretus pseudogene band, the intensities of the 
mutant specific band are obviously very different. Clone A5 pH06Nl 4 shows a vast 
reduction in copy number of the mutant gene, compared to A5 pH06Nl 3 and 5, 
which are more akin to the A5 parental pattern shown in figure 8A.
Figure 2IB provides a graphic illustration of the average size of the nude mouse 
tumours in millimetres, 3 weeks post-injection. These measurements are an average 
of 10 injection points, two injection points per mouse. The clones represented on the 
Southern blot are lined up with their corresponding tumorigenicity measurements.
It was immediately obvious that the cell lines which were less tumorigenic displayed 
a dramatic loss in copy number of the mutant H-ras gene. The correlation was strong, 
even to the extent that clone A5pH06Nl H which showed an intermediate reduction 
in the number of copies of mutant H-ras, showed a corresponding intermediate level 
of tumour suppression.
A5 Homer 3 and clones A5 pAGNl 2 and 3 which had a reduction in the level of 
tumorigenicity, but the conspicuous absence of any exogenous normal ras, showed a 
decrease in the amount of mutant H-ras present.
The relative levels of normalrmutant p21 in the clones were analysed by the Western 
blotting technique ( Figure 22). Although the separation between normal and mutant 
p21 was not ideal, and the loading difficult to quantify, the results were interesting.
In clone A5pH06Nl 4 which showed the highest level of expression of the 
exogenous normal construct, there was a correspondingly high level of normal p21H- 
ras. In addition, there appeared to be a reduction or loss in the mutant p21H-ras 
species, which correlates with the Southern blot and RNase protection data on loss 
and corresponding reduction in expression levels of the endogenous mutant alleles.
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Figure 22.
Western blot analysis of A5 transfectants
Position of normal p21 H-ras and mutant codon 61 Leucine 
species are indicated.
3.3.4 The histology of the 11 suppressed” tumours remained spindle
Histology sections from the "suppressed" tumours displayed an overall spindle 
phenotype. Figure 23 shows two tumour sections taken from tumours about 4mm in 
size, 3 weeks post-injection of clones A5 pH06Nl 4 ( a. and b. ) and A5 pH06Nl E ( 
c. and d. ). Areas of more differentiated cells are visible amongst the typically 
aggressive swirlling pattern of the spindle tumour cells ( Figure 23 a and b )( 
Compare to histology of parental A5 cells, Figure 7 ). Whereas injection of clone A5 
pH06Nl E generated a tumour which shows a large degree of cell death, perhaps 
suggestive of a more differentiated phenotype.
However, if the "suppressed" tumours were left to grow for an additional 2 weeks, 
they increased in size, in some cases to form quite large tumours (about 1cm). 
Tumour suppression was therefore not complete, but rather resulted in an increase in 
the latency period.
3.3.5 Summary of data
Overexpression of normal H-ras in the spindle cell lines A5 and D3 is unable to alter 
the morphology of the cells. Even the clones which displayed high integrated plasmid 
copy number, high exogenous transcript levels, and elevated amounts of normal 
p21H-ras remained characteristically spindle in morphology.
When the cell lines were injected into nude mice, dramatic differences were seen in 
tumour latency between some of the clones. However, variation in tumour size within 
a group of mice injected with the same clone of cells was minimal. Initially, it was 
thought that the reduction in tumorgenicity of individual clones, was due to 
overexpression of the normal gene. However, because of the number of clones 
included in the experiments, and the addition of several control cell lines, it became 
clear that something other than the level of expression of the exogenous normal H-ras 
gene was responsible for the reduction in tumorigenicity.
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Figure 23.
The histology of the "suppressed" tumours 
remains characteristically spindle
a. and b. Histology section from 3-5mm nodules 
4 weeks post-injection of A5 pH06Nl 4.
a. lOx objective
b. 40x objective
c. and d. Histology section from 3-5mm nodules 
4 weeks post-injection of A5 pH06Nl E.
c. lOx objective
d. 40x objective
a. b.
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Figure 23.
Examination of the ratio of the H-ras alleles, by an Xbal Southern blot, showed there 
were marked differences between clones in the quantity of mutant but not normal 
alleles. This variation was due to the loss of mutant genes in many of the clones, and 
appeared independent of the copy number and levels of expression of the transfected 
normal H-ras gene. The clones which displayed loss of mutant H-ras correlated with 
those which showed a reduction in tumorigenicity as measured by subcutaneous 
injection of 10^ cells into nude mice.
These observations explain the RNase protection data, where a reduction in the level 
of endogenous mutant transcripts seen in several clones may be as a direct result of 
loss of the mutant alleles. However, an explanation for the apparent reduction in 
expression of the endogenous normal H-ras genes, observed in figures 18 and 19, was 
more difficult to account for since there appeared to be no loss of normal H-ras alleles 
in the corresponding clones, as determined from the Xbal Southern blot ( Figure 21). 
This anomaly may be explained if one considers that incomplete digestion of the 
mutant alleles would contribute to the intensity of the endogenous normal band. Loss 
of mutant H-ras in several clones would therefore result in a reduced intensity of the 
endogenous normal band.
The histology of the repressed tumours remained spindle, even when removed and 
examined at an early stage. Thus suppression of tumorigenicity correlates with an 
increase in the latency period of tumour development, but not with the overall gross 
morphology of the tumours.
Further experiments with increasing the levels of normal H-ras in the spindle cell 
lines A5 and D3, were carried out using a selectable virus, psi2wt. Conclusive 
expression data on these clones is not yet available. However, injection of these 
clones showed similar variability in tumour latency, with 3 out of 5 clones displaying 
some reduction in tumorigenicity..
It therefore seems clear that overexpression of the normal gene is unable to convert 
the spindle cell to a more differentiated phenotype. In addition, the spontaneous loss 
of mutant H-ras from the spindle cells does not alter the cellular morphology
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Thus the critical factor in determining the tumorigenicity of the individual clones, was 
the level of the endogenous mutant H-ras gene. The morphology of the cells is 
clearly an independent factor and has at least in this particular case little bearing on 
tumorigenicity as measured by the nude mouse assay.
Spontaneous loss of the mutant alleles occurs quite frequently, in about 70% of the 
ring-cloned A5 and D3 cell lines.
The intrinsic instability of these spindle cell lines, may offer a clue as to the 
mechanism for increasing mutant H-ras in the conversion from a squamous to a 
spindle carcinoma. If the increase in mutant H-ras occurs by a genetic amplification 
event, as has been previously suggested, this may provide an explanation for the 
degree of genetic instability encountered, particularly if such an amplicon resided on 
an extra-chromosomal double minute. The fact that one cell line, A5pH06Nl H, 
showed an intermediate reduction in the level of mutant H-ras and a corresponding 
intermediate level of tumorigenicity, may indicate the presence of several such double 
minutes.
Indeed, preliminary data with a chromosome fluorescence technique has identified 
several such extra-chromosomal bodies, most likely double minutes, in the spindle 
cell line D3 (N.Keith; personal communication).
This data together provides the first indication that H-ras resides on an amplicon 
which may be in the form of double minutes. In addition, genetic amplification of 
mutant H-ras has been shown to be a critical event in the squamous to spindle 
transition. However, this does not appear to be the only event that is necessary to 
create the overall spindle phenotype, since complete or partial loss of these amplicons 
does not alter the morphology of the cells.
These observations will be discussed in more detail in the following discussion 
chapter.
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3.4 Increasing normal H-ras in squamous cell lines
Although, overexpression of normal H-ras was unable to alter the phenotype of the 
spindle cells, it still does not rule out a suppressive role for normal H-ras at an earlier 
stage of tumorigenesis. It was decided to include an additional set of experiments. 
To overexpress the normal H-ras gene in the squamous cell lines B9 and SN161. 
SN161 was derived from a DMBA/TPA lymph node metastasis, squamous in 
morphology. Analysis of chromosome 7 RFLPs showed that this cell line had 
completely lost the normal H-ras and Int-2 alleles, indicative of a mitotic 
recombination event (Bremner and Balmain, 1990).
The same pH06Nl normal H-ras plasmid construct as before, was used to transfect 
the squamous cell lines. In addition, a virus, psi2wt, expressing the normal gene ( gift 
from D. Wynford-Thomas ), was used to virally infect the squamous B9 and SN161 
cell lines. The virus contained a neomycin resistance gene, allowing selection for the 
cells infected with the virus.
Preliminary tumorigenicity data, indicates that some clones, both transfectants and 
viral infectants, showed a reproducible degree of suppression. Further data including 
expression analysis of these clones is necessary before any conclusions can be made 
concerning the suppressive effect of normal H-ras on the squamous phenotype.
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Chapter 4 
Results
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Altering ras gene dosage levels by homologous 
recombination in ES cells
4.1. Introduction
Homologous recombination enables an exogenous gene construct, introduced into a 
cell most commonly by means of electroporation, to pair with an endogenous 
homologue in the cellular genome and to undergo a reciprocal exchange event.
With the use of pluripotent embryo-derived stem ( ES ) cells it is possible to introduce 
a genetic mutation by the mechanism of homologous recombination into a specific 
genomic locus. The mutated ES cells can then be returned to a host blastocyst where 
they are able to colonise the developing embryo, in some cases contributing to the 
germline of the resultant mouse.
In this way the ES cells can be modified by homologous recombination in vitro, and 
the mutational event introduced into the mouse germline in vivo.
Through the use of this technique it was hoped to be able to generate a null allele of 
H-ras by the disruption of the coding region of the gene, most commonly by the 
introduction of a neomycin resistance gene.
Creating an ES cell line that possesses only one functional H-ras gene, and the 
ultimate goal a transgenic mouse hemizygous for H-ras should provide the clearest 
means to study the effect of the normal allele in early tumour development.
If the normal allele functions as a suppressor in mouse skin tumorigenesis, then 
carcinogenesis studies on the transgenic mice carrying only one functional allele of 
H-ras should theoretically result in a more susceptible phenotype, producing an 
initiated cell with no normal H-ras alleles.
The H-ras "knock-out" mouse if viable, can be bred to homozygosity enabling an 
examination of the effect on mouse development and tumorigenesis of having no 
functional H-ras.
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Altough the targeted ES cells are undoubtedly the most useful, it was hoped that if 
successful, the same targeting constructs would be used to target the H-ras alleles of 
other cell lines. Cell lines such as PDV and PDVC57 which possess H-ras gene 
dosage ratios of 2:1 and 1:2, normal:mutant respectively, were considered particularly 
relevant. Although both are characteristically epithelial in morphology, PDVC57 is 
much more tumorigenic than PDV. Depending on the particular allele inactivated, it 
was hoped that changes in tumorigenicity or perhaps cellular morphology may occur.
4.2 Alternative strategies for gene targeting
Several techniques for gene targeting utilising homologous recombination have been 
detailed. The main differences between the methods involves the design of the 
targeting vector, and the system of delivery of the construct into the cell.
Alternative strategies were employed to attempt to target the H-ras gene.
Direct nuclear micro-injection of a targeting construct was reputed to dramatically 
increase the overall gene-targeting frequency, presumably by delivering the vector by 
a more direct route. The H-ras targeting vector constructed for microinjection was 
based on the vector design used by Gruss and colleagues (Zimmer and Gruss, 1989). 
The vector contained no selectable marker but an oligonucleotide insert which 
introduced several in frame translation stop codons into the coding sequences of H-ras 
exon 1 as shown in figure 24. The region of the vector including the engineered oligo 
stretch was sequenced using the Sequenase kit as Section 2.14 of Material and 
Methods. It was intended, that screening for correct homologous recombinants would 
be by PCR amplification. Nuclear micrinjection of cells, was accomplished using an 
Eppendorf pneumatic injector. The system was semi-automated, with the movement 
of the needle controlled by a micro-processor. However, despite great efforts to 
obtain viable clones after micro-injection of the cells, the approach was eventually 
abandoned.
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Figure 24.
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An alternative technique to increase the gene targeting frequency was to use a 
promoterless neomycin resistance gene construct. Cloning of such a construct was 
carried out as outlined in figure 25. In theory, only when the construct was correctly 
integrated at the homologous site, or when the construct was randomly integrated 
adjacent to an active cellular promoter, would the clone survive selection.
Despite several electroporations and selection regimes, it was never possible to obtain 
viable ES cell colonies after G418 selection. However, the same construct 
electroporated into PDV epithelial cells provided a selectable phenotype.
A Northern blot of total ES cell RNA compared to PDV RNA showed a much lower 
level of H-ras expression ( Figure 26 ). This pattern was reproduced in a subsequent 
Northern blot of total RNA from ES, PDV and C5N cells (data not shown). This may 
in part explain the inability to derive resistant clones, because the endogenous level of 
H-ras in embryonic stem cells was insufficient to drive a selectable phenotype. 
However, this cannot account for the total lack of resistant clones, since random 
integrants should be independent of the endogenous H-ras transcriptional activity. It 
was decided to however, abandon this approach in favour of a strategy independent of 
endogenous expression levels.
4.3 The positive-negative selection strategy
The positive-negative selection (PNS) protocol has been widely used to target many 
different genes ( for review Capecchi, 1989). It has the advantage of allowing genes 
which are expressed at moderate levels, or not expressed at all in ES cells, to be 
successfully targeted.
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Figure 25.
Abbreviations for restriction endonuclease sites: 
S - Smal 
H - Hindlll
Promoterless H-ras targeting construct: 
Design and cloning strategy
Pst partial generating 
promoterless neomycin gene 
derived from pMClneo
i— i--------- \
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*4 -4 - M
Hindlll linkers 
added
^ ta gT O
neo
NPR.PROJVT
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by Smal restriction digest 
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Figure 26.
Low level expression of H-ras in ES cells
lOug of total RNA from PDV and ES cells 
Hybridisation was carried out with H-ras probe BS9.
A functional HSV-tk gene is positioned at the end of the linearised targeting vector. 
Random integration of the vector results in incorporation of the HSV-tk gene ( Figure 
4). Homologous recombination of the construct, on the other hand, results in the loss 
of the HSV-tk sequences. Cells that contain the tk gene can then be selected against, 
using the anti-viral agent, gancyclovir (GANC). ES cells containing targeted 
disruptions can be enriched several fold, presenting a double resistant 
G418^/GANC^ phenotype ( Figure 4).
4.3.1 Cloning of a positive-negative selection (PNS) vector
The cloning strategy for a positive-negative selection construct is outlined in figure 
27. The neomycin resistance gene under the transcriptional control of the HSV tk 
promoter, was isolated as an Xhol/Sall fragment from the plasmid PmclPolA 
(Thomas and Capecchi, 1987). The ends were converted to Hindlll ends by 
subcloning into the polylinker sequences of pIC20H. This neomycin Hindlll 
fragment was then cloned into the HindlD site in exon 1 of H-ras. The H-ras clone 
pB4 was used as the basic backbone of the vector ( see figure 28 ). This provides 
about 3kb of H-ras homology. The HSV tk gene under the control of the 
phosphogluco-kinase (pGK) promoter was blunt-end ligated into the unique Hpal site 
in the extraneous lambda charon sequences of pB4. The vector termed the PNS 
construct was linearised prior to electroporation with the restriction enzyme Notl.
The ES cells were electroporated as outlined in the Materials and Methods, Section 
2.23.1. Selection was at 200ug/ml of G418 initially for 4-7 days with the subsequent 
addition of gancyclovir at a final concentration of 2uM. Colonies were picked at day 
12-14 of selection using drawn out glass pasteur pipettes and seeded into 24 well 
plates. The cell lines were further expanded into 25cm^ flasks from which DNA and 
frozen aliquots of cells were prepared.
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Figure 27.
Abbreviations for restriction endonuclease sites: 
X - Xhol 
S - Sail 
H - Hindlll 
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N - Notl
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Figure 28.
Abbreviations for restriction endonuclease sites:
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4.3.2 Screening the ES cell clones by Southern blot hybidisation
The general strategy for screening the ES cell clones for a homologous recombinant, 
by Southern blot hybridisation, is outlined in figure 29.
In the first transfection experiment a total of 180 double selected ( G418^/GANC^) 
colonies were picked and analysed by Southern blot hybidisation.
The DNA was made by the rapid lysis method outlined in the Materials and Methods, 
Section 2.18.
Restriction digests were performed overnight using enzymes considered to be 
informative. These included BamHI, EcoRI, Kpnl, and Xbal.
Figure 30 shows a BamHI Southern blot of 33 samples with a restriction map of the 
endogenous and expected targeted loci. The upper panel shows the blot hybridised to 
the H-ras probe, pB5. The pB5 insert, was made by PCR amplification of the H-ras 
cDNA from mouse RNA ( W. Lambie). The cDNA type probe covered exons 1-4 of 
the H-ras gene. The lower panel represents the same blot rehybridised with an insert 
from the neomycin resistance gene.
A correctly targeted clone should display an additional lkb BamHI fragment that 
should hybridise to the H-ras probe. Although the clone indicated by an arrow shows 
a faint band of the right size, this was discounted as being a targeted event by 
additional Southern blot and PCR analysis.
Rehybridistion of the blot with the neomycin probe shows a 3.6kb band indicative of 
random integration of the construct. However, reprobing the BamHI blot with 
neomycin is not strictly informative, since a targeted event would produce a similar 
sized band on the Southern. In addition, it appeared that not all of the clones 
possessed the marker gene, despite almost 2 weeks under selection. One possible 
explanation for this observation, may be that the randomly integrated constructs, 
including the neomycin resistance gene, resided on large genomic fragments that were 
not properly transferred onto the membrane. Another possibility was that the
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SOUTHERN BLOT SCREENING FOR 
HOMOLOGOUS RECOMBINANTS
F6 probe
ENDOGENOUS H-RAS LOCUS 
-1 1 2 3 4
NEO
H-RAS TARGETING VECTOR
PROBES FOR SOUTHERN BLOT SCREENING 
NEO probe
-1
□ — Q
2 3 4
pB5 probe
Figure 29.
Figure 30.
BamHI Southern blot screening of ES cell 
clones electroporated with the PNS 
targeting vector.
(a); Filter hybridised with H-ras pB5 probe
(b); Filter reprobed with neomycin insert
Size markers shown in kb with BamHI restriction map of 
the endogenous locus, targeting vector and expected 
structure of the region if properly targeted
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geneticin (G418) selection was not optimal. Fresh geneticin stocks were prepared for 
future experiments.
A further electroporation and selection was carried out with the same PNS construct, 
and an additional 154 double resistant, G418^/GANC^, clones were isolated.
These were screened in the same way as before. Figure 31 shows an Xbal Southern 
blot of 38 clones which were hybridised to the H-ras probe, pB5, (panel a and c), and 
the same membranes stripped and reprobed with an insert from the neomycin gene 
(panel b and d).
In the case of a targeted event, the endogenous 12kb Xbal fragment should be 
increased in size by about lkb, with the insertion of the neomycin gene. On a 
Southern therefore, the same 13kb fragment should hybridise with both the H-ras and 
neomycin probes. Two clones (indicated by arrows) showed bands of about the right 
size i.e. 13kb. However, when further analysed by PCR and by Southern blotting 
using alternative restriction enzyme digests such as EcoRI, they proved negative. The 
neomycin reprobed filters, Figure 31 panels b. and d. show that almost all of the 
clones have integrated neomycin genes ( in contrast to the previous experiment ), 
which on the whole correspond with the same fragments that hybridise to the H-ras 
probe, as one would expect for randomly integrated copies of the vector.
Figure 32a shows an EcoRI Southern blot of 17 different clones, hybridised to the H- 
ras, pB5 probe. A double cross-over event should disrupt the endogenous EcoRI 
23kb H-ras fragment into two smaller fragments, 9 and 15kb in size ( since the 
neomycin gene contains an EcoRI site). As can be seen from the Southern there were 
no smaller bands of the right size only some larger bands of approximately 25kb in 
size. When the blot was rehybridised with the H-ras probe, P6 Kpnl (Kpnl sub- 
fragment of the BamHI P6 probe), derived from sequences upstream of the targeting 
homology, (termed an external probe), these same bands did not rehybridise. This 
indicates that these larger 25kb fragments represented randomly integrated constructs 
and not some homologously recombined variant.
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Figure 31.
Xbal Southern blot screening of ES cell clones 
electroporated with the PNS targeting vector
(a); Filter of 20 ES cell clones hybridised 
with pB5 H-ras probe, (b) same filter reprobed 
with an insert from the neomycin resistance gene.
(c); Filter of 18 ES cell clones hybridised with 
pB5 H-ras probe, (d) same filter reprobed with 
neomycin probe. Position of endogenous H-ras 
12kb Xbal band is marked as well as some bands 
of about the expected size (13kb) for targeted locus.
X b a  I D i g e s t s
a.
12kb^
b.
12kb^
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12kb^
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Figure 32.
EcoRI screening of ES cell clones electroporated with 
PNS vector.
(a) Filter hybridised with pB5 H-ras probe
(b) Filter hybridised with upstream P6 H-ras probe 
Size markers lambda/Hindlll as indicated
EcoRI Digests
Although the Southern blotting protocol is the most definitive method for confirming 
that a targeted event has taken place, it was in practice tedious and time consuming. 
An alternative to the Southern screening protocol, was to use the PCR technique, 
which offers a more rapid approach to the initial screening of large numbers of cell 
lines (Joyner et al., 1991).
4.3.3 Screening by the PCR technique
The general strategy for screening the ES cell clones for a homologous recombinant 
using the polymerase chain reaction (PCR) assay is outlined in figure 33.
PCR amplification was carried out according to the conditions outlined in the 
Materials and Methods, Section 2.15. Several amplimers were made from sequences 
in the neomycin gene, and from sequences in H-ras exon 3 external to those contained 
in the targeting construct. In theory, only in the case of a legitimate recombination 
event should the neomycin and exon 3 sequences be contiguous. This should enable 
PCR amplification, across the 3' recombination boundary, of a specific sized 
fragment.
It was realised that it was essential to provide a positive control for the PCR screening 
of ES cell clones. It was necessary therefore, to artificially create a H-ras 
homologous recombination event. The positive control construct was engineered as 
outlined in figure 34. Using amplimers complementary to the neomycin gene, to 
exon 2 and to exon 3, the construct was amplified in two halves. The 5' half was 
amplified from the targeting plasmid and the 3' half using genomic DNA as the 
template. The exon 2 amplimers were specially designed with 20 bp overlapping 
tails. These tails were complementary to each other, and when properly annealed 
were designed to form a unique EcoRI restriction site. This was included in the 
design, so that in the likelihood of plasmid contamination of ES cell clones with the 
positive control plasmid, it would be possible to distinguish plasmid contamination 
from legitimate recombination. The positive construct was generated as figure 34
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outlines. In the first set of PCR reactions, amplimers NEO.4 and ExEcol were used 
along with the targeting construct as template DNA, to amplify a fragment from the 3' 
end of the neomycin gene to the middle of exon 2. The amplimers ExEco2 and RC4 
were used in a separate reaction, with mouse genomic DNA as the template, to 
amplify a fragment from H-ras exon 2 to exon 3. In the final PCR reaction the PCR 
products from the previous reactions were mixed in equimolar amounts and 
amplimers NEO.4 and RC4 added to the PCR reaction mix. Annealing of the 
complementary tails and initial extension from the 3f ends of the two template 
fragments resulted in a full length template. Subsequent rounds of amplification 
occurred across the bridged fragments from NEO.4 to RC4. The final product was 
identical to the expected sequences produced by a legitimate homologous 
recombination event with the exception of the 20bp introduced EcoRI linker 
sequences. This fragment was then blunt-end cloned into the Smal site of pUC19. 
PCR reactions were carried out with this positive control plasmid. Reactions were set 
up with the same amplimers and amounts of ES cell genomic DNA with the addition 
of serial dilutions of the control plasmid DNA to the reaction mix. Figure 35 shows a 
typical PCR screen of 25 ES cell clones. Included was a reaction with the same 
quantity of ES genomic DNA (typically 0.5-lug) but spiked with lng of plasmid 
DNA. 20ul of each 50ul reaction was run on a 1.7-2.0% agarose gel. The gel was 
blotted and the membrane hybridised with a H-ras probe. The result can be seen in 
figure 35, with the positive control samples producing a very intense signal. Nothing 
could be visualised in the other lanes with the exception of the lane marked with an 
arrow. A very faint band of approximately the right size could be seen on the original 
autorad. However, further PCR reactions and Southern blot hybridisation proved 
negative. Figure 35, panel c, shows a similar screen of 8 ES cell clones. The three 
lanes with strong signals indicate PCR amplification with O.lng of positive control 
plasmid DNA. The middle of these lanes shows the same positive control except that 
before being run on the gel it was restricted with EcoRI. This shows that the original 
fragment was digested into two smaller fragments with the restiction enzyme EcoRI,
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Figure 35.
PCR screening of ES cell clones using 
amplimers complimentary to neomycin and 
H-ras exon 3 sequences.
(a); Position of amplimers used in screening
(b); Southern blot of PCR products run on 1.7% 
agarose gel and hybridised with pB5 H-ras probe. 
Intense signal from positive control plasmid (lng)
(c); as for b. except positve control product was also 
restricted with EcoRI. ( middle lane of signals)
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and thus verifies the method for distinguishing the positive control fragment from a 
homologous recombinant.
4.3.4 PCR reconstruction experiment
Inorder to confirm the sensitivity of the PCR approach to the screening of ES cell 
clones, a reconstruction experiment was carried out using the positive control 
plasmid. Serial dilutions of positive plasmid DNA ( from 500pg to the equivalent of 
5pg) were mixed with a fixed quantity of genomic DNA (about lug). Figure 36 
shows the results of PCR
amplification, gel electrophoresis and blotting of the PCR products. The membrane 
was hybridised with the H-ras pB5 probe. Although this experiment demonstrates 
that efficient hybridisation of a signal can be visualised from a very small quantity of 
control plasmid DNA it is perhaps not analogous to the PCR amplification of genomic 
DNA. It is thus intended to transfect the positive plasmid into ES cells, and use the 
resultant pool of cells as a more realistic model for the PCR screening approach.
4.3.5 Summary of the data using the Positive-Negative Selection (PNS) 
vector
A total of about 350 double resistant (G418^/GANC^) ES cell clones, electroporated 
with the Positive-Negative Selection (PNS) vector, have been screened by the 
Southern and PCR technique with an additional 70 by PCR alone. So far, all the 
clones which have been screened by both the Southern protocol and the PCR method 
have proved negative.
The reported targeting frequencies vary considerably between different genes. 
However, targeting frequencies such as 5% of the total double resistant clones using 
the positive-negative approach, have been reported for both int-2 ( S.L. Mansour et al, 
1988) and Rb genes (E.Y.-H.P. Lee et al, 1992), and 2% in the case of the p53 locus
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Figure 36.
Serial dilution of the positive control plasmid 
used in PCR screening for an homologous recombinant
10-fold serial dilutions of plasmid (as shown), mixed with 
approximately lug ES genomic DNA. Blot hybridised with 
pB5 H-ras probe.
(L.A. Donehower et al, 1992). According to these frequencies one should expect to 
identify in the region of 8-20 positive targeted events, from the number of clones that 
have been screened to date. However, the targeting frequencies of different genes 
cannot be easily compared. It appears evident from the literature, that certain genes 
are intrinsically more difficult to "knock-out" than others. One of the factors 
considered important in determining the frequency of homologous recombination 
with a specific vector, is the total length of homology the vector possesses (Thomas 
and Capecchi, 1987; Hasty et al., 1991c). The PNS construct has 3kb of total 
homology to the H-ras locus, which is considered to be close to the minimum end of 
the scale. For this reason it was decided to increase the size of H-ras homology with 
the hope of increasing the overall gene targeting frequency.
4.4 Modification of the PNS construct by increasing the length 
of homology to the H-ras genomic locus
4.4.1 Subcloning upstream H-ras sequences
In order to increase the length of H-ras homology in the targeting vectors, it was 
necessary to subclone sequences 5' to the H-ras gene. It has been impossible to 
isolate clones that span the 3' region of the gene despite a great deal of effort. 
However, a very large segment of 5' homology (about 21kb), including the H-ras 
exons -1,1 and 2 has been cloned into lambda charon 30, termed the XN1 clone.
XN1 was restricted with Hpal and a large fragment approximately 15kb in size was 
subcloned into the HincII site of the cloning vector pGEM -3Z (Promega). This 
clone, pGEMHpa was digested with a variety of restriction enzymes inorder to 
determine a rough restriction map of the region. Figure 37 shows a Southern blot of 
several digests of pGEMHpa. Panel a. represents the membrane hybridised to the
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Figure 37.
Restriction mapping of a large upstream H-ras fragment 
isolated from the lambda N1 clone.
Southern blot of plasmid digests of pGEM.HPA subclone
(A);Filter probed with P6 probe (KpnI/BamHI insert) 
represented as solid box in restriction map.
(B); Filter reprobed with pB5 H-ras probe (represents coding 
exons of H-ras).
Restriction map of pGEM.HPA subclone with fragment sizes 
in kb as measured from the blots
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upstream H-ras probe, P6KpnI (600bp KpnI/BamHI fragment of P6). Panel b. 
represents the same filter reprobed with the H-ras probe, pB5.
A 9.5kb EcoRI fragment and a 6.8kb EcoRI/XhoI fragment were subcloned into 
pUC19 and pIC20H respectively, to produce H-ras subclones, pUC9.5Eco and 
pIC6.8E/X. These were further analysed using a variety of restriction enzymes.
4.4.2 Increasing the length of homology of the PNS vector
The length of homology of the original PNS construct was extended as outlined in 
figure 38. A 3.9kb EcoRI/BamHI fragment was isolated from a double digest of 
pUC9.5Eco. The PNS vector was digested with EcoRI/BamHI and the purified 3.9kb 
fragment was ligated to the linearised vector. Finally, the neomycin resistance gene 
and exon -1 and exon 1 sequences were replaced as a BamHI fragment. This 3.9kb 
extension of the original PNS construct termed PNS.EXT, possesses approximately 
7kb of total H-ras homology. This vector has been electroporated into ES cells and 
double resistant colonies grown up and screened. To date 73 G418^/GANC^, double 
resistant colonies, transfected with the PNS.EXT construct, have been screened. As 
yet no positive clones have been isolated using this targeting vector. Experiments are 
continuing in Edinburgh in collaboration with M. Hooper and A. Clarke, Department 
of Pathology.
4.5 The "hit and run" approach to gene targeting
An alternative to the replacement-type targeting vector represented by the PNS and 
PNS.EXT constructs, is the insertion-type vector. This type of vector is linearised in 
the region of homology, and inserts itself into the genomic locus by a single cross­
over event ( Figure 3 ). Through the use of such a vector Allan Bradley and 
colleagues have devised a unique strategy (termed the "hit and run" strategy), for
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introducing subtle mutations into a specific genomic locus (Hasty et al., 1991a). The 
so-called "hit" event describes the insertion of the vector sequences, selected for by 
the introduction of the neomycin gene. The "run" event is selected using the negative 
selectable TK gene ( Figure 39 ). Loss of the TK gene, neomycin gene, and plasmid 
sequences occurs by a looping-out and intrachromosomal recombination event. The 
end-point is restoration of the genomic locus with the only difference being the 
introduction of the specific mutation. The insertion-type vector has been reported to 
target up to nine-fold more frequendy than a replacement vector with the same length 
of homologous sequence (Hasty et al., 1991c). By generating a mutation that 
introduces in frame stop codons into the coding sequences of a gene, they have 
successfully inactivated the hprt and hox 2.6 genes in mouse ES cells (Hasty et al., 
1991b).
It was hoped, that by creating a mutation that alters the open reading frame of the H- 
ras gene, and causes premature translational termination, a null allele of H-ras would 
be achieved. Figure 39 depicts the H-ras "hit and run" vector that was constructed. 
The mutation was made by filling-in the Hindlll site of exon 1 and religation of the 
blunt-ends. This creates a translational frameshift, in theory resulting in premature 
translation at nearby termination codons. The basic vector was constructed from the 
9.5kb EcoRI fragment subcloned into pUC19, or pUC9.5Eco. The Hindlll fill-in 
mutation was recovered as a short Nsil/BbrPI fragment from another H-ras clone ( 
NPR with the exon 1 Hindlll site end-filled, see figure 28 for a map of N PR ). The 
normal Nsil/BbrPI fragment was excised and the mutant fragment inserted. Finally 
the 9.5kb EcoRI fragment carrying the mutation was cloned into the EcoRI site of the 
plasmid PNT (gift from A. Clarke). This plasmid carries a TK gene and a neomycin 
resistance gene both driven by pGK promoters. The fidelity of the Hindin fill-in was 
verified by sequence analysis, using the H-ras primer 12A and the method outlined in 
Section 2.14. Experiments with this H-ras "hit and run" vector are currently in 
progress in Edinburgh.
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4.6 Summary of the gene targeting data
As yet no targeted allele of H-ras has been isolated in ES cells. Initial experiments 
with direct nuclear microinjection of a specially designed construct were unsuccessful 
due to technical difficulties. Attempts to electroporate and select ES cells with a 
promoterless neomycin construct also failed, most probably due to the low 
endogenous level of expression of the H-ras gene in ES cells.
The majority of the electroporation and selection experiments were carried out with 
the positive-negative selection (PNS) vector. This vector has 3kb of H-ras 
homologous sequences, a positive selectable neomycin resistance gene driven from a 
TK promoter, and a negative selectable TK (thymidine kinase) gene driven from a 
pGK (phosphogluco kinase) promoter. This construct has been electroporated into ES 
cells on a number of occasions and selected with both geneticin (G418), and the drug 
gancyclovir (GANC). Over 400 double resistant colonies have been grown up and 
analysed by Southern blot hybridisation and PCR analysis. As yet, no positive clone 
has been identified. In an attempt to increase the targeting frequency, the length of 
homology of the PNS vector, was increased from 3kb to 7kb. The length of 
homology has been reported to increase linearly with the targeting frequency of a 
particular gene (Thomas and Capecchi, 1987; Hasty et al., 1991c). This extended 
PNS construct, PNS.EXT, has been electroporated into ES cells but as yet only 73 
double resistant colonies have been screened, all so far negative.
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In addition to the replacement strategy of gene targeting, an insertion vector, with 9kb 
of H-ras homology has been designed and cloned. The insertion-type vector has been 
reported to increase the targeting frequency up to nine-fold compared to a 
replacement vector with the same homologous sequences. Bradley and colleagues 
have utilised a modified version of the insertion vector in their "hit and run" strategy. 
It is hoped that with the use of the H-ras "hit and run" vector a subtle mutation can be 
introduced into the H-ras locus that will result in premature termination of translation. 
The predicted product should be a short 34 amino acid peptide with only the first 5 
amino acids the same as H-ras. This should therefore create a null-allele of H-ras. 
This vector is currently being electroporated into ES cells in Edinburgh.
Preliminary experiments in cells other than ES cells, such as PDV, have been carried 
out (data not shown), with as yet no positive targeted clones. Most promising perhaps 
are experiments with the mouse cell line, PEC A (gift from J.Schweizer, Heidelberg). 
This cell line is derived from the mouse strain (NMRI), the same as that from which 
our H-ras genomic clone was obtained. Bems and colleagues have reported that the 
frequency of gene targeting increases dramatically when isogenic DNA is used in the 
construction of the targeting vector (te Riele et al., 1992). This may imply that with 
this particular cell line, the frequency of gene targeting will be greatly enhanced. 
However, preliminary transfections using both electroporation and lipofection 
protocols have proved unsuccessful. Further refinements to the transfection protocol 
for these particular cells is apparently necessary.
Through the use of the new, "improved" vectors, it is hoped that the H-ras gene can 
be inactivated by a legitimate homologous recombination event in ES cells, enabling 
the creation of a transgenic mouse, hemizygous or nullizygous for H-ras. These mice 
should provide the clearest answer to the role of normal H-ras both in mouse 
development and the early stages of tumorigenesis.
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Chapter 5 
Discussion
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5.1 Introduction
The results section of this thesis has been split into two chapters, outlining the 
alternative approaches to the study of the H-ras proto-oncogene in mouse skin 
carcinogenesis. The in vitro approach has taken advantage of a number of unique 
carcinoma cell lines isolated in our group, which have provided an interesting insight 
into the final stages of tumour progression. In addition, we have embarked on the 
novel technique of gene targeting which at the time this thesis was begun, was still in 
its infancy. Much has since been learnt about the parameters affecting the frequency 
of homologous recombination in ES cells and the intricacies in the design of the 
targeting vector. In the following sections of this thesis, it is my intention to 
summarize and speculate upon both the successes and failures of these alternative 
approaches.
5.2 The significance of the spindle cell phenotype
Through analysis of the mouse-skin model system, we have been able to define 
discrete stages in the multi-step process of tumorigenesis. In addition, we have been 
able to determine the genetic alterations associated with primary lesions and show 
that these correlate with those found in mouse tumour cell lines of the same stage. It 
has therefore been possible, to identify candidate genes responsible for specific stages 
of tumour progression in vivot manipulate these genes in vitro, and ultimately return 
them to an in vivo environment by injecting the cells into nude mice.
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Perhaps the most useful of the cell lines isolated to date, are those that represent the 
squamous to spindle transition event described in previous sections of this thesis. 
Derived from the same mouse skin carcinoma, MSC11, the cell lines B9, A5 and D3 
were isolated by a process of single cell cloning. B9, the squamous counterpart, 
showed a characteristically well-differentiated histology and was unable to grow in 
soft agar (Figure 7). However, the spindle cell lines A5 and D3 produced 
undifferentiated, aggressive tumours in nude mice, and in addition, grew in anchorage 
independent conditions (Figures 7 and 13). There were marked differences in tumour 
latency between the squamous and spindle cell lines. Sub-cutaneous injection of 10^ 
B9 cells produced 1cm tumours after about 6 weeks, whereas the spindle A5 and D3 
cell lines produced similar sized tumours after only 2-3 weeks. A discrete conversion 
event had occurred in vivo, which resulted in the spindle cell variants.
This transition from an epithelial to spindle derivative is not unique to the mouse-skin 
system. As discussed in Section 1.17 of the introduction to this thesis, spindle cells 
have been characterised as components of a number of different human tumours 
(Matsui and Kitagawa, 1991; Kaufman et al., 1983; Steeper et al., 1983).
Indeed changes in the state of differentiation and morphology of a cell are known to 
play important roles not only in carcinogenesis but embryogenesis as well.
The first tissues to emerge in the early vertebrate embryo are epithelial in nature. The 
mesenchymal cells are all derived from the embryonic epithelia. The epithelial cells 
exhibit an assymmetry that is referred to as apical-basal polarity. It now seems 
evident that this polarity can be modulated by a variety of signals including growth 
factors (Boyer et al., 1989a), tumour promoting phorbol esters (Ojakian, 1981), or 
oncoproteins such as v-src (Warren et al., 1988), and ras (Schoenenberger et al.,
1991). These changes in polarity result in a more motile, fibroblastic-type cell, and 
correlate with changes in the cytoskeletal organisation with the mesenchymal cells no 
longer producing cytokeratin filaments but instead vimentin intermediate filaments.
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In addition, the cell-cell adhesion of the epithelial cells, mediated by specific cell 
adhesion molecules is decreased in the transition. These observations have led to the 
concept of an epithelial-mesenchymal transition, defined as a reversible process 
(Boyer et al., 1989b).
This plasticity in cell type, is clearly important in terms of the study of cancer. It 
offers an explanation for tumour cell heterogeneity, whereby a differentiated 
carcinoma cell can convert to a less differentiated spindle form within an isolated 
tumour mass, as seen in many human tumours and our example in the mouse 
carcinoma, MSC11. It is also thought to play a role in tumour metastasis, whereby a 
motile tumour cell can escape the confines of the primary tumour. A molecular 
understanding of the changes associated with this transition to a dedifferentiated state 
is therefore clearly important to our understanding of cancer biology as a whole. In 
vitro models now exist which reflect the intrinsic motility of a tumour cell. Thiery 
and colleagues have shown that the bladder carcinoma cell line, NBT-II, when grown 
in the presence of the serum substitute, Ultroser-G, displays a conversion from an 
epithelial cell type to a motile, spindle-like cell (Boyer et al., 1989a). This transition 
correlates with redistribution of desmosomal plaque protein, cytokeratin and actin 
filament systems, as well as de novo expression of vimentin ( characteristic of a 
mesenchymal cell). Furthermore this transition is reversible with re-expression of the 
differentiated phenotype upon removal of the inducing factors (Boyer et al., 1989b).
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The presence or absence of the calcium-dependent cell-cell adhesion molecule, E- 
cadherin ( or uvomorulin ), has been shown by a number of investigators to tightly 
correlate with this conversion process (Frixen et al., 1991; Vleminckx et al., 1991; 
Navarro et al., 1991). Canine epithelial (MDCK) cells transformed with Harvey and 
Moloney sarcoma virus acquired fibroblastic, invasive properties and were 
consequently shown to have lost E-cadherin. Similar phenotypes were produced by 
the addition of antibodies against E-cadherin. This down-regulation of E-cadherin 
was shown to be reversible, in that an epithelial MDCK-ras clone which stained 
positive for E-cadherin when injected into nude mice produced tumours with a 
heterogeneous E-cadherin profile. Prolonged culture of these cells from the primary 
tumour eventually resulted in reversion to a E-cadherin positive phenotype (Mareel et 
al., 1991). It seems that host factors present in the in vivo environment were capable 
of down-regulating E-cadherin. Indeed analysis of tumour sections from squamous 
cell carcinomas (SCCs) of the head and neck indicated a similar correlation between 
the state of differentiation and the expression of E-cadherin whereby the most poorly 
differentiated SCCs were E-cadherin negative (Schipper et al., 1991).
Other extracellular matrix components have also been shown to influence the 
epithelial morphology of tumour cells. Reexpression of the cell surface proteoglycan 
syndecan in spindle cells ( created by steroid treatment of mouse mammary epithelial 
cells ), has been shown to restore the epithelial morpholgy of the cells (Leppa et al.,
1992).
In addition, the importance of c-Fos in the modulation of the epithelial phenotype has 
been reported in a recent paper (Reichmann et al., 1992). Prolonged activation of c- 
Fos using an inducible estrogen receptor fusion construct in mammary epithelial cells 
led to an invasive spindle phenotype. Loss of epithelial characteristics such as 
disruption of tight junctions and disruption of E-cadherin distribution were noticeable 
as well as de novo expression of vimentin. This may represent the mechanism by 
which v-src and ras exert their effect on cell polarity, since it has been shown that 
these oncogenes induce c-Fos expression.
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Thus in summary, although the exact mechanisms controlling the epithelial to 
mesenchymal transitions remain unclear, the squamous to spindle transition 
represented by B9 and A5/D3 is clearly not an isolated example, but rather typifies a 
more common state of dedifferentiation seen in both embryogenesis and 
carcinogenesis.
5.3 The squamous to spindle transition correlates with an 
increase in mutant to normal H-ras gene dosage ratio
Molecular analysis of the squamous to spindle cell lines isolated from MSC11 have 
led to a number of interesting observations. A role for p53 in the squamous to spindle 
carcinoma transition event was discounted, since all three clones already possessed 
the same p53 mutations (Bums et al., 1991). The most obvious difference between 
the squamous and spindle cell lines, as outlined in the results section of this thesis, 
was the level of mutant H-ras ( Figure 8 ). The copy number of mutant H-ras 
increased 5-10 fold in the conversion to a spindle cell carcinoma. This increase in 
copy number of the oncogenic species was best explained by a local genetic 
amplification event. Data to support this has come from PCR microsatellite studies 
with markers flanking H-ras indicating a trisomy of chromosome 7, as expected 
(CJ.Kemp, unpublished results). Expression data in the form of RNase protection 
and Western blot analysis correlated with this increase in mutant H-ras ( Figures 8B 
and 10).
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However, in addition to the increase in mutant p21 H-ras, there was a reduction in the 
level of expression of the normal gene. This appeared to occur by a mechanism 
involving transcriptional down-regulation rather than loss of genetic material as 
determined by the RNase protection data, and Southern blot analysis (Figure 8 A and 
B ). Examination of the ratios of the p21 species on a Western blot agreed with the 
RNase protection data. Namely that concurrent with the transition to a spindle cell 
phenotype, was an increase in the mutant leu61 p21 species, and an apparent decrease 
in the normal p21 H-ras species ( Figure 10 ). The mechanism for this down- 
regulation of the normal gene remains unclear, but may involve some form of 
competition possibly for a limited supply of transcription factors. In this way a 5-10- 
fold genetic amplification of the mutant H-ras gene, may result in down-regulation of 
the normal gene by competing out any available transcription factors.
Regardless of the exact mechanism involved, the overall result is an increase in the 
mutant to normal gene dosage ratio concurrent with the squamous to spindle 
conversion.
The obvious question that arises is whether alteration of the mutant:normal gene 
dosage ratio is sufficient to drive the transition event ?
5.4 Overexpression of mutant H-ras in the squamous B9 cell line 
is unable to convert it to a spindle phenotype, but induces 
distinct changes in cell morphology
Despite overexpression of mutant H-ras both in the form of viral and plasmid 
constructs, the B9 cell line remained squamous in character ( Figure 11). There was 
an increase in tumorigenicity of the overexpressors when injected sub-cutaneously 
into nude mice, however the tumours remained well differentiated, characteristic of 
the squamous parental cell line B9. In addition, the overexpressor cell line B9HT3 
lml, when plated under anchorage independent conditions failed to produce colonies.
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It seemed therefore, that overexpression of mutant H-ras in a squamous environment 
was insufficient to alter the overall phenotype.
However, overexpression of mutant H-ras in the B9 squamous cell line appeared to be 
cytotoxic to the cells. This was particularly noticeable in the plasmid transfectants, 
perhaps because of the forced selection for presence of the plasmid. Despite efficient 
transfection frequencies with neomycin plasmid vectors, very few mutant H-ras 
transfectant colonies survived selection. Those two clones that did survive selection, 
showed relatively low levels of mutant H-ras expression as compared to the non­
selected HaMSV infected pool of B9 cells, B9HT3 1ml. Therefore despite an overall 
higher level of mutant H-ras, the non-selected pool of infected B9 cells, B9HT3 1ml, 
showed less cell death. This perhaps may be because of the presence of uninfected 
cells which somehow minimise the cytotoxic effect of mutant H-ras.
Growth arrest induced by mutant H-ras has been documented in the past. Hirakawa 
and Ruley described the temperature-dependent transformation of established rat 
embryo fibroblasts (REF52), with a temperature-sensitive SV40 large T antigen, in 
collaboration with the T24 H-ras oncogene (Hirakawa and Ruley, 1988). Two thirds 
of the clones became growth arrested in G2, or late S phase, when shifted to a 
nonpermissive temperature for T antigen stability. Thus, expression of the large T 
antigen allowed the cells to tolerate higher levels of mutant H-ras.
Although the resultant clones overexpressing mutant H-ras were still 
characteristically squamous in appearance, there were however consistent differences 
in the morphology of the cells. Small cytoplasmic vacuoles could be seen only very 
occasionally in the parental B9 cells. In the overexpressor clones they were 
noticeably more numerous, occupying the entire cytoplasm of some cells.
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A paper by Russo and colleagues describes the transfection of an immortalised breast 
epithelial cell line, MCF-10A, with the same plasmid constructs used in the present 
studies, pH06Tl, and pH06Nl (Russo et al., 1991). Transfection of the normal 
construct produced discrete changes in cell shape, and cytoplasmic appearance. 
These changes were made more prominent by transfection with the mutated H-ras 
oncogene. The features described include the lengthening and thickening of cell 
surface microvilli, formation of blebs, and the emission of filopodial projections. 
Cytoplasmic changes included the formation of intracellular lumina, an increase in the 
number of lysosomes, mitochondria and glycogen content. These observations 
together indicate a more metabolically active cell (Russo et al., 1991).
Similar alterations in cell structure have been documented by Bar-Sagi and 
colleagues. Microinjection of human H-ras oncogenic protein into quiescent rat 
embryo fibroblasts stimulated membrane ruffling and fluid-phase pinocytosis as early 
as 30 minutes post-injection (Bar-Sagi and Feramisco, 1986). These effects persisted 
for more than 15 hours after injection. Microinjection of the proto-oncogenic p21 
species produced similar phenotypes but with a more transient 3 hour lifespan. In 
addition, it has been shown that certain mitogens, hormones and immunomediators 
such as, EGF (Haigler et al., 1979), PDGF (Davies and Ross, 1978), NGF (Connolly 
et al., 1979), and insulin (Goshima et al., 1984), produce a similar series of membrane 
responses in certain target cells. However, these effects are more rapid, occurring 
within minutes of exposure, and last for only 1-2 hours, maximum. The fact that both 
oncogenic and proto-oncogenic p21ras were able to induce similar changes in cell 
structure, suggests they share common cellular target(s), except that the oncogenic 
species produces a more constitutive phenotype.
In addition to the mammalian proto-oncogenes, other members of the ras superfamily 
namely the rho and rab genes have been shown to influence both cytoskeletal 
organisation and vesicular transport, respectively (for reviews see Hall, 1992; and 
Balch, 1990).
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Microinjection of the activated form of rhoA, Vall4rhoA, induces rapid 
morphological changes when injected into Swiss 3T3 cells (Paterson et al., 1990). 
These include stress fiber and focal adhesion plaque formation (Ridley and Hall, 
1992a). Growth factors can induce rho-dependent responses, most likely by directly 
increasing the level of GTP-bound rho in the cell, either by inhibiting rhoGAP or by 
stimulating a rho GDP-exchange factor ( for more details see Section 1.9.4 of the 
Introduction to this thesis ). However, these cellular alterations are distinct from 
those induced by another rho-family member, Racl. Introduction of activated racl 
(Vall2racl) into fibroblasts creates ruffling of the plasma membrane 5-15 minutes 
post injection (Ridley et al., 1992). Within 6 hours of microinjection of the protein, 
intracellular vesicles appear. The vesicles gradually accumulate until the entire 
cytoplasm is full and the cell simply rounds up. Microinjection of confluent 
fibroblasts on the other hand rarely induces similar vesicle formation. These 
observations are particularly interesting in terms of this thesis, since the racl double­
mutant, Vall2 Asnl7, has been shown to inhibit the qualitatively similar changes 
induced by oncogenic Vall2H-ras. This suggests that rac may act downstream of H- 
ras. However, prior blockage of ras action by injection with antibody Y 13-259, or the 
Asnl7 H-ras dominant inhibitory mutant (Feig and Cooper, 1988a), did not interfere 
with PDGF, EGF or Vall4rhoA induced stress fiber or membrane ruffling (Ridley et 
al., 1992).
A model to explain these results has been offered by Hall and colleagues ( Figure 40 
). H-ras and PDGF appear to act upstream of rac, to induce actin polymerisation and 
membrane ruffling. Rho on the other hand, can be stimulated by racl, or 
independently of rac, by bombesin and LPA, leading to the formation of focal 
adhesions and stress fibers. This suggests that there are parallel but interconnecting 
pathways involving H-ras and ras-related small GTP-binding proteins, that influence 
the organisation of the actin cytoskeleton.
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The significance of this data to the present studies emanates from the observation that 
introduction of mutant H-ras into the squamous carcinoma cell line B9, produces 
similar alterations in cell morphology compared to Vall2racl injected subconfluent 
fibroblasts (Ridley et al., 1992). It was noticed that vesicles accumulated in the 
cytoplasm of the B9 transfectant and infectant clones. In extreme cases, the entire 
cytoplasm was filled, and the cells simply detached from the dish. It was also 
recognised that the number of vesicles were far more numerous in subconfluent cell 
cultures than in confluent cultures. It is interesting to speculate that the phenotype 
seen in two cell lines of very different origins, results from a similar disruption of the 
ras-rac pathway. Examination of the cells by high power microscopy may reveal 
distinct alterations in the plasma membrane characteristic of fibroblast membrane 
ruffling induced by Vall2H-ras (Bar-Sagi and Feramisco, 1986) and Vall2racl, and 
the filopodial projections seen in the MCF-10A epithelial cell line transfected with 
oncogenic H-ras (Russo et al., 1991).
In addition further investigations may reveal that the phenotype induced in the B9 
cells by overexpression of mutant H-ras can be blocked by co-transfection with the 
Asnl7racl inhibitory mutant, thus verifying a link between the rac and ras pathways 
in our epithelial cells.
5.5 Infection of the squamous cell line B9 with HaMSV results 
in a cell line capable of i n  v iv o  host fibroblast recruitment
Despite the inability to alter the morphology and in vitro growth characteristics of the 
squamous B9 cell line, sub-cutaneous injection of the two clones, B9HT3 1ml and 
B9HT3 2ml, infected with the HaMSV construct, resulted in tumours displaying two 
distinct components. Explants of these tumours produced cell lines with squamous 
and spindle-like morphologies (Figure 14). However, after 1-2 weeks in culture, and 
a reduction in serum concentration, the "spindle" cell lines began to take on a much
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flatter appearance, characteristic of senescing fibroblasts. The origin of these cells 
was examined using the PCR microsatellite approach. Since the parental B9 cells 
were originally from a hybrid musculus/spretus mouse, the two alleles could be 
distinguished using polymorphic microsatellite primers in PCR amplification 
reactions. PCR amplification followed by gel electrophoresis resolved two bands 
representing both the musculus and spretus alleles from the squamous tumour cell 
lines (Figure 15). However, the spindle-like tumour cell lines showed only one band 
representing the musculus allele. This suggests that these cells were indeed of host 
fibroblast origin. From an NRK assay it was shown that the B9 infected cells were 
capable of producing infective virus particles. It was therefore important to examine 
the involvement of virus infection of the surrounding fibroblasts. A Southern blot of 
squamous and fibroblast cell lines from the tumour explants was probed with a H-ras 
specific probe. No copies of the HaMSV could be seen in the fibroblast cell lines 
(Figure 18). It seems therefore, that virus integration is not responsible for 
recruitment of the nude mouse fibroblasts into the tumour mass. Despite several 
injection experiments of parental B9 cells, and plasmid transfected B9 pH06Tl II and 
in  clones, similar dimorphism has not been encountered. Thus this fibroblast 
recruitment appears unique to the virus infected clones. One possible explanation for 
this phenomenon, is that the cells overexpressing the viral p21 are secreting a factor 
which recruits the surrounding host fibroblasts into the tumour mass. Several factors 
that enhance the plasticity and hence the motility of cells have been identified. These 
include the autocrine motility factor (AMF) (Liotta et al., 1986), produced by human 
metastatic melanoma and ras-transformed NIH-3T3 cells, and the migration- 
stimulating factor (MSF), an autocrine agent that is produced by normal fetal and 
adult malignant fibroblasts (Grey et al., 1989). The paracrine factor, scatter factor 
(SF), was originally identified as a non-dialyzable, heat-labile, trypsin-sensitive agent 
that promotes the dispersal of MDCK epithelial cells by disruption of the junctions 
between the epithelial cells (Stoker and Perryman, 1985). Growth factors such as 
IGF-II, EGF, aFGF and TGF-a have also been implicated in the stimulation of cell
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motility and invasiveness (for a review Jouanneau et al., 1991). In the present case, 
TGF-a is perhaps the most likely candidate factor, since it has been shown that viral 
transformation of various cell lines induces the expression of TGF-a (DeLarco and 
Todaro, 1978). In addition, transfection of immortalised rat fibroblasts with a human 
TGF-a cDNA induces fibroblast transformation, creating clones that form tumours in 
nude mice at a much higher frequency than untransfected controls (Rosenthal et al., 
1986). Further experiments are clearly necessary to establish the mechanism of 
fibroblast recruitment.
5.6 Overexpression of normal H-ras in spindle cells is unable to 
alter the spindle phenotype
Transfection of two spindle cell lines A5 and D3 with normal H-ras plasmid 
constructs resulted in transfectant clones some of which overexpressed large 
quantities of normal p21 H-ras (Figure 18). The morphology of these clones 
remained spindle in appearance (Figure 20), and the histology of the tumours induced 
when the cells were injected sub-cutaneously into nude mice was undifferentiated, 
characteristic of the parental spindle cell lines (Figure 23). These results correlate 
with additional findings from our group and others, where overexpression of normal 
H-ras in the spindle carcinoma cell line, carB, was unable to induce a morphological 
reversion despite displaying high levels of normal p21 H-ras (S.Haddow and
A.Balmain, unpublished results). Similarly, data from Paterson and co-workers has 
shown that overexpression of normal N-ras in HT1080 cells (which carry an activated 
N-ras allele), was also unable to cause a phenotypic reversion, as judged by cellular 
morphology and growth in soft agar (Paterson et al., 1987).
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5.7 Spontaneous loss of mutant leads to a dramatic reduction in 
tumorigenicity of the spindle A5 and D3 cells
Expression data on a number of A5 and D3 clones transfected with normal H-ras, 
showed varying levels of expression of the exogenous H-ras gene as well as of the 
endogenous mutant gene. Initially, it was considered that overexpression of the 
exogenous normal H-ras gene resulted in down-regulation of the endogenous mutant, 
perhaps by some form of competition mechanism. However, clones which appeared 
to have no exogenous H-ras sequences and control clones with only a neomycin 
resistance gene (Homer 6), showed similar decreases in the levels of endogenous 
mutant H-ras. Immediate differences in tumour latency were recognised when the 
various transfectant clones were injected into nude mice. The latency period directly 
correlated, not with the level of exogenous normal H-ras in the cells, but with the 
level of endogenous mutant (Figure 21). The spindle cell lines appeared to have 
spontaneously lost copies of the mutant H-ras gene, in the process of selection and 
isolation as individual cell lines. Indeed, this instability was seen in the majority of 
clones, approximately 70%, and has since been noticed by others working with the 
same cell lines. These observations confirm the initial belief that a local genetic 
amplification event best explains the increase in ratio of the mutant alleles in the 
squamous to spindle transition. Indeed, recent data with a chromosome fluorescence 
technique, has identified the presence of numerous extra-chromosomal bodies in the 
spindle cell line, D3 (N.Keith and A.Balmain, unpublished results). Although not yet 
confirmed, this may suggest that H-ras resides on these double minute-like structures, 
providing an explanation to the frequency of loss of mutant H-ras in these particular 
cell lines.
Thus the spontaneous loss of mutant alleles from many of the A5 and D3 
transfectants, provides an explanation for the apparent down-regulation of the 
endogenous mutant gene in the corresponding clones, as indicated by the RNase 
protection data (Figures 18 and 19).
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Despite the reduction in levels of mutant and overexpression of normal H-ras in 
certain clones, such as A5 pH06Nl 2 and 4, the cells remained spindle in 
morphology (Figure 20). In addition, the histology of the "suppresssed" tumours 
remained characteristically spindle in nature (Figure 23). It thus appears, that 
alterations of the mutantrnormal gene dosage ratio are not sufficient to revert the 
overall phenotype of the spindle cell carcinoma. In agreement with these results, are 
cell fusion studies from our group, which indicate that the spindle cell phenotype is 
recessive (A.Stoler and A.Balmain, in press). Fusion experiments between the 
spindle and squamous cell lines showed that the hybrids took on the phenotype of the 
squamous parent, as determined by cell morphology, and expression of keratins and 
E-cadherin. These data suggest that the spindle phenotype involves functional loss of 
a gene(s), which controls the epithelial differentiation program.
The present studies imply that the tumorigenic potential of the spindle cell carcinoma 
is independent of cellular morphology, since even the histology of the "suppressed" 
nude mouse tumours remained spindle in appearance. The critical factor that appears 
to control the tumorigenic potential of these cells therefore, is the copy number and 
expression levels of mutant H-ras.
The correlation between increasing levels of oncogenic ras and the induction of 
neoplastic transformation in vitro, and the enhancement of tumorigenicity in vivo, has 
been reported by a number of investigators (Colletta et al., 1983; Yoakum et al., 1985; 
Fetherston et al., 1989; Aguilar-Cordova et al., 1991; Compere et al., 1989; Paterson 
et al., 1987). Infection of mouse epidermal keratinocyte cell lines with BALB or 
Kirsten murine sarcoma viruses resulted in the rapid acquisition of EGF-independent 
growth and loss of sensitivity to calcium-induced terminal differentiation (Weissman 
and Aaronson, 1983), whereas the introduction of the EJ ras oncogene into chemically 
induced benign mouse skin papilloma cell lines resulted in transfectants that form 
rapidly growing, anaplastic carcinomas in nude mice (Harper et al., 1986).
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Similar results have been seen in immortalised human cell lines. Retroviral infection 
and plasmid transfection of an SV40 immortalised bronchial epithelial cell line, with 
H-ras and K-ras vectors, produced clones that displayed an increase in ploidy 
(Amstad et al., 1988), were highly tumorigenic when injected into nude mice, and 
were insensitive to the growth inhibitory effects of TGF-P (Reddel et al., 1988). 
Similarly cervical squamous cell lines immortalised by HPV-16 or 18 were also made 
tumorigenic by the introduction of activated H-ras (DiPaolo et al., 1989).
Experiments by Paterson and colleagues support these findings. Isolation of flat 
revertants of the HT1080 fibrosarcoma cell line, showed a reduction in the level of 
tumorigenicity which corresponded with a loss or under-representation of endogenous 
mutant N-ras. Retransformants derived from nude mouse tumours that developed 
after a long latency period, were shown to have regained their transformed phenotype 
and had correspondingly increased levels of mutant N-ras. Furthermore, transfection 
of the revertants clones with mutant N-ras or the EJ oncogene, was shown to 
retransform the cells and regain the tumorigenic potential of the parental HT1080 
cells (Paterson et al., 1987).
Thus from these experiments and the work of others, it appears that the tumorigenic 
potential and growth factor independence of the cells, directly correlate with the 
expression levels of oncogenic ras. However, this correlation may not be as steadfast 
as suggested. Boukamp and colleagues transfected a spontaneously immortalised 
human keratinocyte cell line with the EJ oncogene (Boukamp et al., 1990). The 
transfectants were categorised into separate classes according to their in vivo 
tumorigenicity values. Some clones formed slowly growing papillomatous-type 
benign tumours whereas others formed highly differentiated locally invasive 
squamous cell carcinomas. However, on the basis of Western blot analysis of the 
transfectants, some of the so-called malignant clones showed lower levels of H-ras 
p21-vall2 than one of the benign transfectants.
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A similar lack of correlation has been seen by our group with two cell lines, HT1 
derived by transfection of the immortalised keratinocyte cell line MCA-3D, and a 
NIH3T3 transformant, ldlA . Both cell lines displayed similar levels of mutant p21 
ras but whereas the NIH3T3 transformants produced tumours within 1 week of 
injection, HT1 produced only one tumour in 4 mice after a long latency period (8-12 
weeks) (Quintanilla et al., 1991). It seems therefore, that although a strong 
correlation exists between levels of mutant p21 ras and the tumorigenic potential of a 
cell, the genetic background of the cell in particular additional genetic alterations, 
must also play a role.
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5.8 Overexpression of normal H-ras in squamous carcinoma 
cells appears to induce a suppressive effect on tumour 
development
Overexpression of normal H-ras in the spindle cell lines A5 and D3, was unable to 
produce a detectable suppressive effect on tumour development However, the 
inherent genetic instability, and high levels of endogenous mutant H-ras characteristic 
of these cells, makes them perhaps intrinsically less amenable to the proposed 
suppressive effect, if any, of normal H-ras. It may be that the mutantmormal ratio 
plays an important role at an earlier stage of tumour development.
Preliminary experiments with the squamous cell lines B9 and SN161, reveal slight 
differences in tumour latency ( l-3mm rather than 3-6mm nodules 11 days post­
injection) in some of the normal transfectant and infectant clones. However, 
histological examination does not indicate any significant differences in the 
differentiated state of the tumours ( data not shown ), although this may not entirely 
rule out a suppressive role for normal H-ras, since the tumorigenically suppressed A5 
and D3 tumours were still spindle in morphology.
It is thus still too early to draw firm conclusions on the suppressive role of normal H- 
ras in the squamous cell carcinoma stage of tumour progression. However, if real, it 
may explain the impetus for the alterations in gene dosage of mutantmormal H-ras, 
concurrent with the squamous to spindle transition. If normal H-ras is still able to 
induce a suppressive effect on tumour development in the squamous cell carcinoma, it 
may thus be necessary to down-regulate expression of the normal gene, as well as 
increase the copy number of mutant H-ras. Further analysis of the B9 and SN161 
normal transfectant and infectant clones is clearly essential.
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5.9 Normal ras as a suppressor of tumour development
Tumour suppressor genes are thought to fall into two distinct classes, those which are 
tumorigenic solely by virtue of their loss or inactivation, and those referred to as 
"recessively-activated proto-oncogenes". The latter have been descibed as "proto­
oncogenes which exert a neoplastic effect when loss of one allele unmasks an 
activating mutation in its homologue" (Green, 1988). The H-ras proto-oncogene may 
fall into this class of tumour suppressor gene. The interaction of suppressor genes 
with proto-oncogenes has been studied by analysing the suppression of cells known to 
contain an activated proto-oncogene. Studies with the HT1080 human fibrosarcoma 
and EJ human bladder cell lines which contain an activated N-ras and H-ras 
respectively, have generated some interesting observations. Suppression of EJ 
tumorigenicity was seen not to involve any changes in the level of mutant H-ras 
protein (Geiser et al., 1986). From this it was postulated to occur by a post- 
translational mechanism, by competition with the ras protein or substrates. In 
addition, suppression appeared to be dosage dependent, in that diploid fibroblasts 
could suppress near-diploid HT1080 cells but not near-tetraploid HT1080 variants 
(Benedict et al., 1984). It was also shown that suppression of HT1080 cells appeared 
to be mediated by chromosome 1, the chromosome where N-ras itself resides, 
suggesting that normal N-ras itself was capable of tumour suppression, although the 
results of Paterson and colleagues do not confirm this (Paterson et al., 1987). In 
addition to these cell fusion studies are the observations that losses of all three ras 
alleles occur in several tumour types (Kraus et al., 1984; Diamond et al., 1988; 
Guerrero et al., 1985). We have some evidence to suggest that in some cases loss of 
normal H-ras may be occur by transcriptional down-regulatory mechanism. This 
seems to be the case for carcinoma SN158 which shows a mitotic recombination 
distal to H-ras thus the normal allele remains intact. However, RNase protection 
analysis of this particular tumour shows the complete absence of normal transcript 
These data together lend some support to the theory of ras as a suppressor of
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tumourigenesis. Indeed this proposed suppression by normal ras may account for the 
necessity for trisomy of chromosome 7. It seems that a single point mutation is not in 
itself dominant, and duplication in the form of chromosome non-disjunction is 
necessary to enable tumour development to continue.
The concept of normal H-ras as a tumour suppressor gene, and the fact that it may 
function in a dose-dependent manner, provoke an interest in understanding the 
mechanism of such tumour suppression.
5.10 A proposed mechanism for tumour suppression by normal 
H-ras
The proposed suppressive effect of normal ras on its' oncogenic counterpart most 
likely involves some form of competition between the proteins, possibly for an 
effector molecule.
Some interesting observations that may pertain to this tentative mechanism, have been 
considered by Bourne and Stryer, in a recent Nature News and Views article (Bourne 
and Stryer, 1992). Studies of heterotrimeric G proteins, in particular the G protein a- 
subunit, have shown that both GAP and effector activities reside in the same 
polypeptide. Association of such activities in the same molecule may provide a 
precedent for regulation of the mammalian p21 ras pathway. The slow turn-off of a- 
GTP may act to maintain the effector molecule refractory to further stimuli, by 
prolonging the effector-GDP bound complex. Although still very speculative, such a 
model may offer a mechanism by which normal p21-ras can sequester the available 
effector molecules and maintain them in an inactive complex. In this way, it can be 
imagined how the normal protein could suppress the oncogeneic effect of the mutant 
product when both proteins are present at approximately equal ratios.
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5.11 Conclusions from the in vitro approach to investigating the
role of H-ras in tumorigenesis
In summary, it seems that neither overexpression of mutant H-ras in squamous cell 
lines, or overexpression of normal H-ras in spindle cell lines can dramatically alter 
their respective phenotypes. Clearly another locus is involved in the squamous to 
spindle transition. This observation correlates with data from cell fusion studies, 
which infer that the spindle phenotype is recessive, indicating a loss of genetic 
material. The exact nature of these alterations remain uncertain. Transfection and re­
expression of E-cadherin in the spindle cell line carB was unable to alter the 
morphology of the spindle cells. Experiments reintroducing E-cadherin into A5 and 
D3 cells are in progress, yet it seems that E-cadherin in itself is not sufficient. 
Extensive searches of the mouse genome using the microsatellite approach may 
identify candidate loci that are responsible for the transition event. The fact that the 
spindle phenotype is reversible, as shown by fusion studies with epithelial cells, may 
suggest that the gene or genes of interest may be identified by transfection of a cDNA 
expression library, followed by selection for epithelial revertants. This may be 
accomplished by selecting cells on the basis of induced re-expression of E-cadherin, 
or of the keratin genes. Both these markers have been shown to be re-expressed in the 
epithelial revertants derived by fusion of a spindle with a squamous cell line 
(A.Stoler, in press). These experiments are in progress in our laboratory.
In respect to the proposed suppressive effect of normal H-ras, no conclusive evidence 
for the existence of such a mechanism has been realised from the present studies. 
Even those cell lines which displayed high level expression of normal H-ras as well as 
loss of mutant H-ras, for example A5 pH06Nl 2 and 4, showed no dramatic 
difference in terms of a suppressed phenotype than the likes of A5 Homer 3, which 
showed a similar reduction in copy number of mutant, but no expression of 
exogenous normal H-ras.
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The evidence to date to support a suppressor role for normal p21 ras has come mainly 
from the studies indicating loss or under-representation of the normal gene in several 
tumour types. However, these losses of normal H-ras may be as an indirect 
consequence of increasing the dosage of the mutant gene, most probably in the form 
of a non-disjunction event.
The difficulty exists in distinguishing whether the alterations in gene dosage ratio 
occur as a mechanism for increasing the relative amount of mutant protein, possibly 
as a driving force for in vivo tumour growth, or whether they result in order to 
overcome some form of suppressive effect instigated by the normal gene. From the 
present studies, some suggestion of suppression, in respect to tumour size, of some of 
the squamous transfectant and infectant clones may represent genuine tumour 
suppression. However, these results await more detailed analysis. Thus we are still 
unable to fully rule out a role for normal ras in suppressing tumour development, in 
particular at early stages of tumorigenesis, where the gene dosage ratios may be more 
critical. The necessity for the trisomy of mouse chromosome 7 in the development of 
benign papillomas, may indicate that it is at this stage that the mutantrnormal gene 
dosage ratio is critical.
Perhaps the most definitive method of examining the role of normal H-ras in early 
tumour development is to use the in vivo approach outlined previously, and the results 
of which are discussed in the Section below.
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5.12 Gene targeting: the in vivo approach to investigating the
role of H-ras
5.12.1 Alternative approaches to achieving the same goal
Alternative strategies have been employed to attempt to "knock-out" the H-ras gene in 
ES cells and in other relevant cell lines. Initial efforts to use direct nuclear 
microinjection to introduce a targeting construct were unsuccessful due to technical 
difficulties. In addition, a promoterless targeting construct failed to produce viable 
ES clones following G418 selection possibly because of the low endogenous levels of 
H-ras in ES cells.
Further experiments have been carried out, in collaboration with Martin Hooper and 
Alan Clarke at the Department of Pathology, Edinburgh, using a targeting construct 
with both positive and negative selectable markers. This vector termed the PNS 
construct has been electroporated a number of times into ES cells, and the cells 
selected with geneticin and gancyclovir. The resultant clones have been screened 
both by Southern blot hybridisation and PCR analysis. In addition, to ensure that the 
PCR screening technique was accurate, a positive control plasmid was generated by 
the method outlined in Section 4.3.3.
The end result, after screening over 400 double G418^/GANC^ resistant colonies, is 
that so far it has not been possible to isolate a positive, legitimate recombinant.
Several articles from laboratories involved in the targeting field, have reported a 
linear correlation between the length of homology of the targeting construct and the 
frequency of homologous recombination (Hasty et al., 1991c; Mansour et al., 1988). 
This prompted us to increase the length of homology, from the initial 3kb, for the 
PNS construct to a total of 7kb for the PNS.EXT construct In addition, an insertion- 
type vector was created, based on the "hit-and-run" approach. It was reported by 
Bradley and colleagues that insertion vectors targeted 9-fold more efficiently than 
replacement vectors possessing the same homologous sequences (Hasty et al., 1991c).
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The H-ras "hit and run" vector possesses 9kb of H-ras homology, mostly upstream of 
the coding exons. Experiments with these latest constructs are currently in progress 
in Edinburgh, in collaboration with M.Hooper and A. Clarke.
5.12.2 Summary of the gene targeting data
Despite a great deal of effort, in the generation of the different targeting constructs, 
and mastering of the various techniques, a legitimate H-ras targeted clone has not yet 
been isolated. Various factors have been reported to effect the frequency of 
homologous recombination. Amongst the most prominent is the length of homology 
that the vector has in relation to the gene of interest. Although vectors with as little as 
1.4kb of homology have proved successful (Doetschman et al., 1988), in general the 
greater the length of homology the better the gene targeting frequency. However, 
reviewing the literature for the frequencies of gene targeting, it becomes immediately 
obvious that certain genes are more easily targeted than others. For instance 
disruption of the N-myc gene occurred in 20% of the G418^ colonies (Charron et al.,
1990) compared to only 1 in 5000 for N-ras (Cases and Dautry, 1992). The precise 
reason for such a variation in frequencies is unclear, but may involve a number of 
factors. The H-ras gene may simply fall into the class of genes which are particularly 
difficult to target. The fact that other groups have reportedly been trying to inactivate 
H-ras in ES cells, and as yet no successful results have been published, perhaps 
supports this theory.
One possible biological explanation for the difficulty encountered in targeting H-ras, 
is that inactivation of one allele of H-ras would provide a growth disadvantage to the 
cell, similar perhaps to the haplo-insufficiency seen in the developmental Pax genes 
(Gruss and Walther, 1992). If this were the case, it would perhaps explain why a 
correctly targeted ES cell clone has not yet been isolated.
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However, in a recent article, the successful inactivation of the N-ras gene in murine 
ES cells was detailed (Cases and Dautry, 1992). Although perhaps distinct from H- 
ras, the inactivation of one allele of N-ras did not appear to have a detrimental effect 
on the in vitro growth of the cells. In addition, chimareic mice were established from 
blastocyst injection of the targeted ES cells, indicating that inactivation of one allele 
had little effect on the developmental potential of embryonic stem cells. As for H-ras, 
the story remains unclear. An abstract article from a meeting (Finney and Bishop,
1991), outlines the successful homologous recombination of H-ras in Rat-1 
fibroblasts. Although the details are sketchy, and no article on this matter has since 
been published, hope remains for the successful targeting of the H-ras gene in ES 
cells. If it is felt, that the gene dosage of the normal H-ras gene is critical for the 
proper growth and maintenance of the cells, then ES cell lines carrying transfected 
copies of the normal H-ras gene, can be experimentally generated and tested in the 
system.
Finally if successful, the targeted mice would be studied in the context of our skin 
carcinogenesis system. Heterozygous null mice if treated with carcinogens may 
provide an answer to the proposed suppressor role of normal H-ras. If as previously 
discussed, trisomy of chromosome 7 is necessary to overcome some suppressive 
effect of proto-oncogenic ras, then initiation of the skin in heterozygous null mice by 
point mutation of H-ras would result in a target cell with no normal H-ras. This may 
lead to a reduction in the latency period for papilloma development or indeed an 
increase in the papilloma yield. One can only speculate as to the consequences of a 
reduction or complete loss of H-ras in mouse skin tumorigenesis, or indeed in the 
overall process of cellular differentiation concurrent with normal embryonic 
development.
These as with many other aspects of ras biology await further investigation.
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